

CITATION REPORT

List of articles citing

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

DOI: 10.1016/j.jacc.2014.03.022

Journal of the American College of Cardiology, 2014, 64, e1-76.

Source: <https://exaly.com/paper-pdf/58888599/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2241	Acute effects of adrenergic agents on post-defibrillation arrest time in a cultured heart model. 2004 , 61, 3093-9		3
2240	Association, mutual stabilization, and transcriptional activity of the STRA13 and MSP58 proteins. 2005 , 62, 471-84		32
2239	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in		1314
2238	Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments. 2014 , 10, 885-900 of Cardiology (ESC) and the E. 2012, 9, 632-696.e21		1
2237	Stroke and bleeding risk in atrial fibrillation. 2014 , 44, 281-90		29
2236	A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?. 2014 , 10, 507-22		14
2235	Novel oral anticoagulants in non-valvular atrial fibrillation. 2014 , 12, 3-8		17
2234	Management of pulmonary hypertension due to heart failure with preserved ejection fraction. 2014 , 16, 501		3
2233	Oral carvedilol in escalating doses in the acute treatment of atrial fibrillation. 2014 , 5, 239-44		1
2232	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. 2014 , 35, 3377-85		127
2231	Clinician's guide to the updated ABCs of cardiovascular disease prevention. 2014 , 3, e001098		17
2230	Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. 2014 , 39, 628-36		8
2229	New-onset atrial fibrillation during hospitalization. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2432-3	15.1	21
2228	Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. 2014 , 9, 861-70		21
2227	Case report: paravalvular leak as a complication of percutaneous catheter ablation for atrial fibrillation. 2014 , 9, 187		8
2226	A standardized bleeding risk score aligns anticoagulation choices with current evidence. 2014 , 13, 109-13		3
2225	Preoperative arrhythmias such as atrial fibrillation: cardiovascular surgery risk factor. 2014 , 2014, 584918		4

2224	Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. 2014 , 168, 239-247.e1		41
2223	The debate on warfarin use in dialysis patients with atrial fibrillation: more fuel for the fire. 2014 , 64, 677-80		3
2222	Increased risk of first-ever stroke in younger patients with atrial fibrillation not recommended for antithrombotic therapy by current guidelines: a population-based study in an East Asian cohort of 22 million people. 2014 , 89, 1487-97		12
2221	Balancing ischaemia and bleeding risks with novel oral anticoagulants. 2014 , 11, 693-703		20
2220	Novel balloon catheter device with pacing, ablating, electroporation, and drug-eluting capabilities for atrial fibrillation treatment--preliminary efficacy and safety studies in a canine model. 2014 , 164, 508-14		15
2219	Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis. 2014 , 25, 1411-8		9
2218	Antiarrhythmic drug therapy for atrial fibrillation. 2014 , 32, 533-49		5
2217	Left atrial appendage exclusion for atrial fibrillation. 2014 , 32, 601-25		11
2216	Diagnostic evaluation and follow-up of patients with atrial fibrillation. 2014 , 32, 507-19		2
2215	Complications from catheter ablation of atrial fibrillation: impact of current and emerging ablation technologies. 2014 , 16, 344		6
2214	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2645-2687	15.1	132
2213	Atrial fibrillation: antiarrhythmic therapy. 2014 , 39, 351-91		5
2212	[It is time to optimize the anticoagulant therapy in elderly patients with atrial fibrillation]. 2014 , 49, 201-2		1
2211	2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2373-2405	15.1	64
2210	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. 2014 , 3,		33
2209	Edoxaban: an update on the new oral direct factor Xa inhibitor. 2014 , 74, 1209-31		75
2208	2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 64, e77-137	15.1	855
2207	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 64, e139-e228	15.1	1822

2206	Novel anticoagulants for stroke prevention in patients with atrial fibrillation. 2014 , 28, 247-62		4
2205	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2246-2280	15.1	505
2204	Assessment and impact of cardiac fibrosis on atrial fibrillation. 2014 , 16, 518		20
2203	Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. 2014 , 45, 2286-91		56
2202	Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. 2014 , 112, 276-86		94
2201	Rotors and focal sources for human atrial fibrillation: mechanistic paradigm with direct clinical relevance. 2014 , 78, 2357-66		7
2200	Clinical research and the development of medical therapeutics. 2014 , 78, 1267-71		3
2199	Comment on "Stroke Prevention in Atrial Fibrillation: A Systematic Review" 2015 , 34, 509-510		
2198	Comment on "Stroke prevention in atrial fibrillation: a systematic review". 2015 , 34, 509-10		
2197	2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2767-2802	15.1	22
2196	Is Human Long-Standing Persistent Atrial Fibrillation More Stable Than Assumed?. 2015 , 1, 25-28		
2195	Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels. 2015 , 11, 228-34		41
2194	Changes in Left Atrial Appendage Dimensions Following Volume Loading During Percutaneous Left Atrial Appendage Closure. 2015 , 8, 1935-1941		51
2193	2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview: A professional societal overview from the American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions. 2015 , 86, 791-807		25
2192	Commonly consumed beverages in daily life: do they cause atrial fibrillation?. 2015 , 38, 317-22		13
2191	Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives. 2015 , 95, 389-404		56
2190	Antiarrhythmic and electrophysiologic effects of flecainide on acutely induced atrial fibrillation in healthy horses. 2015 , 29, 339-47		22
2189	Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta-analysis of 16 Clinical Trials and 9,185 Patients. 2015 , 38, 499-509		22

2188	Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review. 2015 , 38, 684-91	6
2187	Postoperative atrial fibrillation in non-cardiac and cardiac surgery: an overview. 2015 , 13 Suppl 1, S304-12	72
2186	Risk Factors for Progression of Degenerative Aortic Valve Disease in the Japanese- The Japanese Aortic Stenosis Study (JASS) Prospective Analysis. 2015 , 79, 2050-7	12
2185	Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol. 2015 , 5, e007613	11
2184	How can we bridge the results of global clinical trials and region/country specific clinical practice by region/country specific registry data?. 2015 , 79, 287-8	0
2183	The prognostic effects of ventricular heart rate among patients with permanent atrial fibrillation with and without coronary artery disease: a multicenter prospective observational study. 2015 , 94, e920	5
2182	Erweiterte Reanimationsmaßnahmen für Erwachsene (âadult advanced life supportâ) 2015 , 18, 770-832	37
2181	The presence of left atrial posterior wall fibrillation despite restoration of sinus rhythm after posterior box ablation. 2015 , 1, 416-418	1
2180	Patients with hemophilia: Unique challenges for atrial fibrillation management. 2015 , 1, 445-448	4
2179	Impact of B-type natriuretic peptide level on the risk of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation: a prospective study. 2016 , 14, 4	15
2178	Patients with atrial fibrillation and diabetes: does apixaban remain the drug of choice?. 2015 , 1, 95-6	
2177	Nieuwe orale anticoagulantia. 2015 , 44, 230-236	
2176	Sequential Percutaneous LAA Ligation and Pulmonary Vein Isolation in Patients with Persistent AF: Initial Results of a Feasibility Study. 2015 , 26, 608-14	27
2175	Effect of Different Ablation Settings on Acute Complications Using the Novel Irrigated Multipolar Radiofrequency Ablation Catheter (nMARQ). 2015 , 26, 1063-8	17
2174	Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ? 2. 2015 , 3, 2050312115613350	10
2173	Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. 2015 , 15, 104	3
2172	Rapid automatic segmentation of abnormal tissue in late gadolinium enhancement cardiovascular magnetic resonance images for improved management of long-standing persistent atrial fibrillation. 2015 , 14, 88	9
2171	A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. 2015 , 13, 29	1

2170	Nocturnal hypoxia and the success rate of standard atrial fibrillation treatment: a case report. 2015 , 9, 133	
2169	Incident atrial fibrillation in the emergency department in Ontario: a population-based retrospective cohort study of follow-up care. 2015 , 3, E182-91	9
2168	Demographic and Clinical Characteristics to Predict Paroxysmal Atrial Fibrillation: Insights from an Implantable Loop Recorder Population. 2015 , 38, 1217-22	5
2167	Atrial fibrillation care improvement collaborative. 2015 , 4,	3
2166	A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. 2015 , 114, 1290-8	99
2165	Surface ECG f Wave Analysis of Dofetilide Drug Effect in the Atrium. 2015 , 26, 644-8	9
2164	Effect of Pulmonary Vein Anatomy and Pulmonary Vein Diameters on Outcome of Cryoballoon Catheter Ablation for Atrial Fibrillation. 2015 , 38, 989-96	19
2163	Evaluation of initial dofetilide dosing recommendation based on actual body weight in overweight and obese patients. 2015 , 40, 635-9	1
2162	Better adherence to antithyroid drug is associated with decreased risk of stroke in hyperthyroidism patients. 2015 , 69, 1473-85	3
2161	A Pilot Study to Evaluate Effectiveness of INR Self-Testing in Elderly Patients. 2015 , 30, 720-7	
2160	Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. 2015 , 40, 447-51	26
2159	Pulmonary Vein Isolation Using the First-Generation Cryoballoon Technique in Chinese Patients. 2015 , 38, 1073-81	6
2158	Demographic Differences in Catheter Ablation After Hospital Presentation With Symptomatic Atrial Fibrillation. 2015 , 4, e002097	21
2157	The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?. 2015 , 66, 530-9	1
2156	Myocardial Sleeve Tissues in Surgical Lung Specimens. 2015 , 39, 1427-32	1
2155	Smoking, atrial fibrillation, and ischemic stroke: a confluence of epidemics. 2015 , 30, 512-7	10
2154	Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. 2015 , 35, 560-8	27
2153	Analysis of Nursing Home Prescriptions for Atrial Fibrillation: Practitioners and Guidelines, Which Is Wrong?. 2015 , 63, 1724-5	1

2152	Intraoperative Magnesium Administration Does Not Reduce Postoperative Atrial Fibrillation After Cardiac Surgery. 2015 , 121, 861-867	21
2151	A Multicenter Evaluation of Off-Label Medication Use and Associated Adverse Drug Reactions in Adult Medical ICUs. 2015 , 43, 1612-21	22
2150	Cardiomyocyte Remodeling in Atrial Fibrillation and Hibernating Myocardium: Shared Pathophysiologic Traits Identify Novel Treatment Strategies?. 2015 , 2015, 587361	13
2149	Impact of Impaired Renal Function on the Incidence of Atrial Fibrillation following Radiofrequency Ablation of Cavotricuspid Isthmus-Dependent Atrial Flutter. 2015 , 45, 473-8	3
2148	Inappropriate combination of warfarin and aspirin. 2016 , 16, 189-96	5
2147	Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study. 2015 , 10, 515-9	6
2146	Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review. 2015 , 105, 519-26	22
2145	Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity?. 2015 , 8, 217-28	11
2144	Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. 2015 , 7, 808-16	24
2143	Anticoagulation in Atrial Fibrillation - Current Concepts. 2015 , 4, 100-7	4
2142	Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. 2015 , 10, 1431-44	14
2141	Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care. 2015 , 8, 283-91	6
2140	Long-term Prognosis of Paroxysmal Atrial Fibrillation and Predictors for Progression to Persistent or Chronic Atrial Fibrillation in the Korean Population. 2015 , 30, 895-902	12
2139	DRUGS EFFICIENCY AND SAFETY: THE ROLE OF PHARMACEUTICAL INDUSTRY. 2015 , 11, 420-425	2
2138	Blending Quality Improvement and Research Methods for Implementation Science, Part II: Analysis of the Quality of Implementation. 2015 , 26, 366-71	2
2137	Wavelet Entropy as a Measure of Ventricular Beat Suppression from the Electrocardiogram in Atrial Fibrillation. 2015 , 17, 6397-6411	7
2136	Variation in Anticoagulant Recommendations by the Guidelines and Decision Tools among Patients with Atrial Fibrillation. 2015 , 3, 130-45	8
2135	The SAME-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation?. 2015 , 114, 657-9	17

2134	Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation. 2015 , 4, 44-6	2
2133	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. 2015 , 10, 63-73	2
2132	Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. 2015 , 11, 317-32	9
2131	Prospectively quantifying the propensity for atrial fibrillation: a mechanistic formulation. 2015 , 10, e0118746	3
2130	An automated clinical alert system for newly-diagnosed atrial fibrillation. 2015 , 10, e0122153	17
2129	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. 2015 , 10, e0125164	9
2128	Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease. 2015 , 10, e0131479	2
2127	Norepinephrine-Induced Adrenergic Activation Strikingly Increased the Atrial Fibrillation Duration through α - and β -Adrenergic Receptor-Mediated Signaling in Mice. 2015 , 10, e0133664	21
2126	Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study. 2015 , 10, e0141377	26
2125	Detailed Anatomical and Electrophysiological Models of Human Atria and Torso for the Simulation of Atrial Activation. 2015 , 10, e0141573	33
2124	Detecting and monitoring arrhythmia recurrence following catheter ablation of atrial fibrillation. 2015 , 6, 90	11
2123	Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. 2015 , 114, 1113-26	52
2122	Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options. 2015 , 8, 231-42	29
2121	Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. 2015 , 114, 826-34	77
2120	Developing a New Computer-Aided Clinical Decision Support System for Prediction of Successful Postcardioversion Patients with Persistent Atrial Fibrillation. 2015 , 2015, 527815	2
2119	Improvement of Predictive Value for Thromboembolic Risk by Incorporating Left Atrial Functional Parameters in the CHADS2 and CHA2DS2-VASc Scores. 2015 , 56, 286-92	13
2118	Surgical Left Atrial Appendage Exclusion Does Not Impair Left Atrial Contraction Function: A Pilot Study. 2015 , 2015, 318901	14
2117	Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality. 2015 , 2015, 314041	14

2116	New-onset atrial fibrillation in critically ill patients. 2015 , 22, 179-82	25
2115	Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation. 2016 , 16, 474-481	17
2114	Edoxaban. 2015 , 50, 619-34	3
2113	Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals. 2015 , 2015,	18
2112	Ablation Therapy for Atrial Fibrillation: Implications for the Anesthesiologist. 2015 , 29, 1341-56	5
2111	Association of sleep characteristics with atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. 2015 , 70, 873-9	58
2110	Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs. 2015 , 8, 292-300	7
2109	Valvular heart disease and postoperative considerations. 2015 , 19, 130-42	1
2108	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. 2015 , 75, 979-98	9
2107	Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation. 2015 , 15, 323-35	8
2106	Effect of early direct current cardioversion on the recurrence of atrial fibrillation in patients with persistent atrial fibrillation. 2015 , 116, 225-9	6
2105	Management and prognosis of atrial fibrillation in the diabetic patient. 2015 , 13, 643-51	16
2104	Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials. 2015 , 8, 103-14	7
2103	Modified HAS-BLED Score and Risk of Major Bleeding in Patients Receiving Dabigatran and Rivaroxaban: A Retrospective, Case-Control Study. 2015 , 30, 395-402	5
2102	New oral anticoagulants for patients with nonvalvular atrial fibrillation. 2015 , 28, 28-34	
2101	Deciding on a combination of anticoagulant and antiplatelet drugs. 2015 , 76, 638-41	
2100	Left Atrial Appendage Closure for Stroke Prevention in AF: The Quest for the Holy Grail. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2740-2742	15.1 1
2099	Advances in the prevention and treatment of atrial fibrillation. 2015 , 58, 103-4	2

2098	Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial. 2015 , 29, 551-561	10
2097	Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. 2015 , 8, 1925-1932	61
2096	Atrial Fibrillation and the Risk of Stroke: Does Timing Matter?. 2015 , 8, 1002-4	
2095	Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. 2015 , 4, e001349	6
2094	Nursing best practices to prevent stroke in women. 2015 , 46, e75-7	1
2093	Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation: The Fushimi Atrial Fibrillation Registry. 2015 , 46, 3354-61	75
2092	Conundrums for Atrial Fibrillation Management in Older Adults. 2015 , 4, 368-376	
2091	New Oral Anticoagulants in Elderly Adults With Chronic Kidney Disease. 2015 , 90, 1587-9	2
2090	Effect of the electrograms density in detecting and ablating the tip of the rotor during chronic atrial fibrillation: an in silico study. 2015 , 17 Suppl 2, ii97-104	12
2089	Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): Rationale and design. 2015 , 170, 1184-94	59
2088	New Oral Anticoagulants: Clinical Parameters and Uses in Practice. 2015 , 30, 329-45	3
2087	Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves. 2015 , 30, 644-56	7
2086	Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2899-2906	15.1 96
2085	Poor scar formation after ablation is associated with atrial fibrillation recurrence. 2015 , 44, 247-56	29
2084	Atrial Fibrillation: Would You Prefer a Pill or 150 Joules?. 2015 , 66, 655-7	2
2083	Symptom burden, Metabolic profile, Ultrasound findings, Rhythm, neurohormonal activation, haemodynamics and health-related quality of life in patients with atrial Fibrillation (SMURF): a protocol for an observational study with a randomised interventional component. 2015 , 5, e008723	9
2082	Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation Recurrence: A Meta-Analysis. 2015 , 1, 41-51	65
2081	Direct factor Xa inhibitor edoxaban: from bench to clinical practice. 2015 , 8, 707-25	1

2080 Pharmacotherapy for Cardiac Diseases. **2015**, 457-468

2079 Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. **2015**, 36, 653-6 41

2078 Catheter ablation for asymptomatic atrial fibrillation?. **2015**, 13, 243-8 1

2077 Postoperative atrial fibrillation in liver transplantation. **2015**, 15, 687-94 40

2076 Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. *Journal of the American College of Cardiology*, **2015**, 65, 635-42 15.1 187

2075 Pulmonary vein isolation for atrial fibrillation in the postpneumonectomy population: a feasibility, safety, and outcomes study. **2015**, 26, 385-389 11

2074 Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience. **2015**, 5, 234-44 8

2073 Left atrial volume is more important than the type of atrial fibrillation in predicting the long-term success of catheter ablation. **2015**, 184, 56-61 41

2072 Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. **2015**, 17, 370-8 117

2071 Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. **2015**, 30, 777-82 8

2070 Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: A cohort study. **2015**, 12, 886-92 31

2069 Quantification of the cryoablation zone demarcated by pre- and postprocedural electroanatomic mapping in patients with atrial fibrillation using the 28-mm second-generation cryoballoon. **2015**, 12, 283-90 105

2068 Warfarin therapy for atrial fibrillation in haemodialysis patients: mind the (evidence) gap. **2015**, 30, 337-9 3

2067 Device-detected atrial fibrillation: what to do with asymptomatic patients?. *Journal of the American College of Cardiology*, **2015**, 65, 281-94 15.1 43

2066 Inflammation and the pathogenesis of atrial fibrillation. **2015**, 12, 230-43 419

2065 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Developed in collaboration with the American College of Surgeons, American Society of Anesthesiologists, 123

2064 Adding rigor to stroke risk prediction in atrial fibrillation. *Journal of the American College of Cardiology*, **2015**, 65, 233-5 15.1 11

2063 Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. **2015**, 13, 495-504 110

2062	Novel oral anticoagulants in patients undergoing cardioversion for atrial fibrillation. 2015 , 40, 139-43		6
2061	Criteria for prescribing dabigatrin extexilate and rivaroxaban really appropriate? Comment. 2015 , 49, 154		1
2060	Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 225-32	15.1	160
2059	Pathophysiology and clinical management of cardiac sarcoidosis. 2015 , 12, 278-88		64
2058	Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation. 2015 , 43, 161-7		17
2057	Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. 2015 , 37, 53-9		25
2056	Safety and efficacy of external electrical cardioversion in patients with left ventricular leads. 2015 , 104, 439-45		3
2055	Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. 2015 , 115, 1095-101		49
2054	Managing atrial fibrillation. 2015 , 65, 532-9		15
2053	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. 2015 , 385, 2280-7		126
2052	Presence and severity of obstructive sleep apnea and remote outcomes of atrial fibrillation ablations - a long-term prospective, cross-sectional cohort study. 2015 , 19, 849-56		30
2051	Neurologic Complications of Chronic Kidney Disease. 2015 , 15, 50		8
2050	Target-specific oral anticoagulants and the hospitalist. 2015 , 43, 1-12		0
2049	The case against using hypertension as the only criterion for oral anticoagulation in atrial fibrillation. 2015 , 31, 576-9		4
2048	The changing face of team care, and a challenge for the future. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2137-9	15.1	5
2047	Left Atrial Appendage Ligation and Ablation for Persistent Atrial Fibrillation: The LAALA-AF Registry. 2015 , 1, 153-160		45
2046	Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis. 2015 , 46, 2477-81		41
2045	2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1497-513	15.1	46

2044	HRS/NSA 2014 survey of atrial fibrillation and stroke: Gaps in knowledge and perspective, opportunities for improvement. 2015 , 12, e105-13		19
2043	Triple Therapy...Can We Replace More With Better?. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 628-30	15.1	0
2042	Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 616-27	15.1	72
2041	Atrial fibrillation ablation: indications, emerging techniques, and follow-up. 2015 , 58, 202-12		4
2040	Highly sensitive detection of cardiac troponin I in human serum using gold nanoparticle-based enhanced sandwich immunoassay. 2015 , 221, 537-543		21
2039	Reasons for non-adherence to practice guidelines on stroke prevention in patients with atrial fibrillation: A cross-sectional study in primary care. 2015 , 187, 525-6		7
2038	Relationship between left atrial appendage morphology and thrombus formation in patients with atrial fibrillation. 2015 , 188, 86-8		6
2037	Pacing for treatment and prevention of atrial fibrillation: Is there an end to this story?. 2015 , 12, 1726-7		2
2036	Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. 2015 , 199, 264-73		37
2035	2015 ACC/HRS/SCAI left atrial appendage occlusion device societal overview. 2015 , 12, e122-36		11
2034	Atrial Fibrillation and Mortality in Critically Ill Patients: A Retrospective Study. 2015 , 24, 336-41		9
2033	Effect of Nocturnal Intermittent Hypoxia on Left Atrial Appendage Flow Velocity in Atrial Fibrillation. 2015 , 31, 846-52		8
2032	Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2691-8	15.1	66
2031	Patient outcomes according to adherence to treatment guidelines for rhythm control of atrial fibrillation. 2015 , 4,		9
2030	How to define valvular atrial fibrillation?. 2015 , 108, 530-9		74
2029	Management of Anticoagulation in Patients With Atrial Fibrillation. 2015 , 314, 291-2		9
2028	Patients with minimal atrial fibrillation events should not undergo concomitant atrial ablation during open heart procedures. 2015 , 7, 395-401		3
2027	Effect of atrial fibrillation ablation on gastric motility: the atrial fibrillation gut study. 2015 , 8, 531-6		46

2026	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. 2015 , 46, 2168-74	56
2025	The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis. 2015 , 195, 237-42	22
2024	Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2614-2623	151 328
2023	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. 2015 , 17, 1007-17	40
2022	Asymptomatic atrial fibrillation after cryptogenetic stroke: incidence, clinical significance, and therapeutic implications. 2015 , 8, 249-51	
2021	Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation. 2015 , 17, 41	
2020	Atrial ectopy predicts late recurrence of atrial fibrillation after pulmonary vein isolation. 2015 , 8, 569-74	21
2019	[Oral anticoagulation for non-valvular atrial fibrillation in the elderly]. 2015 , 50, 134-42	5
2018	Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. 2015 , 135, 621-9	26
2017	"Asymptomatic" persistent or permanent atrial fibrillation: A misnomer in selected patients. 2015 , 185, 112-3	6
2016	Effective practical management of patients with atrial fibrillation when using new oral anticoagulants. 2015 , 47, 278-88	
2015	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1619-1629	151 331
2014	Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. 2015 , 87, 1209-15	51
2013	Dose-finding study of rivaroxaban in hemodialysis patients. 2015 , 66, 91-8	94
2012	Pharmacological strategies for prevention of postoperative atrial fibrillation. 2015 , 8, 233-50	15
2011	Managing comorbidities in patients with chronic heart failure: first, do no harm. 2015 , 15, 171-84	10
2010	Management of atrial fibrillation: What is new in the 2014 ACC/AHA/HRS guideline?. 2015 , 127, 396-404	1
2009	Variation in practice patterns among specialties in the acute management of atrial fibrillation. 2015 , 15, 21	5

2008	Oral Anticoagulant Prescription in Patients With Atrial Fibrillation and a Low Risk of Thromboembolism: Insights From the NCDR PINNACLE Registry. 2015 , 175, 1062-5		17
2007	International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation. 2015 , 15, 205-11		27
2006	Optimizing atrial fibrillation management: from ICU and beyond. 2015 , 148, 859-864		35
2005	Electrocardiographic monitoring for detecting atrial fibrillation after ischemic stroke or transient ischemic attack: systematic review and meta-analysis. 2015 , 8, 263-9		52
2004	Epidemiology, prevention, and treatment of new-onset atrial fibrillation in critically ill: a systematic review. 2015 , 3, 19		50
2003	Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1385-94	15.1	115
2002	Atrial fibrillation ablation in the era of cryoballoon and force-sensing catheters: freeze or burn?. 2015 , 17, 374		2
2001	Patients with atrial fibrillation and a CHA2DS2-VASc score of 1: are they at low or high stroke risk?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1395-7	15.1	8
2000	Digoxin use in atrial fibrillation: a critical reappraisal. 2015 , 385, 2330-2		10
1999	Misconceptions and Facts About Atrial Fibrillation. 2015 , 128, 938-42		8
1998	Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation. 2015 , 187, 345-53		10
1997	Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. 2015 , 14, 683-95		9
1996	Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis. 2015 , 88, 378-85		19
1995	HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. 2015 , 12, 1483-9		42
1994	Revolving thrombus within the left atrium at atrial fibrillation ablation. 2015 , 26, 54-5		
1993	New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials. 2015 , 13, 577-83		5
1992	A Clinical Decision Instrument for 30-Day Death After an Emergency Department Visit for Atrial Fibrillation: The Atrial Fibrillation in the Emergency Room (AFTER) Study. 2015 , 66, 658-668.e6		13
1991	Atrial Fibrillation and Cognition: Epidemiological Data and Possible Mechanisms. 2015 , 46, 3316-21		40

1990	Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment. A meta-analysis. 2015 , 40, 1070-83		15
1989	Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. 2015 , 66, 677-88		102
1988	Obesity: physiologic changes and implications for preoperative management. 2015 , 15, 97		37
1987	Edoxaban: a review in nonvalvular atrial fibrillation. 2015 , 15, 351-61		4
1986	Comparison Between the 2007 and 2014 American College of Cardiology/American Heart Association Guidelines on Perioperative Evaluation for Noncardiac Surgery. 2015 , 29, 1639-50		2
1985	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. 2015 , 17, 64		1
1984	Differences in Quality of Life Between Atrial Fibrillation Patients with Low Stroke Risk Treated With and Without Catheter Ablation. 2015 , 4, e002130		12
1983	Cardiac risk of noncardiac surgery. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2140-2148	15.1	31
1982	HRS/NSA 2014 Survey of Atrial Fibrillation and Stroke: Gaps in Knowledge and Perspective, Opportunities for Improvement. 2015 , 24, 1691-700		23
1981	Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation. 2015 , 24, 2845-53		5
1980	European Resuscitation Council Guidelines for Resuscitation 2015: Section 3. Adult advanced life support. 2015 , 95, 100-47		896
1979	Clinical development of rivaroxaban: emerging new clinical evidences?. 2015 , 11, 565-83		
1978	Asymptomatic Atrial Fibrillation: The Case for Screening to Prevent Stroke. 2015 , 314, 1911-2		32
1977	Fibrillation atriale pfiopfatoire : facteurs de risque et conduite ^tenir (podcast). 2015 , 19, 178-185		
1976	Clinical Prediction Models for Cardiovascular Disease: Tufts Predictive Analytics and Comparative Effectiveness Clinical Prediction Model Database. 2015 , 8, 368-75		58
1975	Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. 2015 , 63, 71-6		62
1974	Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1851-9	15.1	116
1973	The Genetic Basis of Coronary Artery Disease and Atrial Fibrillation: A Search for Disease Mechanisms and Therapeutic Targets. 2015 , 29, 1328-32		5

1972	The Long-Term Use of Warfarin Among Atrial Fibrillation Patients Discharged From an Emergency Department With a Warfarin Prescription. 2015 , 66, 347-354.e2	27
1971	Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation: a cohort study. 2015 , 13, 1971-9	28
1970	Medical and Invasive Management of Coronary Artery Disease in Patients on Anticoagulants. 2015 , 163-174	
1969	Automatically finding relevant citations for clinical guideline development. 2015 , 57, 436-45	7
1968	Cardiac computed tomography in current cardiology guidelines. 2015 , 9, 514-23	64
1967	Stroke Risk Factors Beyond the CHA ₂ DS ₂ -VASc Score: Can We Improve Our Identification of "High Stroke Risk" Patients With Atrial Fibrillation?. 2015 , 116, 1781-8	47
1966	Thirty-day mortality in ED patients with new onset atrial fibrillation and actively treated cancer. 2015 , 33, 1483-8	12
1965	Assessment of the CHA ₂ DS ₂ -VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. 2015 , 314, 1030-8	192
1964	Stroke: advances in medical therapy and acute stroke intervention. 2015 , 17, 79	10
1963	No Benefit of Complex Fractionated Atrial Electrogram Ablation in Addition to Circumferential Pulmonary Vein Ablation and Linear Ablation: Benefit of Complex Ablation Study. 2015 , 8, 1316-24	67
1962	Task Force 6: Pediatric Cardiology Fellowship Training in Adult Congenital Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 723-31	15.1 4
1961	Increasing incidence of non-valvular atrial fibrillation in the UK from 2001 to 2013. 2015 , 101, 1748-54	35
1960	Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients. 2015 , 4,	21
1959	Significant Association Between CAV1 Variant rs3807989 on 7p31 and Atrial Fibrillation in a Chinese Han Population. 2015 , 4,	21
1958	Bridging Anticoagulation: Primum Non Nocere. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1392-403	15.1 94
1957	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. 2015 , 351, h4451	172
1956	Dosing of rivaroxaban by indication: getting the right dose for the patient. 2015 , 11, 1665-77	2
1955	Consider safety when managing co-morbid conditions in heart failure patients. 2015 , 31, 397-401	

1954	Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients. 2015 , 20, 573-8		9
1953	Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study. 2015 , 170, 1033-1041.e1		9
1952	Vagal atrial fibrillation: What is it and should we treat it?. 2015 , 201, 415-21		36
1951	Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based Study From the Netherlands. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1000-7	15.1	153
1950	Rate-control treatment and mortality in atrial fibrillation. 2015 , 132, 1604-12		90
1949	Management of device-detected atrial high-rate episodes. 2015 , 7, 515-25		7
1948	Utility of Routine Exercise Testing to Detect Rate-Related QRS Widening in Patients Without Structural Heart Disease on Class Ic Antiarrhythmic Agents (Flecainide and Propafenone). 2015 , 116, 730-2		8
1947	Catheter Ablation of Atrial Fibrillation: Advent of Second-Generation Technologies. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1361-3	15.1	5
1946	Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. 2015 , 16, 2661-78		2
1945	Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2271-2281	15.1	127
1944	Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. 2015 , 4,		38
1943	Major publications in the critical care pharmacotherapy literature: January-December 2014. 2015 , 72, 1974-85		4
1942	Antiarrhythmic drug use in patients . 2015 , 115, 316-22		18
1941	Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. 2015 , 49, 278-84		46
1940	Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. 2015 , 12, e5-e29		64
1939	Ablation of atrial fibrillation. 2015 , 25, 409-19		8
1938	Association of epicardial and peri-atrial adiposity with the presence and severity of non-valvular atrial fibrillation. 2015 , 31, 649-57		31
1937	Effect of obstructive sleep apnea on frequency of stroke in patients with atrial fibrillation. 2015 , 115, 461-5		64

1936	Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation. 2015 , 39, 129-38	2
1935	Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. 2015 , 180, 1-5	30
1934	Mechanisms of new-onset atrial fibrillation complicating acute coronary syndrome. 2015 , 40 Suppl 1, 18-26	17
1933	Validation of the Risk Estimator Decision Aid for Atrial Fibrillation (RED-AF) for predicting 30-day adverse events in emergency department patients with atrial fibrillation. 2015 , 65, 13-21.e3	15
1932	The Educational Needs of Clinicians Regarding Anticoagulation Therapy for Prevention of Thromboembolism and Stroke in Patients With Atrial Fibrillation. 2016 , 31, 38-46	6
1931	Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation. 2016 , 12, 443-449	
1930	Olmесartan Reduces New-onset Atrial Fibrillation and Atrial Fibrillation Burden after Dual-chamber Pacemaker Implantation in Atrioventricular Block Patients. 2016 , 129, 2143-8	1
1929	Perioperative use for cardiac surgery may increase kidney injury risk. 2016 , 22, 10	
1928	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. 2016 , 115, 257-70	11
1927	Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin. 2016 , 57, 342-9	11
1926	Interplay between Clinical Guidelines and Organizational Workflow Systems. Experience from the MobiGuide Project. 2016 , 55, 488-494	7
1925	Risk impact of edoxaban in the management of stroke and venous thromboembolism. 2016 , 12, 329-35	2
1924	Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility. 2016 , 9, 309-16	1
1923	THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE. 2016 , 12, 220-226	1
1922	Prevalence and Spectrum of TBX5 Mutation in Patients with Lone Atrial Fibrillation. 2016 , 13, 60-7	13
1921	Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation. 2016 , 10, 677-86	14
1920	Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease. 2016 , 10, 110-6	5
1919	Functional Role and Mechanism of microRNA-28b in Atrial Myocyte in a Persistent Atrial Fibrillation Rat Model. 2016 , 22, 3073-8	4

1918	Dabigatran treatment simulation in patients undergoing maintenance haemodialysis. 2016 , 115, 562-9	8
1917	Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries. 2016 , 22, 281-92	23
1916	Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure?. 2016 , 2, 35-39	7
1915	Individualising Anticoagulant Therapy in Atrial Fibrillation Patients. 2016 , 5, 102-9	4
1914	Five years of keeping a watch on the left atrial appendage-how has the WATCHMAN fared?. 2016 , 8, E1726-E1733	6
1913	Vitamin C for the Prevention of Postoperative Atrial Fibrillation after Cardiac Surgery: A Meta-Analysis. 2016 , 6, 243-50	18
1912	Atrial fibrillation: review of current treatment strategies. 2016 , 8, E886-E900	35
1911	The statin therapy to prevent atrial fibrillation after cardiac surgery: Shakespearean dilemma. 2016 , 8, 2986-2990	3
1910	Update on Atrial Fibrillation. 2016 , 43, 412-414	1
1909	Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians. 2016 , 2016, 1781684	17
1908	Evaluating the Primary Prevention of Ischemic Stroke of Oral Antithrombotic Therapy in Head and Neck Cancer Patients with Radiation Therapy. 2016 , 2016, 6205158	3
1907	Utilization and Predictors of Electrical Cardioversion in Patients Hospitalized for Atrial Fibrillation. 2016 , 2016, 8956020	9
1906	Sanguineous Pericardial Effusion and Cardiac Tamponade in the Setting of Graves' Disease: Report of a Case and Review of Previously Reported Cases. 2016 , 2016, 9653412	1
1905	Cerebrovascular Accident due to Thyroid Storm: Should We Anticoagulate?. 2016 , 2016, 5218985	1
1904	Uso de los anticoagulantes orales directos en la práctica clínica. 2016 , 64, 295	1
1903	Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAf) in the US. 2016 , 8, 215-26	13
1902	Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation. 2016 , 22, 1319-1329	46
1901	MMP9 Rs3918242 Polymorphism Affects Tachycardia-Induced MMP9 Expression in Cultured Atrial-Derived Myocytes but Is Not a Risk Factor for Atrial Fibrillation among the Taiwanese. 2016 , 17, 521	6

1900	Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. 2016 , 115, 622-31	21
1899	Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. 2016 , 115, 184-92	17
1898	Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. 2016 , 11, e0147245	20
1897	Simulation of Daily Snapshot Rhythm Monitoring to Identify Atrial Fibrillation in Continuously Monitored Patients with Stroke Risk Factors. 2016 , 11, e0148914	16
1896	Efficacy of Short-Term Antiarrhythmic Drugs Use after Catheter Ablation of Atrial Fibrillation-A Systematic Review with Meta-Analyses and Trial Sequential Analyses of Randomized Controlled Trials. 2016 , 11, e0156121	9
1895	Determinants and Time Trends for Ischaemic and Haemorrhagic Stroke in a Large Chinese Population. 2016 , 11, e0163171	2
1894	Fatores relacionados ^ flebite em idosos com infusã intravenosa de amiodarona. 2016 , 29, 260-266	6
1893	Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature. 2016 , 115, 663-77	43
1892	Periinterventionelle Antikoagulation bei der Vorhofflimmerablation. 2016 , 12, 233-236	
1891	Which components of the CHA2DS2-VASc score are the most important in obstructive sleep apnea patients with atrial fibrillation?. 2016 , 27, 347-51	2
1890	The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate. 2016 , 27, 389-95	7
1889	Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. 2016 , 179, 59-68	29
1888	Clinical pre-test of a computerised antithrombotic risk assessment tool for stroke prevention in atrial fibrillation patients: giving consideration to NOACs. 2016 , 22, 892-898	3
1887	New-onset atrial fibrillation. 2016 , 46, 29-30	
1886	Electrical PR Interval Variation Predicts New Occurrence of Atrial Fibrillation in Patients With Frequent Premature Atrial Contractions. 2016 , 95, e3249	11
1885	Investigating relationships between left atrial volume, symmetry, and sphericity. 2016 ,	
1884	Minimally Invasive Atrial Fibrillation Surgery: Hybrid Approach. 2016 , 12, 37-40	2
1883	Long-term events following atrial fibrillation rate control or transcatheter ablation: a multicenter observational study. 2016 , 17, 187-93	17

1882	False Prolongation of Prothrombin Time in the Presence of a High Blood Concentration of Daptomycin. 2016 , 119, 353-9		4
1881	Audit of the use of anticoagulation for atrial fibrillation in hemodialysis patients. 2016 , 20, 327-8		
1880	Catheter Ablation for "Lone" Atrial Fibrillation: Efficacy and Predictors of Recurrence. 2016 , 27, 536-41		5
1879	Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation. 2016 , 27, 899-906		2
1878	Association of Increased Epicardial Adipose Tissue Thickness With Adverse Cardiovascular Outcomes in Patients With Atrial Fibrillation. 2016 , 95, e2874		25
1877	Digoxin Use and Adverse Outcomes in Patients With Atrial Fibrillation. 2016 , 95, e2949		14
1876	How to manage patients on rivaroxaban in the emergency department: a statement of the Italian society of emergency medicine advisory board. 2016 , 23, 320-9		2
1875	Cryoablation in persistent atrial fibrillation - a critical appraisal. 2016 , 24, 498-507		2
1874	Comparing Measurements of CT Angiography, TEE, and Fluoroscopy of the Left Atrial Appendage for Percutaneous Closure. 2016 , 27, 414-22		50
1873	Long-Term Outcome of Catheter Ablation for Atrial Fibrillation in Patients With Apical Hypertrophic Cardiomyopathy. 2016 , 27, 788-95		8
1872	Paroxysmal atrial fibrillation and related thromboembolism may be a hidden factor in the development of dementia. 2016 , 16, 382-383		1
1871	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 525-568	15.1	38
1870	Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample. 2016 , 16, 2684-94		87
1869	Intermittent drivers anchoring to structural heterogeneities as a major pathophysiological mechanism of human persistent atrial fibrillation. 2016 , 594, 2387-98		86
1868	Ischemic Stroke or Systemic Embolism After Transeptal Ablation of Arrhythmias in Patients With Cardiac Implantable Electronic Devices. 2016 , 5, e003163		5
1867	Selective downregulation of mitochondrial electron transport chain activity and increased oxidative stress in human atrial fibrillation. 2016 , 311, H54-63		24
1866	Circulating Biomarkers Predictive of Postoperative Atrial Fibrillation. 2016 , 24, 76-87		25
1865	Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. 2016 , 13, 549-59		59

1864	Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. 2016 , 37, 3515-3522	218
1863	Using bispectral index monitoring to gauge depth of sedation/analgesia. 2016 , 46, 60-3	3
1862	Validation of a Novel Digital Tool in Automatic Scoring of an Online ECG Examination at an International Cardiology Meeting. 2016 , 21, 376-81	1
1861	Atrial Fibrillation Ablation: Indications, New Advances, and Complications. 2016 , 1, 165-168	
1860	The Optimal Duration of Dual Antiplatelet Therapy After PCI. 2016 , 436-442	
1859	Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants After PCI. 2016 , 443-452	
1858	Left Atrial Appendage Exclusion. 2016 , 525-529	
1857	Management of Atrial Fibrillation in Athletes. 2016 , 406-414	
1856	The cardiac consult for patients undergoing non-cardiac surgery. 2016 , 102, 1322-32	1
1855	Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. 2016 , 5,	12
1854	Anticoagulation Therapy and NOACs in Heart Failure. 2017 , 243, 515-535	4
1853	Detection of the propagating direction of electrical wavefront in atrial fibrillation. 2016 , 2016, 2749-2752	0
1852	Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. 2016 , 102, 1533-43	60
1851	Idiopathic Atrial Fibrillation and Coronary Arteriovenous Fistulae: Is There a Link. 2016 , 134, 433-5	1
1850	CHA2DS2-VASc score, left atrial size and atrial fibrillation as stroke risk factors in the Tromsø Study. 2016 , 3, e000439	14
1849	Expression of connexin 43, ion channels and Ca-handling proteins in rat pulmonary vein cardiomyocytes. 2016 , 12, 3233-3241	5
1848	Spectral Analysis of Baseline Electrocardiogram During Atrial Fibrillation Predicts Response to Antiarrhythmic Drug Therapy in Patients With Persistent Atrial Fibrillation. 2016 , 27, 1312-1318	1
1847	Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. 2016 , 6, 30271	35

1846	How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?. 2016 , 18, I1-I6	1
1845	Feasibility Study on Cardiac Arrhythmia Ablation Using High-Energy Heavy Ion Beams. 2016 , 6, 38895	67
1844	Rotor pivot point identification with intrinsic mode function complexity index using empirical mode decomposition. 2016 ,	1
1843	Diagnosis and management of heart disease in the elderly. 2016 , 157-186	
1842	Surgeon's guide to anticoagulant and antiplatelet medications part two: antiplatelet agents and perioperative management of long-term anticoagulation. 2016 , 1, e000022	17
1841	Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial. 2016 , 16, 113	14
1840	Increased risk of atrial fibrillation in end-stage renal disease patients on dialysis: A nationwide, population-based study in Taiwan. 2016 , 95, e3933	24
1839	Cardiovascular complications in chronic dialysis patients. 2016 , 25, 536-544	22
1838	Mecanismos electrofisiológicos y diagnóstico de la fibrilación auricular. 2016 , 16, 12-19	
1837	Dose-dependent pulmonary vein reconnection in response to adenosine: relevance of atrioventricular block during infusion. 2016 , 47, 117-123	11
1836	Fibrilación auricular de aparición reciente: ¿Cuáles su importancia?. 2016 , 33, 16-21	
1835	Uso de monitorización del índice bispectral para medir la profundidad de la sedación/analgesia. 2016 , 33, 38-41	
1834	Anticoagulantes orales directos para el tratamiento de los pacientes con fibrilación auricular no valvular. 2016 , 23, 82-88	1
1833	Utilidad de los catéteres con sensor de fuerza de contacto en la ablación de la fibrilación auricular. 2016 , 23, 159-164	
1832	Fibrilación auricular y poblaciones especiales. 2016 , 23, 178-185	
1831	Tratamiento no farmacológico de la fibrilación auricular. Ablación, cardioversión eléctrica, marcapasos y cierre de la orejuela. 2016 , 16, 40-46	
1830	Challenging Achievement of Bidirectional Block After Linear Ablation Affects the Rhythm Outcome in Patients With Persistent Atrial Fibrillation. 2016 , 5,	30
1829	Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry. 2016 , 2, 299-305	23

1828	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. 2016 , 6, 24376	40
1827	Photoplethysmography-Based System for Atrial Fibrillation Detection During Hemodialysis. 2016 , 79-82	3
1826	A clustered randomized trial to IMPROVE treatment with AntiCoagulantTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. 2016 , 176, 107-13	7
1825	Impact of Diastolic Function Parameters on the Risk for Left Atrial Appendage Thrombus in Patients with Nonvalvular Atrial Fibrillation: A Prospective Study. 2016 , 29, 545-53	30
1824	Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis. 2016 , 47, 1364-7	60
1823	Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation: Meta-Analysis of Quality of Life, Morbidity, and Mortality. 2016 , 2, 170-180	25
1822	Prevalence of Left Atrial Thrombus Detection by Transesophageal Echocardiography: A Comparison of Continuous Non-Vitamin K Antagonist Oral Anticoagulant Versus Warfarin Therapy in Patients Undergoing Catheter Ablation for Atrial Fibrillation. 2016 , 2, 295-303	38
1821	Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view. 2016 , 19, 769-76	12
1820	Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. 2016 , 76, 200-8	16
1819	Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation. 2016 , 781, 250-7	15
1818	A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized trial. 2016 , 54, 157-164	2
1817	Focal-, Circular-, or Balloon-Based Atrial Fibrillation Ablation: How to Interpret the Data in a Rapidly Developing Field?. 2016 , 2, 391-392	
1816	Analysis of the process of representing clinical statements for decision-support applications: a comparison of openEHR archetypes and HL7 virtual medical record. 2016 , 40, 163	10
1815	Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?. 2016 , 47, 1831-6	47
1814	Physician and Patient Preferences for Nonvalvular Atrial Fibrillation Therapies. 2016 , 19, 451-9	11
1813	Triple terapia antitrombótica en práctica real: utilidad pronóstica de la escala HAS-BLED. 2016 , 23, 155-156	
1812	Invasive treatment of atrial fibrillation. 2016 , 31, 366-73	1
1811	Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF Trial. 2016 , 178, 102-7	29

1810	A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras. 2016 , 33, 427-36		24
1809	Multimorbidity in Older Adults with Atrial Fibrillation. 2016 , 32, 315-29		13
1808	SCAI/ACC/HRS Institutional and Operator Requirements for Left Atrial Appendage Occlusion. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2295-2305	15.1	12
1807	Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation. 2016 , 42, 196-204		14
1806	Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. 2016 , 129, 1110-6		17
1805	Is Less More for the Treatment of Atrial Fibrillation after Cardiac Surgery?. 2016 , 374, 1977-8		2
1804	Atrial Fibrillation Is Associated With a Worse 90-Day Outcome Than Other Cardioembolic Stroke Subtypes. 2016 , 47, 1486-92		38
1803	Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. 2016 , 149, 960-8		43
1802	Gender, Race, and Health Insurance Status in Patients Undergoing Catheter Ablation for Atrial Fibrillation. 2016 , 117, 1117-26		50
1801	Practice Variation in Patients Eligible for Triple Therapy: Designing Systems to Assess Risk and Tailor Treatment. 2016 , 2, 44-46		
1800	Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. 2016 , 217, 85-91		27
1799	Safety of antithrombotic drugs in patients with atrial fibrillation and non-end-stage chronic kidney disease: Meta-analysis and systematic review. 2016 , 137, 46-52		16
1798	Cryo-Balloon Catheter Localization Based on a Support-Vector-Machine Approach. 2016 , 35, 1892-902		4
1797	Is there still a role for additional linear ablation in addition to pulmonary vein isolation in patients with paroxysmal atrial fibrillation? An Updated Meta-analysis of randomized controlled trials. 2016 , 209, 266-74		8
1796	Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? The CHA2 DS2-VASc 1 Conundrum: Decision Making at the Lower End of the Risk Spectrum. 2016 , 133, 1504-11; discussion 1511		13
1795	Knowledge Gaps in Cardiovascular Care of the Older Adult Population: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Geriatrics Society. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2419-2440	15.1	95
1794	Pre-Procedural Serum Atrial Natriuretic Peptide Levels Predict Left Atrial Reverse Remodeling After Catheter Ablation in Patients With Atrial Fibrillation. 2016 , 2, 151-158		8
1793	Impact on Outcomes of Changing Treatment Guideline Recommendations for Stroke Prevention in Atrial Fibrillation: A Nationwide Cohort Study. 2016 , 91, 567-74		23

1792	Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset. 2016 , 2, 487-494	21
1791	Digoxin Toxicity and Use of Digoxin Immune Fab: Insights From a National Hospital Database. 2016 , 4, 357-64	25
1790	Left atrial thrombi and spontaneous echo contrast in patients with atrial fibrillation : Systematic analysis of a single-center experience. 2016 , 41, 706-714	9
1789	Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. 2016 , 47, 1555-61	37
1788	Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study. 2016 , 129, 843-9	75
1787	Dronedarone: Basic Pharmacology and Clinical Use. 2016 , 8, 453-65	10
1786	Contact force sensing during atrial fibrillation ablation: clinical experience and effects on outcomes. 2016 , 14, 749-59	6
1785	Atrial Fibrillation Genetics: Is There a Practical Clinical Value Now or in the Future?. 2016 , 32, 1300-1305	27
1784	Perioperative Rosuvastatin in Cardiac Surgery. 2016 , 374, 1744-53	186
1783	SCAI/ACC/HRS institutional and operator requirements for left atrial appendage occlusion. 2016 , 13, e241-e250	2
1782	Results of Cryoablation for Atrial Fibrillation Concomitant With Video-Assisted Minimally Invasive Mitral Valve Surgery. 2016 , 28, 271-280	6
1781	The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion. 2016 , 217, 42-8	4
1780	Patient Activity Decreases and Mortality Increases After the Onset of Persistent Atrial Fibrillation in Patients With Implantable Cardioverter-Defibrillators. 2016 , 2, 518-523	10
1779	Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization. 2016 , 168, 126-142	21
1778	DIAGNOSIS OF MULTICLASS TACHYCARDIA BEATS USING RECURRENCE QUANTIFICATION ANALYSIS AND ENSEMBLE CLASSIFIERS. 2016 , 16, 1640005	46
1777	Evaluation of the association between diabetic retinopathy and the incidence of atrial fibrillation: A nationwide population-based study. 2016 , 223, 953-957	49
1776	Rhythm Control and Its Relation to Symptoms during the First Two Years after Radiofrequency Ablation for Atrial Fibrillation. 2016 , 39, 914-25	7
1775	Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System. 2016 , 179, 186-91	5

- 1774 Short-term amiodarone treatment for atrial fibrillation after catheter ablation induces a transient thyroid dysfunction: Results from the placebo-controlled, randomized AMIO-CAT trial. **2016**, 33, 36-41 8
- 1773 Persistent left atrial thrombus on treatment with rivaroxaban and subsequent resolution after warfarin therapy. **2016**, 46, 855-6 3
- 1772 Low-Dose Aspirin in the Cardiovascular System. **2016**, 133-142
- 1771 Performance of an Implantable Cardiac Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. **2016**, 27, 1403-1410 38
- 1770 Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders. **2016**, 175, 359-364 21
- 1769 Acute coronary syndromes and atrial fibrillation. **2016**, 57, 141-2 6
- 1768 Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. **2016**, 69, 939.e1-939.e87 10
- 1767 New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. **2016**, 39, 739-746 10
- 1766 Pathophysiology of Atrial Fibrillation and Clinical Correlations. **2016**, 19-26
- 1765 Anticoagulation for Atrial Fibrillation in the Emergency Department or Observation Unit. **2016**, 87-100
- 1764 Assessing Intracardiac Thrombus Before Atrial Fibrillation Ablation: Challenges Faced After Testing. **2016**, 2, 304-306
- 1763 Técnicas de imagen en el intervencionismo percutáneo estructural: cierre de comunicación interauricular y oclusión de la orejuela izquierda. **2016**, 69, 766-777 8
- 1762 Cost Effectiveness of Implantable Cardiac Monitor-Guided Intermittent Anticoagulation for Atrial Fibrillation: An Analysis of the REACT.COM Pilot Study. **2016**, 27, 1304-1311 8
- 1761 Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. **2016**, 20, 273 16
- 1760 Patient factors associated with quality of life in atrial fibrillation. **2016**, 182, 135-143 32
- 1759 Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. **2016**, 30, 1019-34 7
- 1758 Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. **2016**, 18, 65 6
- 1757 Nonsustained Atrial Fibrillation in Ischemic Stroke Patients and Stroke-Free Controls From the Perspective of Stroke Pathophysiology. **2016**, 5, 5

1756 Too Fast for Comfort: Tachycardia in Postablation Wolff-Parkinson-White. **2016**, 129, e269-e272

1755 [Not Available]. **2016**, 48 Suppl 1, 4-26

5

1754 Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. **2016**, 150, 1302-1312

165

1753 Knowledge Gaps in Cardiovascular Care of Older Adults: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society: Executive Summary. **2016**, 64, 2185-2192

37

1752 New oral anticoagulants versus Warfarin in patients undergoing cardioversion of atrial fibrillation. **2016**, 225, 244-246

4

1751 Repeat procedures after second-generation cryoballoon ablation as an index procedure for persistent atrial fibrillation: one-year follow-up. **2016**, 47, 365-371

2

1750 New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban. **2016**, 225, 154-158

1749 Association of Left Atrial Function Index With Late Atrial Fibrillation Recurrence after Catheter Ablation. **2016**, 27, 1411-1419

10

1748 [Platelet aggregation inhibitors and anticoagulants during ophthalmic interventions]. **2016**, 113, 1010-1022

2

1747 A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome. **2016**, 4, 107-118

10

1746 Inadequate stroke prevention in Korean atrial fibrillation patients in the post-warfarin era. **2016**, 220, 647-52

15

1745 Outpatient Medications in Atrial Fibrillation. **2016**, 195-217

1744 Reversal agents for direct oral anticoagulants: A focused review. **2016**, 223, 244-250

9

1743 Short Stay Management of Atrial Fibrillation. **2016**,

1

1742 Atrial fibrillation and chronic kidney disease requiring hemodialysis - Does warfarin therapy improve the risks of this lethal combination?. **2016**, 222, 47-50

18

1741 Stroke Prediction in Atrial Fibrillation: Is it Black and White?. *Journal of the American College of Cardiology*, **2016**, 68, 471-472

15.1 1

1740 Association of Physical Fitness With the Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis. **2016**, 39, 421-8

17

1739 Initial 3-year outcomes with left ventricular assist devices in a country with a nascent heart transplantation program. **2016**, 3, 26-34

12

- 1738 Impact of Warfarin on Atrial-Fibrillation Outcomes Related to Economic Consumption Patterns: Hospitalization, Cost, and Mortality may be Predictable and Modifiable at the Population Level. **2016**, 33, 1579-99
- 1737 Anesthesia and Transesophageal Echocardiography for WATCHMAN Device Implantation. **2016**, 30, 1685-1692 10
- 1736 Efficacy and Safety of Atrial Fibrillation Ablation Using Remote Magnetic Navigation: Experience from 1,006 Procedures. **2016**, 27 Suppl 1, S23-8 12
- 1735 Comparison of Radiofrequency Catheter Ablation Between Asymptomatic and Symptomatic Persistent Atrial Fibrillation: A Propensity Score Matched Analysis. **2016**, 27, 531-5 18
- 1734 Novel oral anticoagulant management issues for the stroke clinician. **2016**, 11, 759-67 4
- 1733 Underuse of anticoagulation in stroke patients with atrial fibrillation--the FibStroke Study. **2016**, 23, 133-9 26
- 1732 Meta-Analysis of Efficacy and Safety of Apixaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation. **2016**, 39, 54-9 9
- 1731 Atrial Fibrillation and Atrial Flutter in Pregnant Women-A Population-Based Study. **2016**, 5, e003182 27
- 1730 NSAIDs and Aspirin. **2016**, 4
- 1729 The impact of advanced Interatrial block on new-onset atrial fibrillation following TAVR procedure. **2016**, 223, 672-673 15
- 1728 Predictors of significant coronary artery disease in atrial fibrillation: Are cardiac troponins a useful measure. **2016**, 223, 744-749 13
- 1727 Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. **2016**, 33, 555-564 58
- 1726 Atrial fibrillation, liver disease, antithrombotics and risk of cerebrovascular events: A population-based cohort study. **2016**, 223, 829-837 13
- 1725 Gerontechnologies for Older Patients with Heart Failure: What is the Role of Smartphones, Tablets, and Remote Monitoring Devices in Improving Symptom Monitoring and Self-Care Management?. **2016**, 10, 1 17
- 1724 Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation: Outcomes From a Controlled Nonrandomized Study. **2016**, 9, 15
- 1723 A Fresh Perspective on Atrial Fibrillation. *Journal of the American College of Cardiology*, **2016**, 68, 905-7 15.1
- 1722 Contact-Force Catheters: Efficacy Versus Safety? Case Report of 2 Atrioesophageal Fistulae. **2016**, 27, 1483-1487 6
- 1721 Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants. **2016**, 64, 1996-2002 21

1720	Can Big Data Simplify the Complexity of Modern Medicine?: Prediction of Right Ventricular Failure After Left Ventricular Assist Device Support as a Test Case. 2016 , 4, 722-5	5
1719	Rate control in atrial fibrillation. 2016 , 388, 818-28	88
1718	Rhythm control in atrial fibrillation. 2016 , 388, 829-40	83
1717	Characteristics and Outcomes of Concurrently Diagnosed New Rapid Atrial Fibrillation or Flutter and New Reduced Ejection Fraction. 2016 , 39, 1394-1403	8
1716	Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. 2016 , 80, 605-12	3
1715	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. 2016 , 5,	14
1714	Effects of Triple Therapy in Patients With Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Regarding Thromboembolic Risk Stratification. 2016 , 80, 354-62	17
1713	Safety and Efficacy of Cryoballoon Ablation for Paroxysmal Atrial Fibrillation in Japan - Results From the Japanese Prospective Post-Market Surveillance Study. 2016 , 80, 1744-9	25
1712	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. 2016 , 181, 92-100	17
1711	Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. 2016 , 47, 2462-9	55
1710	Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis. 2016 , 36, e166-e171	14
1709	Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding. 2016 , 151, 1105-1112.e10	48
1708	Increased Susceptibility to Atrial Fibrillation Secondary to Atrial Fibrosis in Transgenic Goats Expressing Transforming Growth Factor- β . 2016 , 27, 1220-1229	29
1707	Association of platelet-to-lymphocyte ratio with silent brain infarcts in patients with paroxysmal atrial fibrillation. 2016 , 38, 753-8	10
1706	Imaging Techniques in Percutaneous Cardiac Structural Interventions: Atrial Septal Defect Closure and Left Atrial Appendage Occlusion. 2016 , 69, 766-77	0
1705	Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. 2016 , 9, 1473-83	20
1704	Cryoballoon versus Radiofrequency Catheter Ablation in Atrial Fibrillation: A Meta-Analysis. 2016 , 27, 1151-1159	62
1703	Refining Stroke Prediction in Atrial Fibrillation Patients by Addition of African-American Ethnicity to CHA2DS2-VASc Score. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 461-470	15.1 42

1702	Left Atrial Sphericity Index Predicts Early Recurrence of Atrial Fibrillation After Direct-Current Cardioversion: An Echocardiographic Study. 2016 , 39, 406-12		14
1701	High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. 2016 , 42, 558-65		1
1700	Cardiovascular Critical Care: Therapeutic Hypothermia, Atrial Fibrillation, and Cardiopulmonary Resuscitation. 2016 , 194, 762-4		3
1699	Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation. 2016 , 41, 667-676		10
1698	Delayed recurrence of atrial fibrillation 2years after catheter ablation is associated with metabolic syndrome. 2016 , 223, 276-281		15
1697	The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1898-1907	15.1	53
1696	Impacto y riesgos del tratamiento con antiarrítmicos en el control de la fibrilaci3n auricular. 2016 , 23, 118-125		
1695	Automated detection of atrial fibrillation episode using novel heart rate variability features. 2016 , 2016, 3461-3464		9
1694	Mechanistically based mapping of human cardiac fibrillation. 2016 , 594, 2399-415		28
1693	Postoperative Arrhythmias: Diagnosis and Management. 2016 , 295-315		
1692	Prevenci3n primaria en fibrilaci3n auricular. 2016 , 23, 186-191		
1691	Left Atrial Appendage Isolation in Patients With Longstanding Persistent AF Undergoing Catheter Ablation: BELIEF Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1929-1940	15.1	213
1690	Derivation and validation of E/e' ratio as a parameter in the evaluation of left atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation. 2016 , 32, 1349-1356		6
1689	The rs6771157 C/G polymorphism in SCN10A is associated with the risk of atrial fibrillation in a Chinese Han population. 2016 , 6, 35212		1
1688	New perspectives on atrial fibrillation and stroke. 2016 , 102, 1788-1792		17
1687	Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. 2016 , 13, 319-328		17
1686	The State of the Art: Atrial Fibrillation Epidemiology, Prevention, and Treatment. 2016 , 91, 1778-1810		82
1685	Sex Effect in Atrial Fibrillation: Is It All About Atrial Function?. 2016 , 9,		1

1684	Clinical Implications of Brief Device-Detected Atrial Tachyarrhythmias in a Cardiac Rhythm Management Device Population: Results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes. 2016 , 134, 1130-1140	98
1683	Blending Quality Improvement and Research Methods for Implementation Science, Part III: Analysis of the Effectiveness of Implementation. 2016 , 27, 103-10	2
1682	Atrial fibrillation. 2016 , 2, 16016	115
1681	PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1881-1894	15.1 50
1680	Cognitive decline in patients with atrial fibrillation: can we do something about it?. 2016 , 45, 749-751	
1679	Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation. 2016 , 224, 252-255	19
1678	Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis. 2015 , 5, 17731	5
1677	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. 2016 , 6, 27410	48
1676	Up-regulation of miR-31 in human atrial fibrillation begets the arrhythmia by depleting dystrophin and neuronal nitric oxide synthase. 2016 , 8, 340ra74	49
1675	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. 2016 , 9,	73
1674	Left atrial posterior wall isolation: the icing on the cake. 2016 , 46, 199-201	6
1673	Brain embolism. 2016 , 15-18	
1672	Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. 2016 , 115, 1056-63	27
1671	Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. 2016 , 116, 975-986	190
1670	Role of Novel Oral Anticoagulants in the Treatment of Antiphospholipid Syndrome. 2016 , 51, 759-767	6
1669	Use of Aspirin and P2Y12 Response Assays in Detecting Reversal of Platelet Inhibition With Platelet Transfusion in Patients With Traumatic Brain Injury on Antiplatelet Therapy. 2017 , 80, 98-104	10
1668	Editorial 4TH issue CCE. 2016 , 2, 124-125	
1667	Invasive management of atrial fibrillation. 2016 , 2, 158-166	

1666	Atrial Electrophysiological Remodeling and Fibrillation in Heart Failure. 2016 , 10, 41-46	10
1665	Burden of upper gastrointestinal symptoms in patients prescribed dabigatran for stroke prevention. 2016 , 4, 2050312116662414	3
1664	Presence of diabetic microvascular complications does not incrementally increase risk of ischemic stroke in diabetic patients with atrial fibrillation: A nationwide cohort study. 2016 , 95, e3992	5
1663	Guideline Recommended Medical Therapy for Cardiovascular Diseases in the Obese: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program. 2016 , 5,	4
1662	Left atrial appendage closure versus oral anticoagulation for preventing stroke in people with atrial fibrillation. 2016 ,	78
1661	Cardiac Radiofrequency Ablation: A Clinical Update for Nurses. 2016 , 35, 255-67	1
1660	Comparing the clinical outcomes in patients with atrial fibrillation receiving dual antiplatelet therapy and patients receiving an addition of an anticoagulant after coronary stent implantation: A systematic review and meta-analysis of observational studies. 2016 , 95, e5581	13
1659	Thrombolytic Action of Apixaban on Intra-Atrial Thrombus Developed after Previous Treatment with Warfarin: A Case Report. 2016 , 25, 491-3	5
1658	Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies. 2016 , 88, E12-22	17
1657	Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk. 2016 , 41, 279-84	9
1656	The role of CHADS2 and CHA2 DS2 -VASc scores in the prediction of stroke in individuals without atrial fibrillation: a population-based study. 2016 , 14, 1155-62	17
1655	Two years outcome in patients with persistent atrial fibrillation after pulmonary vein isolation using the second-generation 28-mm cryoballoon. 2016 , 13, 1817-22	36
1654	Cardiac implantable electronic device lead-based masses and atrial fibrillation ablation: a case-based illustration of periprocedural anticoagulation management strategies. 2016 , 46, 237-43	4
1653	From left bundle branch block to Icelandic whales: the multiple perils of atrial fibrillation management in the elderly. 2016 , 28, 573-6	
1652	Detecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke. 2016 , 128, 620-8	3
1651	Carotid Intima-Media Thickness and Arterial Stiffness and the Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study, Multi-Ethnic Study of Atherosclerosis (MESA), and the Rotterdam Study. 2016 , 5,	51
1650	Atrial remodelling in atrial fibrillation: CaMKII as a nodal proarrhythmic signal. 2016 , 109, 542-57	35
1649	Sedation in the Electrophysiology Laboratory: A Multidisciplinary Review. 2016 , 5,	28

1648	Aspirin in Atrial Fibrillation: The Clot Thickens. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2924-6	15.1	2
1647	New-onset atrial fibrillation: What's the significance?. 2016 , 46, 24-9; quiz 29-30		3
1646	Defining nonvalvular atrial fibrillation: A quest for clarification. 2016 , 178, 161-7		15
1645	Short-term Antiarrhythmic Drugs After Catheter Ablation for Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. 2016 , 50, 697-705		2
1644	How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?. 2016 , 118, 697-9		9
1643	Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study. 2016 , 1, 433-41		72
1642	The Role of Platelet-Derived Growth Factor-B/Platelet-Derived Growth Factor Receptor- β Signaling in Chronic Atrial Fibrillation. 2016 , 133, 242-56		6
1641	Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. 2016 , 178, 74-84		32
1640	The role of catheter ablation in the management of atrial fibrillation. 2016 , 16, 267-71		2
1639	The importance of catheter stability evaluated by Visitag(TM) during pulmonary vein isolation. 2016 , 46, 161-6		10
1638	Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation. 2016 , 3, 165-173		1
1637	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. 2016 , 129, 1117-1123.e2		12
1636	Effect of a Multidisciplinary Approach for the Management of Patients With Atrial Fibrillation in the Emergency Department on Hospital Admission Rate and Length of Stay. 2016 , 118, 64-71		14
1635	A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. 2016 , 178, 45-54		42
1634	Learning to Make Decisions: Are Medical Postgraduate Trainees Getting With the Atrial Fibrillation Guidelines?. 2016 , 32, 714-6		
1633	Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation. 2016 , 32, 1355.e9-1355.e14		15
1632	Network analysis of human diseases using Korean nationwide claims data. 2016 , 61, 276-82		6
1631	Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. 2016 , 37, 2455-64		27

1630	Percutaneous closure of left atrial appendage for stroke prevention. 2016 , 58, e250-e260	1
1629	Multiple atrial thrombi in a neonate presenting with supraventricular tachycardia. 2016 , 2, 71-73	1
1628	Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. 2016 , 13, 5	12
1627	Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. 2016 , 14, 14	27
1626	Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals' views. 2016 , 38, 985-95	5
1625	Clinical pearls in perioperative medicine 2016. 2016 , 62, 231-9	
1624	Anticoagulation for Cardioversion of Acute Onset Atrial Fibrillation: Time to Revise Guidelines?. 2016 , 2, 495-497	4
1623	Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. 2016 , 5,	261
1622	Detection of LA and LAA Thrombus by CMR in Patients Referred for Pulmonary Vein Isolation. 2016 , 9, 809-818	39
1621	Perioperative Heparin Bridging in Atrial Fibrillation Patients Requiring Temporary Interruption of Anticoagulation: Evidence from Meta-analysis. 2016 , 25, 2215-21	18
1620	Targeted Anticoagulation for Atrial Fibrillation Guided by Continuous Rhythm Assessment With an Insertable Cardiac Monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study. 2016 , 27, 264-70	70
1619	Genetics of atrial fibrillation: from families to genomes. 2016 , 61, 61-70	49
1618	Left atrial appendage isolation using percutaneous (endocardial/epicardial) devices: Pre-clinical and clinical experience. 2016 , 26, 182-99	10
1617	Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. 2016 , 149, 951-9	145
1616	Colchicine for Prevention of Post-Operative Atrial Fibrillation: A Meta-Analysis. 2016 , 2, 78-85	8
1615	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. 2016 , 30, 201-14	15
1614	Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model. 2016 , 47, 895-900	305
1613	Management of Arrhythmic Patients in the Emergency Department: General Principles. 2016 , 1-17	

1612	Men's Health in Primary Care. 2016,		1
1611	Practice Patterns and Outcomes of Treatments for Atrial Fibrillation During Sepsis: A Propensity-Matched Cohort Study. 2016, 149, 74-83		45
1610	Atrial fibrillation is associated with hematopoietic tissue activation and arterial inflammation. 2016, 32, 113-9		10
1609	CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis. <i>Journal of the American College of Cardiology,</i> 2016, 67, 343-4	15.1	8
1608	A Diabetes-Atrial Fibrillation Conundrum: Does Duration Trump Glycemia?. <i>Journal of the American College of Cardiology,</i> 2016, 67, 248-50	15.1	2
1607	Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. 2016, 13, 230-7		97
1606	. 2016, 104, 416-431		19
1605	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. 2016, 129, 592-599.e1		40
1604	Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients: Three-Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. 2016, 9, e003333		101
1603	Exercise at the Extremes: The Amount of Exercise to Reduce Cardiovascular Events. <i>Journal of the American College of Cardiology,</i> 2016, 67, 316-29	15.1	154
1602	Underuse of anticoagulation in patients with atrial fibrillation. 2016, 128, 191-200		26
1601	Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation. 2016, 10, 37-49		6
1600	Direct Oral Anticoagulants for the Management of Thromboembolic Disorders: The Importance of Adherence and Persistence in Achieving Beneficial Outcomes. 2016, 22, 605-16		16
1599	Comorbidity of atrial fibrillation and heart failure. 2016, 13, 131-47		88
1598	Meta-Analysis of Oral Anticoagulants with Dual versus Single Antiplatelet Therapy in Patients after Percutaneous Coronary Intervention. 2016, 16, 103-10		7
1597	Efficacy and safety of catheter ablation vs. rate control of atrial fibrillation in systolic left ventricular dysfunction : A meta-analysis and systematic review. 2016, 41, 342-50		9
1596	Rapport de l'efficacité des traitements médicamenteux et interventionnels dans la fibrillation atriale. 2016, 8, 144-156		
1595	Ablation of Complex Fractionated Atrial Electrograms for Atrial Fibrillation Rhythm Control: A Systematic Review and Meta-analysis. 2016, 32, 791-802		8

1594	Oral Anticoagulation After Successful Atrial Fibrillation Ablation Operations: Is It Necessary?. 2016 , 101, 1471-6	9
1593	Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry. 2016 , 13, 1197-202	37
1592	The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. 2016 , 9, 273-9	60
1591	How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. 2016 , 95, 437-49	47
1590	New-onset atrial fibrillation and thromboembolic risk: Cardiovascular syzygy?. 2016 , 13, 1355-61	11
1589	Guidelines for Potassium Channel Blocker Use. 2016 , 8, 495-501	1
1588	Emerging Tools for Stroke Prevention in Atrial Fibrillation. 2016 , 4, 26-39	9
1587	Asymptomatic atrial fibrillation burden and thromboembolic events: piecing evidence together. 2016 , 14, 761-9	5
1586	SCAI/ACC/HRS institutional and operator requirements for left atrial appendage occlusion. 2016 , 87, 351-62	5
1585	Left atrial appendage morphology assessment for risk stratification of embolic stroke in patients with atrial fibrillation: A meta-analysis. 2016 , 13, 1402-9	70
1584	Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation. 2016 , 46, 213-24	3
1583	Moving Beyond Beta-Blockers and Amiodarone: The Use of Anti-Inflammatories to Treat Post-Cardiac Surgery Atrial Fibrillation. 2016 , 2, 86-88	
1582	The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. 2016 , 37, 1591-602	190
1581	Ablation for Persistent Atrial Fibrillation-Is There a Role for More Than PVI?. 2016 , 18, 15	9
1580	Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?. 2016 , 16, 183-200	52
1579	Anticoagulation in Older Adults with Multimorbidity. 2016 , 32, 331-46	10
1578	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. 2016 , 209, 181-3	30
1577	The association between influenza infection, vaccination, and atrial fibrillation: A nationwide case-control study. 2016 , 13, 1189-94	36

1576	EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. 2016 , 17, 355-83	170
1575	Is atrial fibrillation a risk factor for contrast-induced nephropathy in patients with ST-elevation myocardial infarction?. 2016 , 67, 327-30	10
1574	Management of antithrombotic therapy during cardiac implantable device surgery. 2016 , 32, 163-9	12
1573	Determinants of New-Onset Atrial Fibrillation in Patients Receiving CRT: Mechanistic Insights From Speckle Tracking Imaging. 2016 , 9, 99-111	16
1572	New Appraisal of Atrial Fibrillation Burden and Stroke Prevention. 2016 , 47, 570-6	33
1571	Atrial fibrillation management: evaluating rate vs rhythm control. 2016 , 14, 713-24	3
1570	Effect of Frailty and Age on Platelet Aggregation and Response to Aspirin in Older Patients with Atrial Fibrillation: A Pilot Study. 2016 , 5, 51-62	11
1569	Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation. 2016 , 18, 24	2
1568	Galectin-3: A potential new target for upstream therapy of atrial fibrillation. 2016 , 203, 1131-2	1
1567	Association of atrial fibrillation risk alleles and response to acute rate control therapy. 2016 , 34, 735-40	3
1566	Appropriate Use of Antithrombotic Medication in Canadian Patients With Nonvalvular Atrial Fibrillation. 2016 , 117, 1107-11	13
1565	Making better scar: Emerging approaches for modifying mechanical and electrical properties following infarction and ablation. 2016 , 120, 134-48	25
1564	Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions. 2016 , 5,	42
1563	Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). 2016 , 117, 1294-8	31
1562	Association between the N-terminal plasma brain natriuretic peptide levels or elevated left ventricular filling pressure and thromboembolic risk in patients with non-valvular atrial fibrillation. 2016 , 68, 110-6	8
1561	The atrial fibrillation conundrum in dialysis patients. 2016 , 174, 111-9	20
1560	Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. 2016 , 16, 171-82	2
1559	External prolonged electrocardiogram monitoring in unexplained syncope and palpitations: results of the SYNARR-Flash study. 2016 , 18, 1265-72	47

1558	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. 2016 , 18, 973-8	16
1557	Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. 2016 , 13, 1418-24	80
1556	Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. 2016 , 5,	232
1555	Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials. 2016 , 5,	5
1554	Association Between Left Atrial Stiffness Index and Atrial Fibrillation Recurrence in Patients Undergoing Left Atrial Ablation. 2016 , 9,	42
1553	The Stiff Left Atrium Is to Atrial Fibrillation as the Stiff Left Ventricle Is to Diastolic Heart Failure. 2016 , 9,	4
1552	Dental extraction without stopping single or dual antiplatelet therapy: results of a retrospective cohort study. 2016 , 45, 1293-8	23
1551	Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. 2016 , 138, 1-6	11
1550	Relationship of Provider and Practice Volume to Performance Measure Adherence for Coronary Artery Disease, Heart Failure, and Atrial Fibrillation: Results From the National Cardiovascular Data Registry. 2016 , 9, 48-54	7
1549	Classification of persistent and long-standing persistent atrial fibrillation by means of surface electrocardiograms. 2016 , 61, 19-27	2
1548	Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. 2016 , 205, 17-22	23
1547	Aerobic Interval Training Reduces the Burden of Atrial Fibrillation in the Short Term: A Randomized Trial. 2016 , 133, 466-73	120
1546	Acute and early outcomes of focal impulse and rotor modulation (FIRM)-guided rotors-only ablation in patients with nonparoxysmal atrial fibrillation. 2016 , 13, 830-5	94
1545	Is hyperuricemia a recognizable biomarker for low risk of stroke in patients with atrial fibrillation?. 2016 , 203, 624-5	2
1544	The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use. 2016 , 14, 163-76	6
1543	The Arrhythmic Patient in the Emergency Department. 2016 ,	
1542	Strokes after cardioversion of atrial fibrillation--The FibStroke study. 2016 , 203, 269-73	25
1541	The management of antithrombotic agents for patients undergoing GI endoscopy. 2016 , 83, 3-16	383

1540	Lack of regional association between atrial late gadolinium enhancement on cardiac magnetic resonance and atrial fibrillation rotors. 2016 , 13, 654-60		40
1539	Paroxysmal atrial fibrillation: A window of opportunity to modify disease progression. 2016 , 13, 340-1		
1538	[A case report on embolism prevention in atrial fibrillation/flutter: dual antiplatelet therapy, please no!]. 2016 , 42, 195-7		
1537	The Quandary of Oral Anticoagulation in Patients With Atrial Fibrillation and Chronic Kidney Disease. 2016 , 117, 477-82		15
1536	2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). 2016 , 13, e3-e37		23
1535	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2016 , 13, e136-221		58
1534	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> , 2016 , 67, e27-e115	15.1	246
1533	Postoperative atrial fibrillation: Is there a need for prevention?. 2016 , 151, 913-5		10
1532	Statin Antiarrhythmic Effect on Atrial Fibrillation in Statin-Naive Patients Undergoing Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials. 2016 , 21, 167-76		20
1531	Case Report: Apixaban-Associated Gluteal Artery Extravasation Reversed With PCC3 Without FFP. 2016 , 29, 427-30		5
1530	Incidence and risk factors for symptomatic heart failure after catheter ablation of atrial fibrillation and atrial flutter. 2016 , 18, 521-30		12
1529	First-line catheter ablation of paroxysmal atrial fibrillation: outcome of radiofrequency vs. cryoballoon pulmonary vein isolation. 2016 , 18, 368-75		57
1528	[Cardiogenic shock after drug therapy for atrial fibrillation with tachycardia : Case report of an 89-year-old woman]. 2016 , 111, 458-62		2
1527	Left atrial appendage occlusion in atrial fibrillation for stroke prevention: A systemic review. 2016 , 203, 55-9		2
1526	Long-term clinical outcomes of focal impulse and rotor modulation for treatment of atrial fibrillation: A multicenter experience. 2016 , 13, 636-41		159
1525	Left atrial appendage obliteration in atrial fibrillation patients undergoing bioprosthetic mitral valve replacement. 2016 , 41, 87-94		3
1524	Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. 2016 , 172, 19-25		23
1523	The effect of transesophageal echocardiography on the incidence of thromboembolism after electrical cardioversion in atrial fibrillation: A multicenter analysis. 2016 , 202, 880-2		1

1522	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. 2016 , 37, 1145-53	319
1521	Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score of ≥2 and without anticoagulant therapy. 2016 , 31, 1148-53	5
1520	Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation. 2016 , 67, 471-6	17
1519	Left atrial remodelling assessed by 2D and 3D echocardiography identifies paroxysmal atrial fibrillation. 2017 , 18, 46-53	39
1518	Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation. 2017 , 23, 5-19	9
1517	Comparison of mid-term outcomes between patients with and without atrial fibrillation undergoing coronary stenting in the second-generation drug-eluting stent era: from the SHINANO registry. 2017 , 32, 206-215	4
1516	Gender differences in management and clinical outcomes of atrial fibrillation patients. 2017 , 69, 195-200	15
1515	Minimal energy requirement for external cardioversion and catheter ablation for long-standing persistent atrial fibrillation. 2017 , 69, 162-168	4
1514	Drug-Induced Atrial Fibrillation Complicates the Results of Flap Surgery in a Rat Model. 2017 , 78, 476	
1513	Heart rate control by carvedilol in Japanese patients with chronic atrial fibrillation: The AF Carvedilol study. 2017 , 69, 293-301	11
1512	Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. 2017 , 12, 853-859	8
1511	On-X Valve: The Next Generation Aortic Valve. 2017 , 25, 77-83	16
1510	Spectral Analysis of Electrocardiograms in Patients with Inducible Atrial Fibrillation after Catheter Ablation Predicts Sinus Rhythm Maintenance. 2017 , 22,	2
1509	Influence of Inflammation and Atherosclerosis in Atrial Fibrillation. 2017 , 19, 2	26
1508	Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. 2017 , 37, 412-419	80
1507	Insulin Therapy and Stroke Risk in Patients With Diabetes and Atrial Fibrillation: Guilty by Association?. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 420-422	15.1 2
1506	Factors Associated With Cardiac Electrophysiologist Assessment and Catheter Ablation Procedures in Patients With Atrial Fibrillation. 2017 , 3, 302-309	2
1505	Pulmonary vein potential mapping in atrial fibrillation with high density and standard spiral (lasso) catheters: A comparative study. 2017 , 33, 192-200	6

1504	Increased maximum p wave duration in smoking patients with ST-elevation acute myocardial infarction and its relationship with inflammatory markers. 2017 , 59, e246-e250		1
1503	Authors' Reply. 2017 , 30, 198-200		
1502	Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in randomized trials. 2017 , 230, 572-576		4
1501	2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 871-898	15.1	234
1500	Warfarin in Complex Older Patients: Have we Reached a Tipping Point?. 2017 , 65, 236-237		1
1499	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. 2017 , 7, 41565		25
1498	Early Canadian Multicenter Experience With WATCHMAN for Percutaneous Left Atrial Appendage Closure. 2017 , 28, 396-401		20
1497	Cryoablation vs. radiofrequency ablation for treatment of paroxysmal atrial fibrillation: a systematic review and meta-analysis. 2017 , 19, 784-794		28
1496	Optimizing the use of oral anticoagulant therapy for atrial fibrillation in primary care: a pharmacist-led intervention. 2017 , 39, 173-180		9
1495	The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature. 2017 , 49, 329-342		5
1494	His-Bundle Pacing for Identifying Optimal Ablation Sites in Patients Undergoing Atrioventricular Junction Ablation: Teaching an Old Dog a New Trick. 2017 , 40, 242-246		2
1493	Personalizing Bridging Anticoagulation in Patients with Nonvalvular Atrial Fibrillation-a Microsimulation Analysis. 2017 , 32, 464-470		4
1492	Relation of Low-Density Lipoprotein Cholesterol to Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation. 2017 , 119, 1224-1228		14
1491	Ischemic stroke risk in East Asian patients with CHADS-VASc score of 1: systematic review and meta-analysis. 2017 , 15, 145-150		4
1490	Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. 2017 , 33, 737-746		39
1489	Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. 2017 , 14, 801-807		71
1488	Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically ill patients. 2017 , 39, 59-61		
1487	SAME-TTR predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI experience. 2017 , 22, 197-203		10

1486	Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?. 2017 , 14, 652-653		
1485	Lessons from individualized cryoballoon sizing. Is there a role for the small balloon?. 2017 , 70, 374-381		4
1484	Effects of Alpha Lipoic Acid on Multiple Cytokines and Biomarkers and Recurrence of Atrial Fibrillation Within 1 Year of Catheter Ablation. 2017 , 119, 1382-1386		45
1483	Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. 2017 , 6,		74
1482	The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 777-785	15.1	193
1481	Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. 2017 , 177, 563-570		58
1480	Frequency Gradient Within Coronary Sinus Predicts the Long-Term Outcome of Persistent Atrial Fibrillation Catheter Ablation. 2017 , 6,		6
1479	Heart Rhythm Society: expert consensus statements-part 2. 2017 , 40, 186-190		1
1478	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2017 , 14, e155-e217		74
1477	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> , 2017 , 70, e39-e110	15.1	95
1476	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> , 2017 , 70, e39-e110	15.1	154
1475	Sleep-Disordered Breathing and Arrhythmia in Heart Failure Patients. 2017 , 12, 229-241		13
1474	Tachyarrhythmias and Bradyarrhythmias: Differential Diagnosis and Initial Management in the Primary Care Office. 2017 , 101, 495-506		7
1473	Prevention of Bleeding in Atrial Fibrillation. 2017 , 376, 994		1
1472	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2017 , 14, e218-e254		19
1471	Atrial Arrhythmias and Electroanatomical Remodeling in Patients With Left Ventricular Assist Devices. 2017 , 6,		26
1470	Controversies in postoperative atrial fibrillation after noncardiothoracic surgery: clinical and research implications. 2017 , 40, 329-332		17
1469	Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre. 2017 , 186, 615-620		6

1468	Use of rivaroxaban in patients with stroke. 2017 , 38, 745-754	1
1467	CHADS-VASc score in the prediction of ischemic bowel disease among patients with atrial fibrillation: Insights from a nationwide cohort. 2017 , 235, 56-60	18
1466	Assessment of left atrial mechanical function and synchrony in paroxysmal atrial fibrillation with two-dimensional speckle tracking echocardiography. 2017 , 34, 176-183	18
1465	Pneumatic Burst Pressures After Inverted Closure of the Left Atrial Appendage: An 'Ex Vivo' Model. 2017 , 104, 116-121	
1464	Incidence and Clinical Impact of Device-Associated Thrombus and Peri-Device Leak Following Left Atrial Appendage Closure With the Amplatzer Cardiac Plug. 2017 , 10, 391-399	102
1463	CHADS-VASc Score: A Predictor of Thromboembolic Events and Mortality in Patients With an Implantable Monitoring Device Without Atrial Fibrillation. 2017 , 92, 360-369	25
1462	Con: Atrial Fibrillation Prophylaxis Is Not Necessary in Patients Undergoing Major Thoracic Surgery. 2017 , 31, 751-754	1
1461	The burden of proof: The current state of atrial fibrillation prevention and treatment trials. 2017 , 14, 763-782	23
1460	Personalized, assessment-based, and tiered medical education curriculum integrating treatment guidelines for atrial fibrillation. 2017 , 40, 455-460	4
1459	Recurrent Post-Ablation Paroxysmal Atrial Fibrillation Shares Substrates With Persistent Atrial Fibrillation : An 11-Center Study. 2017 , 3, 393-402	12
1458	Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. 2017 , 69, 699-705	49
1457	The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015. 2017 , 35, e12254	17
1456	Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. 2017 , 15, 835-847	130
1455	Early Cardioversion in Atrial Fibrillation: Earlier Is Better, but Not Always and (Maybe) Not Immediately. 2017 , 19, 3	
1454	Trends in oral anticoagulant use in Qatar: a 5-year experience. 2017 , 43, 411-416	18
1453	Does Additional Electrogram-Guided Ablation After Linear Ablation Reduce Recurrence After Catheter Ablation for Longstanding Persistent Atrial Fibrillation? A Prospective Randomized Study. 2017 , 6,	15
1452	Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: A propensity score-matched analysis. 2017 , 14, 635-642	56
1451	Anticoagulation in Atrial Fibrillation: Is the Paradigm Really Shifting?. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 786-788	15.1 3

1450	High-Sensitivity Troponin as a Biomarker in Heart Rhythm Disease. 2017 , 119, 1407-1413		19
1449	[Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology]. 2017 , 58, 512-521		9
1448	Ethnicity and anticoagulation management of hospitalized patients with atrial fibrillation in northwest China. 2017 , 7, 45884		1
1447	Nonlinear measures characterize atrial fibrillatory dynamics generated using fractional diffusion. 2017 , 541-544		
1446	Pulmonary vein isolation with concomitant renal artery denervation is associated with reduction in both arterial blood pressure and atrial fibrillation burden: Data from implantable cardiac monitor. 2017 , 35, e12264		25
1445	Digoxin versus placebo, no intervention, or other medical interventions for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. 2017 , 6, 71		5
1444	Atrial fibrillation patients with isolated pulmonary veins: Is sinus rhythm achievable?. 2017 , 28, 754-761		8
1443	Improving Atrial Fibrillation Therapy: Is There a Gene for That?. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2088-2095	15.1	12
1442	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. 2017 , 49, 946-952		176
1441	Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. 2017 , 18, 875-883		8
1440	The short-term associations of weather and air pollution with emergency ambulance calls for paroxysmal atrial fibrillation. 2017 , 24, 15031-15043		14
1439	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. 2017 , 14, e275-e444		878
1438	Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study). 2017 , 28, 853-861		6
1437	Antithrombotic treatment for patients with paroxysmal atrial fibrillation and a low CHA2DS2-VASc score. 2017 , 18 Suppl 1, e94-e99		
1436	Health Services Research: Cardiology in the Changing Health Care Landscape. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2242-2245	15.1	0
1435	Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2475-2484	15.1	158
1434	New Treatment Options Fail to Close the Anticoagulation Gap in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2485-2487	15.1	8
1433	Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. 2017 , 58, 2811-2814		28

1432	Automatic detection of paroxysmal atrial fibrillation in patients with ischaemic stroke: better than routine diagnostic workup?. 2017 , 24, 990-994	12
1431	Off-Label Use of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2577-2578	15.1
1430	Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS to the CHADS-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial	54
1429	The relationship between oesophageal heating during left atrial posterior wall ablation and the durability of pulmonary vein isolation. 2017 , 19, 1664-1669	10
1428	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. 2017 , 14, e55-e96	136
1427	Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit. 2017 , 37, 712-724	17
1426	Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. 2017 , 135, 1851-1867	302
1425	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. 2017 , 22, e12447	35
1424	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. 2017 , 189, 137-145	170
1423	Plasma Catecholamine Levels on the Morning of Surgery Predict Post-Operative Atrial Fibrillation. 2017 , 3, 1456-1465	6
1422	Left Atrial Appendage Occlusion for Stroke Prevention. 2017 , 59, 626-635	14
1421	Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients. 2017 , 6,	19
1420	Characteristics and long-term catheter ablation outcome in long-standing persistent atrial fibrillation patients with non-pulmonary vein triggers. 2017 , 241, 205-211	27
1419	VTE Prophylaxis: How to Optimize Patients on Anticoagulation and Avoid Infectious Complications. 2017 , 57-64	
1418	CHADS-VASc Score (Congestive Heart Failure, Hypertension, Age ≥75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean Nationwide Sample Cohort Study. 2017 , 48, 1524-1530	76
1417	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. 2017 , 43, 365-379	62
1416	Impact of Electrical Cardioversion on Quality of Life for the Treatment of Atrial Fibrillation. 2017 , 33, 450-455	14
1415	Trends in Transesophageal Echocardiography Use, Findings, and Clinical Outcomes in the Era of Minimally Interrupted Anticoagulation for Atrial Fibrillation Ablation. 2017 , 3, 329-336	14

1414	Guidelines on the management of atrial fibrillation in the emergency department: a critical appraisal. 2017 , 12, 693-703	10
1413	Management of Atrial Fibrillation in Elderly Adults. 2017 , 65, 185-193	10
1412	Atrial Fibrillation and Pulmonary Venous Electrical Conduction Recovery After Full Surgical Resection and Anastomosis of the Pulmonary Veins: Insights From Follow-Up and Ablation Procedures in Lung Transplant Recipients. 2017 , 3, 559-567	4
1411	ECG of the Month. 2017 , 251, 44-46	
1410	Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer. 2017 , 120, 213-217	36
1409	Intra-Atrial Conduction Delay Revealed by Multisite Incremental Atrial Pacing is an Independent Marker of Remodeling in Human Atrial Fibrillation. 2017 , 3, 1006-1017	14
1408	Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents. 2017 , 10, 1075-1085	31
1407	Normalization of Testosterone Levels After Testosterone Replacement Therapy Is Associated With Decreased Incidence of Atrial Fibrillation. 2017 , 6,	30
1406	Impact of a Perioperative Prophylaxis Guideline on Post-Cardiothoracic Surgery Atrial Fibrillation. 2017 , 51, 743-750	5
1405	Triple Antithrombotic Therapy at the Intercept Between Threats and Opportunities: Don't Throw Out the Baby With the Bath Water. 2017 , 10, 1086-1088	9
1404	Warfarin, Atrial Fibrillation, and CKD: Effective and Safe, but Soon Extinct?. 2017 , 69, 720-722	1
1403	Anticoagulant cessation following atrial fibrillation ablation: limits of the ECG-guided approach. 2017 , 15, 473-479	4
1402	New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation: an appraisal. 2017 , 35, 689-695	3
1401	Evaluation of the effect of torsemide on warfarin dosage requirements. 2017 , 39, 831-835	2
1400	Drug Therapy in Adult Congenital Heart Disease. 2017 , 9, 295-309	4
1399	Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study. 2017 , 6, 261-271	
1398	Arrhythmia Surgery for Adults with Congenital Heart Disease. 2017 , 9, 329-340	4
1397	Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: A crossover study of flecainide and pilsicainide. 2017 , 33, 310-317	3

1396	Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2779-2790	15.1	289
1395	Heart Failure. 2017 ,		4
1394	Who Benefits From Implantable Cardioverter-Defibrillators?: Integrating Absolute, Proportional, and Competing Risk. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2619-2621	15.1	2
1393	Left ventricular mural thrombus and dual coronary embolization associated with hyperthyroid cardiomyopathy and atrial fibrillation: a case report. 2017 , 17, 128		3
1392	Catheter ablation as first-line in atrial fibrillation: is rhythm control finally better than rate control?. 2017 , 15, 425-427		
1391	Impact of treatment crossovers on clinical outcomes in the rate and rhythm control strategies for atrial fibrillation: Insights from the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial. 2017 , 40, 770-778		3
1390	Association between insomnia and atrial fibrillation in a Chinese population: A cross-sectional study. 2017 , 40, 765-769		19
1389	Left atrial appendage volume as a new predictor of atrial fibrillation recurrence after catheter ablation. 2017 , 49, 165-171		14
1388	Additional value of left atrial appendage geometry and hemodynamics when considering anticoagulation strategy in patients with atrial fibrillation with low CHADS-VASc scores. 2017 , 14, 1297-1301		24
1387	Role of contact force-guided radiofrequency catheter ablation for treatment of atrial fibrillation: A systematic review and meta-analysis. 2017 , 28, 994-1005		21
1386	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). 2017 , 120, 588-594		26
1385	How to Use Beta-Blockers in Heart Failure With Reduced Ejection Fraction and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2897-2900	15.1	9
1384	Significant reduction in procedure duration in remote magnetic-guided catheter ablation of atrial fibrillation using the third-generation magnetic navigation system. 2017 , 49, 219-226		9
1383	Causes of death in atrial fibrillation: Challenges and opportunities. 2017 , 27, 494-503		10
1382	Associations of Abdominal Obesity and New-Onset Atrial Fibrillation in the General Population. 2017 , 6,		55
1381	Surgical ablation for persistent atrial fibrillation in concomitant cardiac surgery: mid-long-term result. 2017 , 52, 888-894		6
1380	Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. 2017 , 3, 147-150		14
1379	Lone Pediatric Atrial Fibrillation in the United States: Analysis of Over 1500 Cases. 2017 , 38, 1004-1009		15

1378	Postoperative atrial fibrillation following cardiac surgery: a persistent complication. 2017 , 52, 665-672	115
1377	Factors associated with rhythm control treatment decisions in patients with atrial fibrillation-Insights from the NCDR PINNACLE registry. 2017 , 187, 88-97	6
1376	Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. 2017 , 119, 1862-1865	24
1375	Polymorphic ventricular tachycardia due to change in pacemaker programming. 2017 , 3, 243-247	3
1374	Asociaci3n del tejido adiposo epic3rdico con la fibrilaci3n auricular y su pron3stico posterior a la ablaci3n de venas pulmonares. 2017 , 24, 261-268	
1373	Comentario al art3culo âIntroducci3nâ del suplemento sobre tratamiento de la fibrilaci3n auricular. 2017 , 24, 423-424	
1372	Cardioversion Efficacy Using Pulsed Biphasic or Biphasic Truncated Exponential Waveforms: A Randomized Clinical Trial. 2017 , 6,	6
1371	Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal. 2017 , 130, 773-779	4
1370	Electrical treatment of atrial arrhythmias in heart failure patients implanted with a dual defibrillator CRT device. Results from the TRADE-HF study. 2017 , 236, 181-186	1
1369	New-Onset Atrial Fibrillation in the Critically Ill. 2017 , 45, 790-797	81
1368	Permanent Atrial Fibrillation and 2 Year Clinical Outcomes in Patients with a Left Ventricular Assist Device Implant. 2017 , 63, 419-424	16
1367	Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New-Onset Atrial Fibrillation After Acute Myocardial Infarction. 2017 , 6,	7
1366	Teaching an Old Dog New Tricks: Colchicine in Cardiovascular Medicine. 2017 , 17, 347-360	12
1365	Advanced Colonoscopy and Endoluminal Surgery. 2017 ,	4
1364	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE'AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1372-1382	15.1 87
1363	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1363-1371	15.1 84
1362	NOACs for Stroke Prevention in Atrial Fibrillation With Valve Disease: Filling the Gaps. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1383-1385	15.1 1
1361	Long-Term Risk of Ischemic Stroke After the Cox-Maze III Procedure for Atrial Fibrillation. 2017 , 104, 523-529	1

1360	Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. 2017 , 376, 1627-1636		264
1359	Managing atrial fibrillation after cardiac surgery. 2017 , 12, 130-138		2
1358	Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice. 2017 , 15, 403-413		9
1357	New-onset postoperative atrial fibrillation after aortic valve replacement: Effect on long-term survival. 2017 , 154, 492-498		13
1356	Latin American Clinical Epidemiology Network Series - Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile. 2017 , 86, 75-83		6
1355	Atrial Fibrillation and Heart Failure Prevention: Do We Need a Risk Score?. 2017 , 5, 53-55		4
1354	Safety of warfarin in "high-risk" populations: A meta-analysis of randomized and controlled trials. 2017 , 150, 1-7		9
1353	Association of Rate-Dependent Conduction Block Between Eccentric Coronary Sinus to Left Atrial Connections With Inducible Atrial Fibrillation and Flutter. 2017 , 10,		6
1352	Atrial fibrillation following aortic valve replacement: impact of perioperative use of intravenous Eblocker. 2017 , 65, 194-199		9
1351	Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke. 2017 , 65, 241-248		40
1350	Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. 2017 , 14, 501-507		43
1349	2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1212-1249	15.1	312
1348	Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. 2017 , 48, 223-233		11
1347	Gabor frames for classification of paroxysmal and persistent atrial fibrillation episodes. 2017 , 39, 31-37		1
1346	Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. 2017 , 130, 449-456		16
1345	Amiodarone-induced pulmonary toxicity. 2017 , 30, 23-26		11
1344	Patients With Atrial Fibrillation Who Are Not on Anticoagulant Treatment Due to Increased Bleeding Risk Are Common and Have a High Risk of Stroke. 2017 , 3, 1369-1376		11
1343	Vagal Neuromodulation for Atrial Arrhythmias. 2017 , 3, 939-941		1

1342	Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation. 2017 , 16, 1407-1412	9
1341	Sports Cardiology: Core Curriculum for Providing Cardiovascular Care to Competitive Athletes and Highly Active People. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1902-1918	15.1 44
1340	Gap Between Clinical Practice and Guidelines: A National Survey of the Knowledge of Recommended Heart Failure Guidelines Among Chinese Physicians. 2017 , 26, 196-204	0
1339	Atrial ectopy as a mediator of the association between race and atrial fibrillation. 2017 , 14, 1856-1861	5
1338	WITHDRAWN: 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. 2017 ,	
1337	Cardioverting acute atrial fibrillation and the risk of thromboembolism: not all patients are created equal. 2017 , 17, 419-423	8
1336	Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches. 2017 , 37, 1545-1564	
1335	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. 2017 , 33, 369-409	148
1334	Catheter Ablation of the Superolateral Mitral Isthmus Line: A Novel Approach to Reduce the Need for Epicardial Ablation. 2017 , 10,	21
1333	Stroke Revisited: Diagnosis and Treatment of Ischemic Stroke. 2017 ,	3
1332	Clinical Management of Atrial Fibrillation. 2017 , 183-190	
1331	Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. 2017 , 37, 1366-1373	3
1330	Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation. 2017 , 34, 2274-2294	4
1329	Anticoagulation: The Successes and Pitfalls of Long-Term Management. 2017 , 2, 603-622	
1328	Symptoms and Quality of Life After Atrial Fibrillation Ablation: Two Different Concepts. 2017 , 3, 1177-1179	1
1327	Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation. 2017 , 6,	12
1326	Manual of Cardio-oncology. 2017 ,	1
1325	Comparison of CHADS-VASc, CHADS and HATCH scores for the prediction of new-onset atrial fibrillation in cancer patients: A nationwide cohort study of 760,339 study participants with competing risk analysis. 2017 , 266, 205-211	12

1324	Screening of older patients for atrial fibrillation in general practice: Current evidence and its implications for future practice. 2017 , 23, 246-253	11
1323	Symptom challenges after atrial fibrillation ablation. 2017 , 46, 425-431	10
1322	Omental Infarction after Transarterial Chemoembolization due to Nontarget Embolization of an Extrahepatic Branch from the Right Hepatic Artery. 2017 , 28, 1605-1607	1
1321	Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation. 2017 , 136, 2100-2116	95
1320	Perioperative management of antithrombotic therapy in patients receiving cardiovascular implantable electronic devices: a network meta-analysis. 2017 , 50, 65-83	1
1319	Use of direct oral anticoagulants for treatment of atrial fibrillation in patients with HIV: a review. 2017 , 12, 554-560	11
1318	Effect of New Oral Anticoagulants on Prescribing Practices for Atrial Fibrillation in Older Adults. 2017 , 65, 2405-2412	23
1317	Impact of race and gender on clinical outcomes of catheter ablation in patients with atrial fibrillation. 2017 , 40, 1073-1079	7
1316	Atrial fibrillation decision support tool: Population perspective. 2017 , 194, 49-60	7
1315	Gender Differences in the Trends of Hospitalizations for Acute Stroke Among Patients With Atrial Fibrillation in the United States: 2005 to 2014. 2017 , 120, 1541-1548	7
1314	Femoral venous pressure waveform as indicator of phrenic nerve injury in the setting of second-generation cryoballoon ablation. 2017 , 18, 510-517	7
1313	Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. 2017 , 33, 1955-1963	30
1312	Embolic Stroke of Undetermined Source in Latin America: A Review. 2017 , 22, 171-181	6
1311	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. 2017 , 50, 1-55	58
1310	Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1573-1583	15.1 28
1309	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. 2017 , 14, e445-e494	72
1308	Pills Never Work in the Bottle. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1584-1586	15.1 1
1307	Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients: Results of the Adaptive Cardiac Resynchronization Therapy Trial. 2017 , 14, 1820-1825	35

1306	Clinical predictors of challenging atrioventricular node ablation procedure for rate control in patients with atrial fibrillation. 2017 , 245, 168-173	1
1305	Efficacy of ganglionated plexi ablation in addition to pulmonary vein isolation for paroxysmal versus persistent atrial fibrillation: a meta-analysis of randomized controlled clinical trials. 2017 , 50, 253-260	21
1304	The safety and efficacy of oral anticoagulants with dual versus single antiplatelet therapy in patients after percutaneous coronary intervention: A meta-analysis. 2017 , 96, e8015	6
1303	Severity of Hypertension Correlates with Risk of Thromboembolic Stroke. 2017 , 10, 368-373	1
1302	Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report. 2017 , 70, 859-868	21
1301	Atrial fibrillation, bleeding, and coronary intervention: current recommendations. 2017 , 28, 702-709	
1300	CHADS-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study. 2017 , 48, 2984-2990	56
1299	Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines. 2017 , 6,	7
1298	Antithrombotics: Anticoagulants Including NOACs. 2017 , 307-321	
1297	Colchicine for primary prevention of atrial fibrillation after open-heart surgery: Systematic review and meta-analysis. 2017 , 249, 127-137	45
1296	Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making. 2017 , 245, 174-177	7
1295	Preclinical safety and efficacy ofandexanet alfa in animal models. 2017 , 15, 1747-1756	23
1294	Persistent atrial fibrillation vs paroxysmal atrial fibrillation: differences in management. 2017 , 15, 601-618	23
1293	Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. 2017 , 73, 1417-1425	50
1292	Prevention of atrial fibrillation after cardiac surgery using low-dose landiolol: A systematic review and meta-analysis. 2017 , 42, 1-6	14
1291	Percutaneous isolation of left atrial appendage thrombus. 2017 , 16, 67-69	1
1290	Vitamin K Antagonists Versus Novel Oral Anticoagulants for Elective Electrical Cardioversion of Atrial Fibrillation. 2017 , 24, e553-e558	2
1289	Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients With Atrial Fibrillation. 2017 , 120, 1133-1138	22

1288	Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. 2017 , 103, 210-218		31
1287	Automatic identification of high impact articles in PubMed to support clinical decision making. 2017 , 73, 95-103		7
1286	Periprocedural Anticoagulation for Catheter Ablation of Atrial Fibrillation: Practical Implications for Perioperative Management. 2017 , 31, 1519-1526		3
1285	Factors Associated with Anticoagulation Delay Following New-Onset Atrial Fibrillation. 2017 , 120, 1316-1321		7
1284	Development and Validation of the AFImpact: An Atrial Fibrillation-Specific Measure of Patient-Reported Health-Related Quality of Life. 2017 , 20, 1355-1361		2
1283	Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate. 2017 , 157, 165-166		6
1282	Complicated atrial tachycardia due to atrial fibrillation originating from the superior vena cava: A case report. 2017 , 96, e7192		
1281	Erweiterte Reanimationsmaßnahmen für Erwachsene (âadult advanced life supportâ) 2017 , 20, 25-88		0
1280	Percutaneous left atrial appendage closure: current state of the art. 2017 , 32, 27-38		11
1279	CHA2DS2-VASc Score, Warfarin Use, and Risk for Thromboembolic Events Among HIV-Infected Persons With Atrial Fibrillation. 2017 , 76, 90-97		9
1278	Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. 2017 , 12, 923-934		4
1277	Atrial Fibrillation and Stent Selection (Bare Metal vs Drug Eluting) (from Medicare Claims). 2017 , 120, 1557-1561		1
1276	Increasing Prevalence of Atrial Fibrillation and Permanent Atrial Arrhythmias in Congenital Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 857-865	15.1	62
1275	Applications of Nonlinear Methods to Atrial Fibrillation. 2017 , 387-426		2
1274	Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. 2017 , 120, 1820-1829		7
1273	Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease. 2017 , 7, 207-217		12
1272	5-Year Outcome of Pulmonary Vein Isolation by Loss of Pace Capture on the Ablation Line Versus Electrical Circumferential Pulmonary Vein Isolation. 2017 , 3, 1262-1271		5
1271	Nurse-led clinics for atrial fibrillation: managing risk factors. 2017 , 26, 1245-1248		4

1270	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 3042-3067	15.1	228
1269	Can Implantable Cardiac Devices Be Used to Lower Risk of Stroke?. 2017 , 11, 1		
1268	Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: A case report, and a review of acquired hemophilia A-related hematological malignancies. 2017 , 96, e8669		7
1267	Cardiovascular complications of multiple myeloma in the elderly. 2017 , 15, 933-943		10
1266	Risk of Stroke in Patients With Short-Run Atrial Tachyarrhythmia. 2017 , 48, 3232-3238		12
1265	Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2621-2632	15.1	118
1264	Impact of Atrial Fibrillation on Exercise Capacity and Mortality in Heart Failure With Preserved Ejection Fraction: Insights From Cardiopulmonary Stress Testing. 2017 , 6,		20
1263	Change Is Not Always Good. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2501-2503	15.1	
1262	Atrial fibrillation and use of antithrombotic medications in older people: A population-based study. 2017 , 249, 173-178		13
1261	Comparative Outcomes of Mechanical Thrombectomy for Acute Ischemic Stroke in Patients with and without Atrial Fibrillation. 2017 , 28, 1604-1605		7
1260	Stroke risk in patients with device-detected atrial high-rate episodes. 2018 , 26, 177-181		3
1259	The continuous challenge of AF ablation: From foci to rotational activity. 2017 , 36 Suppl 1, 9-17		7
1258	Race and atrial flutter: a needed update to understand the atrial fibrillation race paradox. 2017 , 13, 423-427		4
1257	Using bispectral index monitoring to gauge depth of sedation/analgesia. 2017 , 12, 12-16		2
1256	Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. 2017 , 60, 51-55		
1255	Paroxysmal atrial fibrillation during intracoronary acetylcholine provocation test. 2017 , 32, 902-908		5
1254	Postoperatives Vorhofflimmern. 2017 , 31, 95-109		1
1253	High molecular weight fibroblast growth factor-2 as a promising prognostic biomarker to predict the occurrence of heart failure in atrial fibrillation patients. 2017 , 32, 1506-1512		1

1252	Availability of patient decision aids for stroke prevention in atrial fibrillation: A systematic review. 2017 , 191, 1-11	24
1251	Effect of Compliance to Updated AHA/ACC Performance and Quality Measures Among Patients With Atrial Fibrillation on Outcome (from Japanese Multicenter Registry). 2017 , 120, 595-600	8
1250	Stroke prediction with CHADS-VASc score in patients with mesenteric ischemia without atrial fibrillation-insights from a nationwide cohort. 2017 , 45, 193-198	0
1249	The Impact of Inclusion in a Quality Indicators Program on Anticoagulant Treatment in Atrial Fibrillation. 2017 , 32, 340-341	
1248	Underuse of Oral Anticoagulants and Inappropriate Prescription of Antiplatelet Therapy in Older Inpatients with Atrial Fibrillation. 2017 , 34, 701-710	14
1247	[New onset atrial fibrillation in patients with sepsis]. 2017 , 66, 786-794	4
1246	Predictive value of CHADS and CHADS-VASc scores for acute myocardial infarction in patients with atrial fibrillation. 2017 , 7, 4730	5
1245	Deep sequencing of atrial fibrillation patients with mitral valve regurgitation shows no evidence of mosaicism but reveals novel rare germline variants. 2017 , 14, 1531-1538	7
1244	Left atrial appendage morphology and risk of stroke following pulmonary vein isolation for drug-refractory atrial fibrillation in low CHADSVasc risk patients. 2017 , 17, 70	4
1243	Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes. 2017 , 16, 75	20
1242	The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. 2017 , 6, 47	4
1241	Hemoglobin A1c and risk of left atrial thrombus and spontaneous echo contrast in non-valvular atrial fibrillation patients. 2017 , 22, 15	5
1240	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. 2017 , 6,	25
1239	Assessment of Atrial Fibrillation-Specific Symptoms Before and 2 Years After Atrial Fibrillation Ablation: Do Patients and Physicians Differ in Their Perception of Symptom Relief?. 2017 , 3, 1168-1176	16
1238	Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. 2017 , 227, 808-812	15
1237	Prognostic Value of Red Blood Cell Distribution Width on Bleeding Events in Nonvalvular Atrial Fibrillation Patients Taking Dabigatran (110 mg b.i.d.) after Catheter Ablation. 2017 , 136, 215-221	3
1236	Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. 2017 , 8, 67-75	33
1235	Diagnosis, pathophysiology, and management of exercise-induced arrhythmias. 2017 , 14, 88-101	54

1234 Cardiovascular Disease. **2017**, 243-267

1233	Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study. 2017 , 43, 157-165	1
1232	Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. 2017 , 227, 443-449	2
1231	Meta-analysis of ATRIA versus CHADS-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. 2017 , 227, 436-442	19
1230	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. 2017 , 150, 123-130	17
1229	Prognosis in patients with atrial fibrillation and a presumed "temporary cause" in a community-based cohort study. 2017 , 106, 202-210	18
1228	Intermittent vs. Continuous Anticoagulation therapy in patients with Atrial Fibrillation (iCARE-AF): a randomized pilot study. 2017 , 48, 51-60	14
1227	Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. 2017 , 176, 32-39	35
1226	Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. 2017 , 135, 208-219	73
1225	Update on atrial fibrillation. 2017 , 27, 14-25	22
1224	The Impact of First Procedure Success Rate on the Economics of Atrial Fibrillation Ablation. 2017 , 3, 129-138	21
1223	Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. 2017 , 116, 276-286	3
1222	Predictors of Atrial Fibrillation After Coronary Artery Bypass Grafting: A Bayesian Analysis. 2017 , 103, 92-97	37
1221	Peri-procedural silent cerebral infarcts after left atrial appendage occlusion. 2017 , 24, 53-57	7
1220	Mortality after stroke in patients with paroxysmal and chronic atrial fibrillation - The FibStroke study. 2017 , 227, 869-874	7
1219	Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation. 2017 , 51, 245-252	5
1218	Commentary: Carotid Artery Revascularization for Stroke Prevention: A New Era. 2017 , 24, 138-148	12
1217	The use of direct oral anticoagulants in inherited thrombophilia. 2017 , 43, 24-30	49

1216	Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial. 2017 , 183, 49-53	8
1215	Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. 2017 , 184, 37-46	55
1214	Virchow's Triad and Failure to "Pacify" the Left Atrial Appendage. 2017 , 3, 76-79	
1213	Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy. 2017 , 3, 139-150	28
1212	Red cell distribution width and all-cause mortality in patients with atrial fibrillation: A cohort study. 2017 , 33, 56-62	9
1211	A multicenter study of the need of additional freezing for cryoballoon ablation in patients with atrial fibrillation: The AD-Balloon study. 2017 , 33, 81-85	2
1210	Impact of Anticoagulant and Antiplatelet Drugs on Perioperative Outcomes of Robotic-assisted Partial Nephrectomy. 2017 , 99, 118-122	9
1209	Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants. 2017 , 10, 163-185	25
1208	Financial Impact of Direct-Acting Oral Anticoagulants in Medicaid: Budgetary Assessment Based on Number Needed to Treat. 2017 , 15, 203-214	2
1207	To use or not to use? Amiodarone before heart transplantation. 2017 , 161, 1273-1278	8
1206	Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. 2017 , 6, 91-117	3
1205	Long-Term Outcome of Left Atrial Voltage-Guided Substrate Ablation During Atrial Fibrillation: A Novel Adjunctive Ablation Strategy. 2017 , 28, 147-155	45
1204	Pulmonary Vein Isolation with the Cryoballoon Technique: Feasibility, Procedural Outcomes, and Adoption in the Real World: Data from One Shot Technologies TO Pulmonary Vein Isolation (1STOP) Project. 2017 , 40, 46-56	19
1203	Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. 2017 , 65, 35-41	9
1202	Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience. 2017 , 33, 7-11	2
1201	Impact of a Pharmacy-Cardiology Collaborative Practice on Dofetilide Safety Monitoring. 2017 , 51, 39-43	5
1200	ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training. 2017 , 19, D333-D353	21
1199	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial. 2017 , 117, 2135-2145	37

1198	Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. 2017 , 117, 1230-1239	265
1197	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). 2017 , 19, 1556-1578	137
1196	MicroRNA-208a-3p contributes to connexin40 remodeling in human chronic atrial fibrillation. 2017 , 14, 5355-5362	9
1195	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia	75
1194	Elective electrical cardioversion of atrial fibrillation in patients with implantable devicesâ€”Insight of left atrium. 2017 , 655, 266-271 Cardíaca y. 2017 , 19, 1757-1758	
1193	Do All Patients With Atrial Fibrillation Need a Cardiologist?. 2017 , 33, 1520-1521	0
1192	Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation. 2017 , 19, iv1-iv9	23
1191	Atrioventricular node ablation and His bundle pacing. 2017 , 19, iv10-iv16	69
1190	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart)	29
1189	Cierre percutáneo de la aurícula izquierda en el manejo de la fibrilación auricular. 2017 , 24, 12-17 Association and Sociedad Latinoamericana de Es. 2017 , 117, 2215-2236	
1188	Automating Clinical Score Calculation within the Electronic Health Record. A Feasibility Assessment. 2017 , 8, 369-380	16
1187	A new algorithm for short term prediction of persistent atrial fibrillation. 2017 ,	1
1186	Representation of cardiovascular magnetic resonance in the AHA / ACC guidelines. 2017 , 19, 70	35
1185	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. 2017 , 356, j510	215
1184	Use of CHADS-VASc Score to Predict New-Onset Atrial Fibrillation in Chronic Obstructive Pulmonary Disease Patients - Large-Scale Longitudinal Study. 2017 , 81, 1792-1797	5
1183	Computed Tomography in the Management of Electrophysiology Procedures. 2017 , 755-776	
1182	Value of Combining Left Atrial Diameter and Amino-terminal Pro-brain Natriuretic Peptide to the CHA2DS2-VASc Score for Predicting Stroke and Death in Patients with Sick Sinus Syndrome after Pacemaker Implantation. 2017 , 130, 1902-1908	4
1181	A pilot process to identify and switch high-risk warfarin patients to direct oral anticoagulants. 2017 , 6, 20	

1180	Atrial Fibrillation Ablation: Indications, Outcomes, Complications, and Future Directions. 2017 , 130, 1891-1893	5
1179	Complexity of Atrial Fibrillation Electrograms Through Nonlinear Signal Analysis: In Silico Approach. 2017 ,	2
1178	DOAC use in patients with chronic kidney disease. 2017 , 37, 286-294	0
1177	Controlled Atrial Fibrillation after Pulmonary Vein Stenting. 2017 , 47, 528-531	1
1176	Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial Fibrillation. 2017 , 117, 761-771	4
1175	After PCI in AF, dual antithrombotic therapy with dabigatran reduced bleeding compared with triple therapy. 2017 , 167, JC70	
1174	Role of Imaging in Left Atrial Appendage Occlusion. 2017 , 2, 4-14	1
1173	A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry. 2017 , 47, 877-887	25
1172	Chemotherapy-Associated Arrhythmias. 2017 , 321-330	1
1171	Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease. 2017 , 117, 2026-2033	9
1170	Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians. 2017 , 12, 175-187	8
1169	SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events. 2017 , 108, 290-296	7
1168	Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran. 2017 , 4, 42	1
1167	Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study. 2017 , 4, 85	7
1166	Potential Roles of Serum Caveolin-3 Levels in Patients with Atrial Fibrillation. 2017 , 9, 90	1
1165	Association of CHADS and CHADS-VASc Scores with Left Atrial Thrombus with Nonvalvular Atrial Fibrillation: A Single Center Based Retrospective Study in a Cohort of 2695 Chinese Subjects. 2017 , 2017, 6839589	14
1164	Future management of cardiac arrhythmias: the shape of the world to come. 2018 , 66, 38-39	
1163	Ten-year outcome of intraoperative treatment of atrial fibrillation using radiofrequency ablation. 2017 , 13, 1233-1237	1

1162	Incidence and risk factors of atrial fibrillation in Asian COPD patients. 2017 , 12, 2523-2530	16
1161	Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation. 2017 , 11, 1827-1837	12
1160	Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System. 2017 , 23, 700-712	9
1159	Utilization and prescribing patterns of direct oral anticoagulants. 2017 , 10, 87-94	45
1158	An integrated epidemiological and neural net model of the warfarin effect in managed care patients. 2017 , 9, 55-64	1
1157	Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort. 2017 , 12, e0179687	21
1156	Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial. 2017 , 18, 443	15
1155	Percutaneous Left Atrial Appendage Closure Devices. 2017 , 10, 1	3
1154	The effects of misclassification in routine healthcare databases on the accuracy of prognostic prediction models: a case study of the CHA2DS2-VASc score in atrial fibrillation. 2017 , 1, 18	7
1153	Tufts PACE Clinical Predictive Model Registry: update 1990 through 2015. 2017 , 1, 20	24
1152	P-wave Analysis in Paroxysmal Atrial Fibrillation Patients before and after Pulmonary Vein Isolation. 2017 ,	1
1151	The Refinement of Risk Stratification for Atrial Thrombus or Spontaneous Echo Contrast in Nonvalvular Atrial Fibrillation. 2017 , 58, 885-893	12
1150	COMPARISON OF EFFECTIVENESS OF ANTIARRHYTHMIC THERAPIES IN POSTOPERATIVE PERIOD OF PULMONARY VEIN OSTIA CATHETER ISOLATION FOR PREVENTION OF EARLY RECURRENCES OF ATRIAL TACHYARRHYTHMIAS IN THE PROOF STUDY. 2017 , 13, 18-24	1
1149	Do All Patients with Atrial Fibrillation Need Long-Term Anticoagulation?. 2017 , 7, 955	1
1148	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. 2017 , 47, 555-643	44
1147	Should Digoxin Continue To Be Used for the Management of Atrial Fibrillation?. 2017 , 70, 391-394	2
1146	Stroke Prevention for Patients with Atrial Fibrillation: Beyond the Guidelines. 2017 , 9, 1475	16
1145	Genome-wide DNA methylation analysis in permanent atrial fibrillation. 2017 , 16, 5505-5514	15

1144	Diabetes mellitus and stroke: A clinical update. 2017 , 8, 235-248	64
1143	Efficacy and safety of triple dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis. 2017 , 8, 81154-81166	7
1142	Automated Detection of Paroxysmal Atrial Fibrillation Using an Information-Based Similarity Approach. 2017 , 19, 677	19
1141	Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. 2017 , 23, 958-967	32
1140	Novel stroke risk reduction in atrial fibrillation: left atrial appendage occlusion with a focus on the Watchman closure device. 2017 , 13, 81-90	2
1139	The Trends of Atrial Fibrillation-Related Hospital Visit and Cost, Treatment Pattern and Mortality in Korea: 10-Year Nationwide Sample Cohort Data. 2017 , 47, 56-64	59
1138	Impact of electronic clinical decision support on adherence to guideline-recommended treatment for hyperlipidaemia, atrial fibrillation and heart failure: protocol for a cluster randomised trial. 2017 , 7, e019087	5
1137	Recent advances in the management of peptic ulcer bleeding. 2017 , 6, 1763	10
1136	Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times. 2017 , 47, 644-662	26
1135	Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials. 2017 , 87, 805	4
1134	Optimum Risk Assessment for Stroke in Atrial Fibrillation: Should We Hold the Status Quo or Consider Magnitude Synergism and Left Atrial Appendage Anatomy?. 2017 , 6, 161-166	8
1133	Ablation of Atrial Fibrillation in Patients with Congenital Heart Disease. 2017 , 6, 191-194	8
1132	Complications of Atrial Fibrillation Cryoablation. 2017 , 10, 1620	9
1131	Atrial tachyarrhythmia in adult congenital heart disease. 2017 , 9, 496-507	9
1130	First results of the Brazilian Registry of Percutaneous Left Atrial Appendage Closure. 2017 , 109, 440-447	7
1129	New-Onset Atrial Fibrillation: What's the Significance?. 2017 , 35, 215-220	1
1128	Medication therapy disease management: Geisinger's approach to population health management. 2017 , 74, 1422-1435	16
1127	Fibrilaci3n auricular: enfoque para el m3dico no card3logo. 2017 , 30, 404-422	2

1126	The absence of effect of ganglionated plexi ablation on heart rate variability parameters in patients after thoracoscopic ablation for atrial fibrillation. 2017 , 9, 4997-5007	1
1125	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. 2018 , 199, 97-104	4
1124	Associations of sleep quality with incident atrial fibrillation: a meta-analysis. 2018 , 48, 964-972	18
1123	Is a little atrial fibrillation still too much?. 2018 , 15, 812-813	1
1122	Digoxin in Atrial Fibrillation?: Leave it Out of the Medicine Cabinet. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1075-1077	15.1 5
1121	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2018 , 39, 2314-2325	104
1120	Anticoagulation use and clinical outcomes after catheter ablation in patients with persistent and longstanding persistent atrial fibrillation. 2018 , 29, 823-832	7
1119	Nicht-Vitamin-K-abhängige orale Antikoagulanzen (NOAK) bei chronischer Niereninsuffizienz. 2018 , 13, 91-98	
1118	Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients. 2018 , 38, 1253-1262	24
1117	Individualized ablation strategy guided by live simultaneous global mapping to treat persistent atrial fibrillation. 2018 , 14, 237-249	12
1116	Fully automatic segmentation and objective assessment of atrial scars for long-standing persistent atrial fibrillation patients using late gadolinium-enhanced MRI. 2018 , 45, 1562-1576	32
1115	Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. 2018 , 84, 1544-1556	11
1114	Incidence and Outcomes of Postoperative Atrial Fibrillation After Left Ventricular Assist Device. 2018 , 64, 581-585	7
1113	Temporal trends of in-hospital complications associated with catheter ablation of atrial fibrillation in the United States: An update from Nationwide Inpatient Sample database (2011-2014). 2018 , 29, 715-724	53
1112	CHADS-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. 2018 , 25, 651-658	43
1111	Safety and feasibility of leadless pacemaker in patients undergoing atrioventricular node ablation for atrial fibrillation. 2018 , 15, 994-1000	11
1110	Age modifies the risk of atrial fibrillation among athletes: A systematic literature review and meta-analysis. 2018 , 18, 25-29	11
1109	Resolving Concerns With the Newer 'Oral' Anticoagulant Medications: Is Hepatotoxicity a Real Concern?. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1114-1116	15.1

1108	Liver Transplantation: Perioperative Care and Update on Intraoperative Management. 2018 , 8, 186-196	0
1107	Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. 2018 , 34, 1945-1957	2
1106	Dofetilide dose reductions and discontinuations in women compared with men. 2018 , 15, 478-484	16
1105	Current State of Left Atrial Appendage Closure. 2018 , 20, 42	7
1104	Caffeine and Arrhythmias: Time to Grind the Data. 2018 , 4, 425-432	23
1103	Antithrombotic Therapy for Patients with Atrial Fibrillation. 2018 , 217-238	
1102	Perioperative Management of Anticoagulants. 2018 , 175-195	
1101	Increased risk of ischemic stroke associated with new-onset atrial fibrillation complicating acute coronary syndrome: A systematic review and meta-analysis. 2018 , 265, 125-131	14
1100	Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. 2018 , 7,	5
1099	Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study. 2018 , 41, 440-449	11
1098	Medical Management of Rheumatic Heart Disease: A Systematic Review of the Evidence. 2018 , 26, 187-195	8
1097	Association between nonsteroidal anti-inflammatory drugs and atrial fibrillation among a middle-aged population: a nationwide population-based cohort. 2018 , 84, 1290-1300	7
1096	Atrial Fibrillation in Patients with Heart Failure: Current State and Future Directions. 2018 , 18, 347-360	5
1095	Atrial Fibrillation in the ICU. 2018 , 154, 1424-1434	66
1094	Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options. 2018 , 28, 469-480	0
1093	Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. 2018 , 39, 2959-2971	97
1092	Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures. 2018 , 26, 245-254	1
1091	Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease. 2018 , 7,	19

1090	The 2017 high blood pressure clinical practice guideline: The old and the new. 2018 , 41, 279-281	1
1089	A single institution's experience with using dabigatran, rivaroxaban and warfarin for prevention of thromboembolism in atrial fibrillation. 2018 , 27, 20-25	3
1088	Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. 2018 , 20, 49	14
1087	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. 2018 , 39, 1726-1735a	112
1086	Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review. 2018 , 23, 191-208	8
1085	Identification, risk assessment, and management of patients with atrial fibrillation in a large primary care cohort. 2018 , 254, 119-124	5
1084	The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease - Where Is the Moon Now?. 2018 , 60, 457-459	
1083	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. 2018 , 20, e1-e160	461
1082	Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis. 2018 , 45, 550-556	14
1081	Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy. 2018 , 15, 159-163	39
1080	Current Readings: An Update on Prevention and Management of Atrial Fibrillation Post Cardiac Surgery. 2018 , 30, 256-261	2
1079	Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. 2018 , 35, 548-556	13
1078	Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the Atherosclerosis Risk in Communities Study. 2018 , 16, 670-679	21
1077	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. 2018 , 38, 892-902	34
1076	When is Device-Detected Atrial Fibrillation Actionable?. 2018 , 10, 75-85	2
1075	Class IC antiarrhythmic agents in structural heart disease: Is nothing CAST in stone?. 2018 , 15, 164-165	
1074	Periprocedural Anticoagulation Management for Atrial Fibrillation Ablation: Current Knowledge and Future Directions. 2018 , 20, 3	6
1073	Management of the Trauma Patient on Direct Oral Anticoagulants. 2018 , 8, 107-118	

1072	Improving Practice Guideline Adherence Through Peer Feedback: Impact of an Ambulatory Cardiology Curriculum. 2018 , 30, 328-336		5
1071	Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting. 2018 , 9, 97-111		6
1070	Incidence of intracardiac thrombus formation prior to electrical cardioversion in respect to the mode of oral anticoagulation. 2018 , 29, 537-547		7
1069	Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. 2018 , 41, 39-45		9
1068	The winding path towards rationale anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation. 2018 , 39, 474-476		2
1067	Stroke in Women: Recognizing Opportunities for Prevention and Treatment. 2018 , 49, 515-517		8
1066	Cigarette smoking causes a worse long-term outcome in persistent atrial fibrillation following catheter ablation. 2018 , 29, 699-706		6
1065	Long-Term Clinical Comparison of Procedural End Points After Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation: Elimination of Nonpulmonary Vein Triggers Versus Noninducibility. 2018 , 11, e005019		23
1064	[S1 guideline - Austrian consensus for anticoagulation in the context of atrial fibrillation ablation]. 2018 , 130, 1-8		
1063	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 727-735	15.1	18
1062	Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?. 2018 , 20, 4		6
1061	Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery. 2018 , 319, 365-374		86
1060	Cryptogenic acute limb ischemia: a retrospective cohort study defining a previously undescribed clinical entity. 2018 , 45, 397-402		2
1059	Atrial Fibrillation Ablation and its Impact on Stroke. 2018 , 20, 2		4
1058	Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. 2018 , 17, 251-258		1
1057	Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. 2018 , 16, 465-473		6
1056	The Extent of Left Atrial Low-Voltage Areas Included in Pulmonary Vein Isolation Is Associated With Freedom from Recurrent Atrial Arrhythmia. 2018 , 34, 73-79		20
1055	Assessment of anticoagulation treatments in non-valvular atrial fibrillation patients diagnosed in a basic health area. 2018 , 30, 56-63		

1054	Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation. 2018 , 54, 320-327		11
1053	Ultra-Short-Acting β Blockers (Esmolol and Landiolol) in the Perioperative Period and in Critically Ill Patients. 2018 , 32, 1415-1425		13
1052	Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations. 2018 , 18, 30-42		70
1051	Opportunities and challenges of large-scale screening for atrial fibrillation. 2018 , 29, 57-61		3
1050	Identification and Characterization of Sites Where Persistent Atrial Fibrillation Is Terminated by Localized Ablation. 2018 , 11, e005258		26
1049	Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. 2018 , 104, 301-310		11
1048	Platelet Toll-like receptor and its ligand HMGB-1 expression is increased in the left atrium of atrial fibrillation patients. 2018 , 103, 50-56		5
1047	Propafenone for supraventricular arrhythmias in septic shock-Comparison to amiodarone and metoprolol. 2018 , 45, 247		1
1046	Clinical Trials for Atrial Fibrillation—What Do We Know?. 2018 , 630-642		
1045	Increased Left Ventricular Filling Pressure and Arterial Occlusion in Stroke Related to Atrial Fibrillation. 2018 , 27, 1275-1282		6
1044	Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 122-132	15.1	114
1043	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. 2018 , 20, 157-208		227
1042	CREM-transgene mice: A step towards understanding thrombogenesis in atrial fibrillation. 2018 , 162, 60-61		
1041	Concomitant atrial fibrillation surgery: worth the effort?. 2018 , 53, i14-i18		1
1040	Predicting AF recurrence after catheter ablation: Is it time to use the force?. 2018 , 29, 272-273		
1039	Thromboembolism and Mortality in the Tasmanian Atrial Fibrillation Study. 2018 , 23, 329-336		0
1038	Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician. 2018 , 72, 717-727		10
1037	Postprocedural LGE-CMR comparison of laser and radiofrequency ablation lesions after pulmonary vein isolation. 2018 , 29, 1065-1072		11

1036	Role of CHADS-VASc score in predicting new-onset atrial fibrillation in patients with type 2 diabetes mellitus with and without hyperosmolar hyperglycaemic state: real-world data from a nationwide cohort. 2018 , 8, e020065	5
1035	Burden of Atrial Fibrillation-Associated Ischemic Stroke in the United States. 2018 , 4, 618-625	36
1034	Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study. 2018 , 201, 149-157	16
1033	Optimal combination strategy of left atrial appendage closure plus catheter ablation in a single procedure in patients with nonvalvular atrial fibrillation. 2018 , 29, 1089-1095	9
1032	Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. 2018 , 41, 119-125	3
1031	Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis. 2018 , 41, 855-861	21
1030	Regularized Atrial Fibrillation. 2018 , 131, e361-e363	1
1029	Reversible or Provoked Atrial Fibrillation?: The Devil in the Details. 2018 , 4, 563-564	1
1028	Hot Balloon Versus Cryoballoon Ablation for Atrial Fibrillation: Lesion Characteristics and Middle-Term Outcomes. 2018 , 11, e005861	34
1027	Real-Time Pathophysiologic Correlates of Left Atrial Appendage Thrombus in Patients Who Underwent Transesophageal-Guided Electrical Cardioversion for Atrial Fibrillation. 2018 , 121, 1540-1547	7
1026	Usefulness of High-Dose Oral Flecainide for Termination of Recent-Onset Atrial Fibrillation in Children. 2018 , 121, 1530-1533	
1025	Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban. 2018 , 15, 496-502	16
1024	Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. 2018 , 8, e018180	31
1023	Indication, Patient Selection, and Referral Pathways for Left Atrial Appendage Closure. 2018 , 7, 169-183	5
1022	Smartwatch Algorithm for Automated Detection of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2381-2388	15.1 218
1021	An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. 2018 , 200, 17-23	56
1020	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. 2018 , 14, 337-351	50
1019	Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation. 2018 , 20, 32	16

1018	Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban. 2018 , 118, S34-S44		1
1017	Selective screening for atrial fibrillation using multivariable risk models. 2018 , 104, 1492-1499		13
1016	Atrial Fibrillation: Beyond Rate Control. 2018 , 93, 373-380		6
1015	Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials. 2018 , 52, 9-18		18
1014	CHA2DS2-VASc score for prediction of ischemic stroke in patients with systemic lupus erythematosus without atrial fibrillation. 2018 , 27, 1240-1246		6
1013	Impact of prophylactic cavotricuspid isthmus ablation in atrial fibrillation recurrence after a first pulmonary vein isolation procedure. 2018 , 259, 82-87		11
1012	Anticoagulation in atrial fibrillation with heart failure. 2018 , 23, 563-571		7
1011	Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. 2018 , 200, 24-31		22
1010	Ablation Outcomes and Predictors of Mortality Following Catheter Ablation for Ventricular Tachycardia: Data From the German Multicenter Ablation Registry. 2018 , 7,		8
1009	Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome: A Case of a Patient With Membranous Nephropathy. 2018 , 11, 1179547618763371		0
1008	Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program. 2018 , 41, 744-751		14
1007	Feasibility of Left Atrial Appendage Occlusion for Left Atrial Appendage Thrombus in Patients With Persistent Atrial Fibrillation. 2018 , 121, 1534-1539		17
1006	Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil. 2018 , 45, 578-587		
1005	Incident Atrial Fibrillation and Stroke in Patients With Atrial Flutter. 2018 , 34, 696-697		1
1004	Rivaroxaban With and Without Amiodarone in Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1395-1397	15.1	14
1003	Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. 2018 , 260, 93-98		10
1002	The Taiwan Heart Registries: Its Influence on Cardiovascular Patient Care. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1273-1283	15.1	24
1001	Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase. 2018 , 24, 247-253		4

1000	Imaging for percutaneous left atrial appendage closure. 2018 , 92, 437-450	9
999	CHA2DS2-VASc score for ischaemic stroke risk stratification in patients with chronic obstructive pulmonary disease with and without atrial fibrillation: a nationwide cohort study. 2018 , 20, 575-581	9
998	Conventional Acupuncture for Cardiac Arrhythmia: A Systematic Review of Randomized Controlled Trials. 2018 , 24, 218-226	9
997	Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation. 2018 , 20, 569-574	24
996	Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk. 2018 , 13, 87-93	14
995	Selecting antithrombotic therapy for stroke prevention in atrial fibrillation: Health professionals' feedback on a decision support tool. 2018 , 24, 309-322	5
994	Atrial Fibrillation Detection via Accelerometer and Gyroscope of a Smartphone. 2018 , 22, 108-118	70
993	A Novel Risk Scoring System to Predict Cardiovascular Death in Patients With Acute Myocardial Infarction: CHADS-VASc-CF Score. 2018 , 24, 273-278	2
992	Atrial fibrillation is associated with anterior predominant white matter lesions in patients presenting with embolic stroke. 2018 , 89, 6-13	32
991	Current Evidence-Based Understanding of the Epidemiology, Prevention, and Treatment of Atrial Fibrillation. 2018 , 43, 241-283	7
990	Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. 2018 , 20, e87-e95	11
989	Von Willebrand Factor: Multimeric Structure and Functional Activity in Patients With Atrial Fibrillation With and Without Oral Anticoagulation. 2018 , 24, 647-654	5
988	Mechanical dyssynchrony of the left atrium during sinus rhythm is associated with history of stroke in patients with atrial fibrillation. 2018 , 19, 433-441	17
987	Temporal pattern/episode duration-based classification of atrial fibrillation as paroxysmal vs. persistent: is it time to develop a more integrated prognostic score to optimize management?. 2018 , 20, f288-f298	9
986	Long-Term Results of Surgical Atrial Fibrillation Radiofrequency Ablation: Comparison of Two Methods. 2018 , 27, 621-628	4
985	Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation. 2018 , 27, 798-803	11
984	Predicting in a predicament: Stroke and hemorrhage risk prediction in dialysis patients with atrial fibrillation. 2018 , 31, 37-47	8
983	First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans. 2018 , 24, 914-919	9

982	Predictors of death in chronic Chagas cardiomyopathy patients with pacemaker. 2018 , 250, 260-265	5
981	Atrial fibrillation occurring transiently with stress. 2018 , 33, 58-65	18
980	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. 2018 , 121, 131-140	15
979	Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA DS VASc 1 or 2): A treatment dilemma. 2018 , 36, e12310	1
978	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2018 , 17, e196-e252	264
977	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2018 ,	151
976	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1677-1749	15.1 180
975	Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). 2018 , 33, 403-412	18
974	Geriatric Medicine. 2018 ,	
973	Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective. 2018 , 24, 22-32	9
972	Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence. 2018 , 52, 277-284	11
971	Optimal endpoint for catheter ablation of longstanding persistent atrial fibrillation: A randomized clinical trial. 2018 , 41, 172-178	6
970	Atrial Fibrillation in Women: Risks and Management. 2018 , 27, 107-114	
969	Burden of atrial fibrillation in Māori and Pacific people in New Zealand: a cohort study. 2018 , 48, 301-309	5
968	Exploring the dark side of left atrial appendage closure devices. 2018 , 29, 14-16	
967	Safety profiles of percutaneous left atrial appendage closure devices: An analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database from 2009 to 2016. 2018 , 29, 5-13	26
966	Special Problems in Management of Atrial Fibrillation in the Elderly. 2018 , 237-250	
965	Shared Decision-Making as the Future of Emergency Cardiology. 2018 , 34, 117-124	18

964	The predictive role of CHA2DS2-VASc score between venous thromboembolism and ischemic stroke: a large-scale cohort study. 2018 , 36, 628-633	8
963	Cardiac Monitoring. 2018 , 623-629	
962	Atrial Fibrillation. 2018 , 724-735	
961	CHAD is Dead: Pragmatic Utility of the CHADS-VASc Score in Non-Valvular Atrial Fibrillation?. 2018 , 33, 7-8	4
960	Effect of Aging on Mitochondrial Energetics in the Human Atria. 2018 , 73, 608-616	23
959	Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions. 2018 , 52, 185-197	3
958	An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. 2018 , 15, 107-115	42
957	Left Atrial Appendage Electrical Isolation for Treatment of Recurrent Atrial Fibrillation: A Meta-Analysis. 2018 , 4, 112-120	22
956	Pulmonary Vein Isolation for Atrial Fibrillation Can Be Achieved With Low Radiation Exposure. 2018 , 27, 812-818	1
955	'It's like a frog leaping about in your chest': Illness and treatment perceptions in persistent atrial fibrillation. 2018 , 23, 3-21	5
954	Achieving ventricular rate control in patients taking chronic beta-blocker therapy. 2018 , 36, 110-113	5
953	Left Atrial Appendage Therapies. 2018 , 473-487	
952	[Fine-tuning of antithrombotic therapy in patients with non-valvular atrial fibrillation. The AFINVA register]. 2018 , 50, 340-349	2
951	Transient Rotor Activity During Prolonged 3-Dimensional Phase Mapping in Human Persistent Atrial Fibrillation. 2018 , 4, 72-83	13
950	Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. 2018 , 59, 1554-1564	29
949	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2017. 2018 , 32, 1-13	5
948	Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. 2018 , 15, 651-657	64
947	Transoesophageal echocardiography prior to catheter ablation could be avoided in atrial fibrillation patients with a low risk of stroke and without filling defects in the late-phase MDCT scan: A retrospective analysis of 783 patients. 2018 , 28, 1835-1843	3

946	Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting. 2018 , 34, 539-546		1
945	Overview of Anticoagulation Agents. 2018 , 275-289		
944	Does "Secondary" Atrial Fibrillation Really Exist?. 2018 , 4, 394-396		
943	Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. 2018 , 34, 487-498		27
942	The impact of sustained new-onset atrial fibrillation on mortality and stroke incidence in critically ill patients: A retrospective cohort study. 2018 , 44, 267-272		16
941	Safety and efficacy analysis of one-stop intervention for treating nonvalvular atrial fibrillation. 2018 , 41, 28-34		5
940	Evaluating the potential for pharmacists to prescribe oral anticoagulants for atrial fibrillation. 2018 , 151, 51-61		3
939	Trends in outpatient anti-arrhythmic prescriptions for atrial fibrillation and left atrial ablation in Australia: 1997-2016. 2018 , 48, 427-432		3
938	Relationship Between Fibrosis Detected on Late Gadolinium-Enhanced Cardiac Magnetic Resonance and Re-Entrant Activity Assessed With Electrocardiographic Imaging in Human Persistent Atrial Fibrillation. 2018 , 4, 17-29		71
937	Medication Management of Patients Undergoing Transcatheter Aortic Valve Replacement. 2018 , 38, 122-138		4
936	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study. 2018 , 3, 54-63		44
935	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2018 , 71, e127-e248	15.1	462
934	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2018 , 71, e127-e248	15.1	2178
933	Vitamin K antagonist use and mortality in dialysis patients. 2018 , 33, 170-176		10
932	Age and sex differences in atrial fibrosis among patients with atrial fibrillation. 2018 , 20, 1086-1092		42
931	Relationship of respiratory muscle strength, pulmonary function, and functional capacity with quality of life in patients with atrial fibrillation. 2018 , 46, 195-203		5
930	What is the Impact of Frailty on Prescription of Anticoagulation in Elderly Patients with Atrial Fibrillation? A Systematic Review and Meta-Analysis. 2018 , 10, 1870		43
929	Management of Oral Anticoagulant-associated Intracerebral Hemorrhage. 2018 , 1, 114-125		

928	THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE. 2018 , 14, 350-355	1
927	Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes. 2018 , 20, 292-301	10
926	Clarifying the management of new-onset atrial fibrillation. 2018 , 13, 585-587	
925	Predictors of de novo atrial fibrillation in a non-cardiac intensive care unit. 2018 , 30, 166-173	3
924	New individualized strategy instructs cryoballoon energy ablation. 2018 , 10, 83-84	1
923	Atrial fibrillation is related to lower incidence of deep venous thrombosis in patients with pulmonary embolism. 2018 , 10, 1476-1482	2
922	Dynamic stroke risk scores of atrial fibrillation. 2018 , 10, 1332-1334	2
921	Arrhythmias and conduction disorders associated with atrial septal defects. 2018 , 10, S2940-S2944	11
920	Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial. 2018 , 37, 973-978	1
919	Heart Failure as a Risk Factor for Stroke. 2018 , 20, 33-45	36
918	Atrial fibrillation in patients with first-ever stroke: Incidence trends and antithrombotic therapy before the event. 2018 , 13, e0209198	2
917	High-grade atrioventricular block. 2018 , 59, 346-350	5
916	Leveraging Multi-modal User-labeled Data for Improved Accuracy in Interpretation of ECG Recordings. 2018 ,	0
915	Atrial Flutter: Diagnosis and Management strategies. 2018 ,	0
914	Comparison of Cryoablation and Radiofrequency Ablation Areas Demarcated by Postprocedural Electroanatomic Mapping in Patients with Atrial Fibrillation Treated by Pulmonary Vein Isolation. 2018 , 77, 7-12	3
913	Surgical left atrial appendage occlusion during cardiac surgery: A systematic review and meta-analysis. 2018 , 10, 242-249	11
912	Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation. 2018 , 2, e420-e427	3
911	OBSOLETE: Clinical Assessment of the Cardiac Arrhythmia Patient. 2018 ,	

910	2018 Korean Guideline of Atrial Fibrillation Management. 2018 , 48, 1033-1080	68
909	Resource use and clinical outcomes in patients with atrial fibrillation with ablation versus antiarrhythmic drug treatment. 2018 , 18, 211	9
908	Arrhythmogenic Substrates for Atrial Fibrillation in Obesity. 2018 , 9, 1482	15
907	Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease. 2018 , 1, e183874	7
906	A loss-of-function mutation underlying familial atrial fibrillation. 2018 , 15, 1564-1572	16
905	Comparison of cryoballoon and radiofrequency ablation techniques for atrial fibrillation: a meta-analysis. 2018 , 19, 725-738	11
904	The effect of body weight on intravenous diltiazem in patients with atrial fibrillation with rapid ventricular response. 2018 , 43, 855-859	1
903	Screening for Atrial Fibrillation During Automatic Blood Pressure Measurements. 2018 , 6, 4400307	3
902	A Review of Warfarin Dosing and Monitoring. 2018 , 13, 40-43	4
901	Reply: Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2546-2547	15.1
900	Relationship between changes in mitochondrial function and hippocampal neuronal apoptosis after recurrent convulsion during developmental stage. 2018 , 16, 127-132	3
899	Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation. 2018 , 38, 618-628	12
898	The effect of complex intramural microstructure caused by structural remodeling on the stability of atrial fibrillation: Insights from a three-dimensional multi-layer modeling study. 2018 , 13, e0208029	8
897	Long term outcomes after left atrial appendage closure with the LARIAT device-Stroke risk reduction over five years follow-up. 2018 , 13, e0208710	16
896	Atrial Fibrillation Screen, Management And Guideline Recommended Therapy (AF SMART II) in the rural primary care setting: an implementation study protocol. 2018 , 8, e023130	11
895	Heart diseases and echocardiography in rural Tanzania: Occurrence, characteristics, and etiologies of underappreciated cardiac pathologies. 2018 , 13, e0208931	12
894	Neural Network Detection of Atrial Fibrillation by Lorenz Plot Images of Interbeat Interval Variation. 2018 ,	1
893	Valve surgery in combination with cryoablation in the treatment of atrial fibrillation. 2018 , 34, 1402-1407	

892	CHADS-VASc score predicts exercise intolerance in young and middle-aged male patients with asymptomatic atrial fibrillation. 2018 , 8, 18039	1
891	Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial. 2018 , 37, 973-978	1
890	Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare. 2018 , 8, 647-662	5
889	Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KOREan Atrial Fibrillation Investigation II. 2018 , 33, e323	3
888	Echocardiographic Guidance of the Novel WaveCrest Left Atrial Appendage Occlusion Device. 2018 , 2, 297-300	3
887	Gender differences in symptoms and functional status in patients with atrial fibrillation undergoing catheter ablation. 2019 , 42, 224-229	8
886	A Novel Atrial Fibrillation Prediction Algorithm Applicable to Recordings from Portable Devices. 2018 , 2018, 4034-4037	4
885	Muscle Thickness and Curvature Influence Atrial Conduction Velocities. 2018 , 9, 1344	5
884	Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. 2018 , 320, 2354-2364	75
883	Relation between health literacy, self-care and adherence to treatment with oral anticoagulants in adults: a narrative systematic review. 2018 , 18, 1157	16
882	Atrial flutter, time to acknowledge its own identity. 2018 , 72, e13266	
881	Antiplatelet Therapy in Primary Spontaneous and Oral Anticoagulation-Associated Intracerebral Hemorrhage. 2018 , 49, 2621-2629	30
880	Development of a core outcome set (COS) and selecting outcome measurement instruments (OMIs) for non-valvular atrial fibrillation in traditional Chinese medicine clinical trials: study protocol. 2018 , 19, 541	10
879	Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk. 2018 , 41, 1395-1402	13
878	Demystifying the EP Laboratory: Anesthetic Considerations for Electrophysiology Procedures. 2018 , 56, 98-119	2
877	Uric Acid and Risk of Atrial Fibrillation in the Korean General Population. 2018 , 82, 2728-2735	8
876	The cessation of oral anticoagulation following left atrial appendage surgery. 2018 , 14, 407-415	0
875	Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges. 2018 , 48, 873-889	7

874	Clinical Assessment of the Cardiac Arrhythmia Patient. 2018 , 609-619	
873	Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions. 2018 , 132, 169-179	29
872	Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. 2018 , 169, 517-527	13
871	Diagnostic accuracy of STAF, LADS, and iPAB scores for predicting paroxysmal atrial fibrillation in patients with acute cerebral infarction. 2018 , 41, 1507-1512	5
870	Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events. 2018 , 49, 2301-2308	39
869	Prevention of venous thrombosis after electrophysiology procedures: a survey of national practice. 2018 , 53, 357-363	1
868	Epidemiology and Prognostic Importance of Atrial Fibrillation in Kidney Transplant Recipients: A Meta-Analysis. 2018 , 7,	6
867	DOAC use in patients with chronic kidney disease. 2018 , 47, 146-154	1
866	Treatment of Atrial Fibrillation in Patients with Co-existing Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines?. 2018 , 7, 91-94	11
865	Role of Echocardiography in Arrhythmia. 2018 , 489-497	
864	The Guideline-Policy Gap in Direct-Acting Oral Anticoagulants Usage in Atrial Fibrillation: Evidence, Practice, and Public Policy Considerations. 2018 , 34, 1412-1425	7
863	Atrial Fibrillation and Ventricular Arrhythmias in ST Segment Elevation Myocardial Infarction: Possibilities of Pharmacotherapy and Non-Pharmacological Treatment. 2018 , 14, 605-611	1
862	Atrial fibrillation occurring initially during acute medical illness: the heterogeneous nature of disease, outcomes and management strategies. 2018 , 2048872618801763	
861	Predictors of Major Bleeding Among Working-Age Adults with Atrial Fibrillation: Evaluating the Effects of Potential Drug-drug Interactions and Switching from Warfarin to Non-vitamin K Oral Anticoagulants. 2018 , 32, 591-600	3
860	Should All Atrial Fibrillation Be Considered a Life-Long Problem Requiring Prophylaxis Against Thromboembolism?. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2037-2039	15.1
859	Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2027-2036	15.1 45
858	Subclinical Hypothyroidism and Coronary Revascularization After Coronary Artery Bypass Grafting. 2018 , 122, 1862-1870	4
857	Termination of Atrial Fibrillation With Epicardial Cooling in the Oblique Sinus. 2018 , 4, 1362-1368	2

856	Novel Therapeutic Approach to Terminate Atrial Fibrillation: Time to Chill?. 2018 , 4, 1369-1371	
855	Left atrial appendage isolation in atrial fibrillation catheter ablation: A meta-analysis. 2018 , 34, 478-484	4
854	Management of atrial fibrillation-flutter: uptodate guideline paper on the current evidence. 2018 , 8, 269-275	6
853	Newer technologies for detection of atrial fibrillation. 2018 , 363, k3946	29
852	Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. 2018 , 118, 2171-2187	96
851	Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis. 2018 , 23, 49	8
850	Modernized Classification of Cardiac Antiarrhythmic Drugs. 2018 , 138, 1879-1896	83
849	The Clinical Dilemma of Anticoagulation Use in Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation. 2018 , 20, 106	12
848	Cardiology Consult Manual. 2018 ,	
847	Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. 2018 , 8, e022690	22
846	Pacing Treatment of Atrial Fibrillation Patients with Heart Failure: His Bundle Pacing Combined with Atrioventricular Node Ablation. 2018 , 10, 519-535	28
845	Revisiting Atrial Fibrillation in the Transcatheter Aortic Valve Replacement Era. 2018 , 7, 459-469	2
844	Meta-analysis of randomized controlled trials on atrial fibrillation ablation in patients with heart failure with reduced ejection fraction. 2018 , 41, 1430-1438	13
843	Patient perspectives of participating in the cardiac CopenHeartRFA rehabilitation program for patients treated with ablation for atrial fibrillation. 2018 , 11, 167-174	10
842	Design and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) follow-up cohort study. 2018 , 41, 1273-1280	12
841	Lifetime Pattern of Atrial Fibrillation and the Risks of Stroke and Death in a Population-based Cohort of Men (from The Manitoba Follow-Up Study). 2018 , 122, 1688-1693	1
840	In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate. 2018 , 8, 13290	10
839	Poor outcomes associated with antithrombotic undertreatment in patients with atrial fibrillation attending Gondar University Hospital: a retrospective cohort study. 2018 , 16, 22	6

838	A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants. 2018 , 13, e0203599	10
837	Cardioversion for atrial fibrillation - how to prevent thromboembolic complications?. 2018 , 50, 549-555	4
836	Sinus node dysfunction after surgical atrial fibrillation ablation with concomitant mitral valve surgery: Determinants and clinical outcomes. 2018 , 13, e0203828	2
835	Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?. 2018 , 20, 105	1
834	Risk of Incident Non-Valvular Atrial Fibrillation after Dialysis-Requiring Acute Kidney Injury. 2018 , 7,	3
833	Current and Future Use of Insertable 'Cardiac' Monitors. 2018 , 4, 1383-1396	27
832	Ideal Blood Pressure in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1233-1245	15.1 63
831	Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease: Atrial Fibrillation. 2018 , 13, 1423-1425	1
830	Comparison of Rhythm and Rate Control Strategies for Stroke Occurrence in a Prospective Cohort of Atrial Fibrillation Patients. 2018 , 59, 258-264	6
829	Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios. 2018 , 20, 56-62	14
828	Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry. 2018 , 11, 1746-1756	50
827	Sex Differences in Atrial Fibrillation-Update on Risk Assessment, Treatment, and Long-Term Risk. 2018 , 20, 79	1
826	New skip parameter to facilitate recurrence quantification of signals comprised of multiple components. 2018 , 28, 085718	1
825	Cost Analysis of Direct Oral Anticoagulants Compared with Warfarin in Patients with Blunt Traumatic Intracranial Hemorrhages. 2018 , 84, 1010-1014	4
824	Trileaflet aortic valve reconstruction using glutaraldehyde fixed autologous pericardium. 2018 , 4, 133-133	
823	Oral anticoagulation and left atrial thrombi resolution in nonrheumatic atrial fibrillation or flutter: A systematic review and meta-analysis. 2018 , 41, 767-774	8
822	Metabolic Syndrome and the Risk of New-Onset Atrial Fibrillation in Middle-Aged East Asian Men. 2018 , 82, 1763-1769	13
821	Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP-RHYTHM Study. 2018 , 3, 601-608	124

820	Uninterrupted Direct Oral Anticoagulant and Warfarin Administration in Elderly Patients Undergoing Catheter Ablation for Atrial Fibrillation: A Comparison With Younger Patients. 2018 , 4, 592-600	8
819	The characteristics of a porcine mitral regurgitation model. 2018 , 67, 463-477	7
818	Activation of TGF- β /SMA/Col I Profibrotic Pathway in Fibroblasts by Galectin-3 Contributes to Atrial Fibrosis in Experimental Models and Patients. 2018 , 47, 851-863	40
817	Arrhythmia-specific settings for automated high-density mapping: A multicenter experience. 2018 , 29, 1210-1220	3
816	The Disease Burden of Atrial Fibrillation in China from a National Cross-sectional Survey. 2018 , 122, 793-798	36
815	Bailout Atrial Balloon Septoplasty to Overcome Challenging Left Atrial Transseptal Access for Catheter Ablation of Atrial Fibrillation. 2018 , 4, 1011-1019	2
814	Prevalence, clinical characteristics, and outcome of atrial functional mitral regurgitation in hospitalized heart failure patients with atrial fibrillation. 2018 , 72, 292-299	16
813	Correlation between CHADS-VASc Score and Glaucoma Treatment and Prognosis. 2018 , 2018, 8931430	
812	Atrial arrhythmias are associated with increased mortality in pulmonary arterial hypertension. 2018 , 8, 2045894018790316	10
811	Relevance of electrical connectivity between the coronary sinus and the left atrial appendage for the intentional electrical isolation of the left atrial appendage in treating persistent atrial fibrillation: Insights from the LEIO-AF study. 2018 , 4, 420-424	2
810	Flecainide toxicity in renal failure. 2018 , 31, 328-330	7
809	Global Prospective Safety Analysis of Rivaroxaban. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 141-153	15.1 35
808	Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population. 2018 , 8, e020676	9
807	Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation. 2018 , 115, 287-294	11
806	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. 2018 , 4, 944-954	4
805	Sustained atrial fibrillation increases the risk of anticoagulation-related bleeding in heart failure. 2018 , 107, 1170-1179	2
804	Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis. 2018 , 46, 134-138	
803	Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban. 2018 , 34, 2053-2061	1

802	Bisoprolol Transdermal Patch Is Effective for the Treatment of AF Tachycardia. 2018 , 2018, 9139302		1
801	Screening for undiagnosed atrial fibrillation. 2018 , 16, 591-598		8
800	Cardiovascular Therapies Targeting Left Atrial Appendage. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 448-463	15.1	28
799	Association between Sleep Apnea Hypopnea Syndrome and the Risk of Atrial Fibrillation: A Meta-Analysis of Cohort Study. 2018 , 2018, 5215868		13
798	A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants. 2018 , 269, 174-181		26
797	Atrial Fibrillation in Athletes. 2018 , 241-256		
796	Atrial fibrillation: is there enough evidence to recommend opportunistic or systematic screening?. 2018 , 47, 1372-1378		6
795	Impact of high-grade atrioventricular block and cumulative frequent pacing on atrial arrhythmias. 2018 , 41, 1158-1164		3
794	Dementia and Atrial Fibrillation: Pathophysiological Mechanisms and Therapeutic Implications. 2018 , 131, 1408-1417		21
793	Left atrial thrombus despite continuous direct oral anticoagulant or warfarin therapy in patients with atrial fibrillation: insights into rates and timing of thrombus resolution. 2018 , 53, 159-167		5
792	Novel Markers for Adverse Events in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 734-737	15.1	1
791	Applications of low-cost 3D printing in left atrial appendage closure using epicardial approaches - initial clinical experience. 2018 , 15, 135-140		4
790	Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force. 2018 , 320, 485-498		69
789	Atrial fibrillation and obstructive lung disease: Don't fear the ß-blocker. 2018 , 15, 1833-1834		0
788	Emergency Department Visits for Atrial Fibrillation in the United States: Trends in Admission Rates and Economic Burden From 2007 to 2014. 2018 , 7,		41
787	Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010-2015. 2018 , 14, 803-809		5
786	Atrial fibrillation in aging population. 2018 , 1, 67-74		9
785	Rationale and Design of the Evaluation of Oral Anticoagulation for Reduction of Thrombo-embolism in Chinese Patients with Device-Detected Subclinical Atrial Fibrillation (ART-CAF) Trial: an Open-Label Registry-Based Clinical Trial. 2018 , 32, 389-396		1

784	Gender-related Differences in Management of Nonvalvular Atrial Fibrillation in an Asian Population. 2018 , 48, 519-528		13
783	Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography. 2018 , 26, 1-25		15
782	Comparison of audio vs. audio + video for the rating of shared decision making in oncology using the observer OPTION instrument: an exploratory analysis. 2018 , 18, 522		10
781	Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients. 2018 , 48, 665-684		31
780	Electronic physician notifications to improve guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. 2018 , 33, 2070-2077		15
779	Response to: "Enlisting Emergency Medicine Clinicians to Help Reduce Strokes in High-Risk Patients With Atrial Fibrillation and Flutter". 2018 , 104, 615		
778	Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan. 2018 , 66, 1567-1574		15
777	Atrial Fibrillation. 2018 , 323-329		0
776	Are NSAIDs Double Trouble?. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 268-270	15.1	4
775	Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 271-282	15.1	37
774	Differential Association of Cx37 and Cx40 Genetic Variants in Atrial Fibrillation with and without Underlying Structural Heart Disease. 2018 , 19,		6
773	Interventional Left Atrial Appendage Closure Affects the Metabolism of Acylcarnitines. 2018 , 19,		5
772	Stroke Prophylaxis After a New Emergency Department Diagnosis of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 471-472	15.1	3
771	Clinical Trials in Atrial Fibrillation: Lessons From the Box Score. 2018 , 4, 955-957		1
770	Age Threshold for Ischemic Stroke Risk in Atrial Fibrillation. 2018 , 49, 1872-1879		19
769	Erectile dysfunction and atrial fibrillation: A systematic review and meta-analysis. 2018 , 25, 752-757		4
768	Surface ECG and intracardiac spectral measures predict atrial fibrillation recurrence after catheter ablation. 2018 , 29, 1371-1378		7
767	Reducing age bias in decision analyses of anticoagulation for patients with nonvalvular atrial fibrillation - A microsimulation study. 2018 , 13, e0199593		2

766	Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities). 2018 , 11, e006350	68
765	Assessment of anticoagulation treatments in non-valvular atrial fibrillation patients diagnosed in a basic health area. 2018 , 30, 56-63	
764	Long-term clinical outcomes of catheter ablation in patients with atrial fibrillation predisposing to tachycardia-bradycardia syndrome: a long pause predicts implantation of a permanent pacemaker. 2018 , 18, 106	6
763	Ischemic stroke risk during long-term follow up in patients with successful catheter ablation for atrial fibrillation in Korea. 2018 , 13, e0201061	4
762	Incident Atrial Fibrillation and the Risk of Stroke in Adults with Chronic Kidney Disease: The Stockholm CREATinine Measurements (SCREAM) Project. 2018 , 13, 1314-1320	25
761	Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome. 2018 , 9, 758	21
760	Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function : Post hoc analysis of a prospective cohort. 2018 , 13, 1059-1067	13
759	The Clinical Benefits and Mortality Reduction Associated With Catheter Ablation in Subjects With Atrial Fibrillation: A Systematic Review and Meta-Analysis. 2018 , 4, 626-635	24
758	Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. 2018 , 18, 317-325	5
757	Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management. 2018 , 19, 4	5
756	Neu Auftreten von Vorhofflimmern bei Sepsis. 2018 , 21, 56-65	
755	Oral Anticoagulation in Patients With Liver Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2162-2175	15.1 83
754	Minimally Invasive Delivery of Hydrogel-Encapsulated Amiodarone to the Epicardium Reduces Atrial Fibrillation. 2018 , 11, e006408	8
753	Editorial commentary: Evolving paradigms for stroke prevention in patients with atrial fibrillation. 2018 , 28, 481-482	
752	A systematic review of clinicians' views and experiences of direct-acting oral anticoagulants in the management of nonvalvular atrial fibrillation. 2018 , 84, 2692-2703	13
751	A survey of reasons for continuing warfarin therapy in the era of direct oral anticoagulants in Japanese patients with atrial fibrillation: the SELECT study. 2018 , 12, 135-143	15
750	Relationship Between Psychosocial Stressors and Atrial Fibrillation in Women >45 Years of Age. 2018 , 122, 1684-1687	11
749	The changing landscape of thromboprophylaxis for atrial fibrillation: insights from the ISPAF-2 survey. 2018 , 13, 1005-1007	0

748	His Bundle Pacing. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 927-947	15.1	138
747	Selected highlights from clinical anesthesia and pain management. 2018 , 51, 108-117		3
746	Evaluation of anticoagulation use and subsequent stroke in patients with atrial fibrillation after empiric surgical left atrial appendage closure: A retrospective case-control study. 2018 , 41, 1578-1582		11
745	Healthcare Utilization and Expenditures in Working-Age Adults with Atrial Fibrillation: The Effect of Switching from Warfarin to Non-Vitamin K Oral Anticoagulants. 2018 , 18, 513-520		1
744	CAD Is an Independent Risk Factor for Stroke Among Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2540-2542	15.1	12
743	Preparation for and Implementation of Shared Medical Appointments to Improve Self-Management, Knowledge, and Care Quality Among Patients With Atrial Fibrillation. 2018 , 2, 218-225		4
742	Outcomes With Novel Oral Anticoagulants in Obese Patients who Underwent Electrical Cardioversion for Atrial Tachyarrhythmias. 2018 , 122, 1175-1178		3
741	Directed graph mapping exceeds phase mapping in discriminating true and false rotors detected with a basket catheter in a complex in-silico excitation pattern. 2021 , 133, 104381		3
740	Racial differences in the incidence of atrial fibrillation after cryptogenic stroke. 2021 , 18, 847-852		1
739	Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update. 2021 , 8, 660986		1
738	Post Procedural Peak Left Atrial Contraction Strain Predicts Recurrence of Arrhythmia after Catheter Ablation of Atrial Fibrillation. 2021 , 19, 22		3
737	Human induced pluripotent stem cell-derived atrial cardiomyocytes carrying an SCN5A mutation identify nitric oxide signaling as a mediator of atrial fibrillation. 2021 , 16, 1542-1554		6
736	Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns. 2021 , 43, 1179-1190.e3		0
735	Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2717-2746	15.1	39
734	Effect of electrical cardioversion on 1-year outcomes in patients with early recurrence after catheter ablation for atrial fibrillation. 2021 , 44, 1128-1138		1
733	Methylation of CYP1A1 and VKORC1 promoter associated with stable dosage of warfarin in Chinese patients. 2021 , 9, e11549		1
732	Cardioversion of Atrial Fibrillation with Acupuncture. 2021 , 33, 235-239		
731	Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. 2021 , 18, e1003599		5

730	Automated left atrial time-resolved segmentation in MRI long-axis cine images using active contours. 2021 , 21, 101	5
729	Supervised Obesity Reduction Trial for AF ablation patients: results from the SORT-AF trial. 2021 , 23, 1548-1558	7
728	Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VerT trial. 2021 , 23, 1539-1547	0
727	Triglyceride-Glucose Index Independently Predicts New-Onset Atrial Fibrillation After Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy Beyond the Traditional Risk Factors. 2021 , 8, 692511	3
726	Factors Affecting Wearable ECG Device Adoption by General Practitioners for Atrial Fibrillation Screening: Cross-Sectional Study (Preprint).	
725	. 2021 , 193, E1107-E1113	
724	Triangular plasty of left atrium in correction of mitral failure. 2021 , 88, 3-7	0
723	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2021 , 162, e23-e106	9
722	Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions. 2021 , 1	6
721	Outpatient Initiation of Sotalol in Patients with Atrial Fibrillation: Utility of Cardiac Implantable Electronic Devices for Therapy Monitoring. 2021 , 21, 693-700	3
720	Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREncE in atrial fibrillation (SmartADHERE) a randomized clinical trial. 2021 , 237, 68-78	2
719	Hypertension control and end-stage renal disease in atrial fibrillation: a nationwide population-based cohort study. 2021 , 1	
718	Quarterly versus annual ECG screening for atrial fibrillation in older Chinese individuals (AF-CATCH): a prospective, randomised controlled trial. 2021 ,	2
717	Mobile Health for Arrhythmia Diagnosis and Management. 2021 , 1	2
716	Higher FT4 level within the normal range predicts the outcome of cryoballoon ablation in paroxysmal atrial fibrillation patients without structural heart disease. 2021 , 26, e12874	1
715	Risk Thresholds for Total and Beverage-Specific Alcohol Consumption and Incident Atrial Fibrillation. 2021 , 7, 1561-1561	3
714	Clinical Significance of Atrial Fibrillation Status in Patients With Percutaneous Coronary Intervention.. 2021 , 3, 1357-1364	0
713	Warfarin Treatment Is Associated to Increased Internal Carotid Artery Calcification. 2021 , 12, 696244	1

712	Fluoroscopy and contrast media use in cryoballoon ablation of atrial fibrillation using a novel imaging system. 2021 , 1	1
711	Health literacy of patients on oral anticoagulation treatment- individual and social determinants and effect on health and treatment outcomes. 2021 , 21, 1363	1
710	The Role of Exosomes and Their Cargos in the Mechanism, Diagnosis, and Treatment of Atrial Fibrillation. 2021 , 8, 712828	1
709	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies. 2021 , 30, 1339-1352	4
708	Simulation Trainings in the Optimization of Medical Care for Patients with Acute Coronary Syndrome. 2021 , 60-63	
707	Prognostic value of troponin I in atrial fibrillation. 2021 , 67, 80-88	1
706	How to Achieve Near Zero Fluoroscopy During Radiofrequency Ablation of Atrial Fibrillation: A Strategy Used at Two Centers. 2021 , 17, 33238846	
705	Atrial fibrillation and atrial cardiomyopathies. 2021 , 32, 2845-2853	0
704	Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical Trial. 2021 , 4, e2121867	5
703	Prognostic impact of the presence of chronic kidney disease on percutaneous left atrial appendage closure for atrial fibrillation: A single center experience. 2021 ,	0
702	Usage Patterns of Web-Based Stroke Calculators in Clinical Decision Support: Retrospective Analysis. 2021 , 9, e28266	1
701	Perioperative Cardiac Risk Reduction in Noncardiac Surgery. 2021 , 96, 2260-2276	1
700	SUPPORT-AF IV: Supporting use of AC through provider prompting about oral anticoagulation therapy for AF clinical trial study protocol.. 2021 , 2, 222-230	
699	Oral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation. 2021 , 27, 857-864	1
698	CHA2DS2-VASc-HSF Score may Better Predict the Development of Total Coronary Artery Occlusion in Acute Coronary Syndrome. 2021 , 33197211040348	1
697	Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment. 2021 , 18, e1003730	2
696	Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. 2021 , 16, e0256338	1
695	Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. 2021 , 398, 1498-1506	33

- 694 Post-ablation P wave characteristics correlate with recurrent atrial fibrillation in the ABCD-AF cohort. **2021**, 1
- 693 Location of Parasympathetic Innervation Regions From Electrograms to Guide Atrial Fibrillation Ablation Therapy: An Modeling Study. **2021**, 12, 674197 0
- 692 The Hidden Value of a CHADS-VASc Score. **2021**, 29, 69-70
- 691 8-hydroxy-pinorensinol-4-O-β-D-glucoside from *Valeriana officinalis* L. Is a Novel Kv1.5 Channel Blocker. **2021**, 276, 114168
- 690 Role of digital health in detection and management of atrial fibrillation. **2021**, 0
- 689 Genetic Determinants of Increased Body Mass Index Partially Mediate the Effect of Elevated Birth Weight on the Increased Risk of Atrial Fibrillation. **2021**, 8, 701549 0
- 688 Is Continuing Anticoagulation or Antiplatelet Therapy Safe Prior to Kidney Transplantation?. **2021**, 26, e931648 0
- 687 Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial. **2021**, 25, 289 1
- 686 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. **2021**, 26, 4594 31
- 685 Rhythm outcomes after aortic valve surgery: Treatment and evolution of new-onset atrial fibrillation. **2021**, 44, 1432-1439 1
- 684 Cardiac tissue conductivity estimation using confirmatory factor analysis. **2021**, 135, 104604 1
- 683 Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study. **2021**, 10, 0
- 682 Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis. **2021**, 1 0
- 681 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. **2021**, 162, e183-e353 22
- 680 Atrial Fibrillation: Overview of Antiarrhythmic Drugs With Rhythm Control Strategy. **2021**,
- 679 CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin. **2021**, 78, 180-189 3
- 678 Evaluating outcomes of same-day discharge after catheter ablation for atrial fibrillation in a real-world cohort. **2021**, 2, 333-340 1
- 677 Systematic review of treatment gaps in oral anticoagulant use in atrial fibrillation. **2021**, 4, 100053

676	Factors influencing the outcome of cardiogenic cerebral embolism: a literature review. 2021 , 1-9	1
675	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: A nationwide, population-based study in Korea. 2021 , 37, 1240-1249	1
674	Plasma carbohydrate antigen-125 for prediction of atrial fibrillation recurrence after radiofrequency catheter ablation. 2021 , 21, 400	0
673	The surgical technique of the convergent procedure. 2021 , 32, 3221-3227	
672	Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. 2021 , 91, 75-80	
671	Absent or Mild Coronary Calcium Predicts Low-Risk Stress Test Results and Outcomes in Patients Considered for Flecainide Therapy. 2021 , 26, 648-655	
670	A cross-sectional analysis of racial differences in accelerated aging and cognitive function among patients with atrial fibrillation: The SAGE-AF study: Forrester, Accelerated aging and cognitive function. 2021 , 39, 101060	
669	Hyperthyroidism With Atrial Fibrillation in Children: A Case Report and Review of the Literature. 2021 , 12, 689497	3
668	Sex Differences and Regulatory Actions of Estrogen in Cardiovascular System. 2021 , 12, 738218	3
667	Calcium Signaling Silencing in Atrial Fibrillation: Implications for Atrial Sodium Homeostasis. 2021 , 22,	1
666	Left atrial appendage orifice area and morphology is closely associated with flow velocity in patients with nonvalvular atrial fibrillation. 2021 , 21, 442	3
665	Anticoagulation in cardiomyopathy: unravelling the hidden threat and challenging the threat individually. 2021 ,	1
664	Outpatient Prescription Practices in Patients with Atrial Fibrillation (From the NCDR PINNACLE Registry). 2021 , 155, 32-39	1
663	Short-term and Long-term Risk of Stroke in Patients With Perioperative Atrial Fibrillation After Cardiac Surgery: Systematic Review and Meta-analysis.. 2022 , 4, 85-96	2
662	Impact of left atrial geometric remodeling on late atrial fibrillation recurrence after catheter ablation. 2021 , 22, 909-916	1
661	Alcohol intake and risk of stroke in atrial fibrillation: the lesser the better, but this is not enough. 2021 , 42, 4769-4771	2
660	Effect of preprocedural pharmacologic cardioversion on pulmonary vein isolation in patients with persistent atrial fibrillation. 2021 , 18, 1473-1479	1
659	Impact of sinus rhythm maintenance on major adverse cardiac and cerebrovascular events after catheter ablation of atrial fibrillation: insights from AF frontier ablation registry. 2021 , 1	1

- 658 Use of risk scores for predicting new atrial fibrillation after ischemic stroke or transient ischemic attack-A systematic review. **2021**, 17474930211045880 3
- 657 Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding. **2021**, 10, 100222 1
- 656 A novel method to demonstrate thrombus formation of the left atrial appendage in patients with persistent atrial fibrillation by cardiac computed tomography. **2021**, 36, 100866
- 655 Association of onset time of new-onset atrial fibrillation with in-hospital mortality among critically ill patients: A secondary analysis of a prospective multicenter observational study. **2021**, 36, 100880
- 654 Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors. **2021**, 52, 3121-3131
- 653 Applying cooperative module pair analysis to uncover compatibility mechanism of Fangjis: An example of Wenxin Keli decoction. **2021**, 278, 114214 1
- 652 The Watchman device for preventing stroke in patients with atrial fibrillation. **2021**, 34, 33-38
- 651 Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry. **2021**, 240, 58-62 1
- 650 Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients with Atrial Fibrillation. **2021**, 22, 2190-2195 1
- 649 AFCNNet: Automated detection of AF using chirplet transform and deep convolutional bidirectional long short term memory network with ECG signals. **2021**, 137, 104783 8
- 648 Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. **2021**, 41, 101139 6
- 647 Intravenous magnesium in the management of rapid atrial fibrillation: A systematic review and meta-analysis. **2021**, 78, 375-381 1
- 646 Hematologic Risk Assessment. **2022**, 101-120
- 645 Atrial Fibrillation Ablation. **2022**, 44-49
- 644 Bigeminal potentials in the pulmonary vein indicate arrhythmogenic trigger of atrial fibrillation. **2021**, 37, 331-337 0
- 643 Sleep Apnea and Atrial Fibrillation: Role of the Cardiac Autonomic Nervous System. **2021**, 17, 49-52 0
- 642 Long-term oral anticoagulant after catheter ablation for atrial fibrillation. **2021**, 23, 1157-1165 3
- 641 Unique Features of Cardiovascular Pharmacology in Pregnancy and Lactation. **2021**, 437-478

640	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.. 2021 ,	21
639	Hemodynamic Instability During Liver Transplantation in Patients With End-stage Liver Disease: A Consensus Document from ILTS, LICAGE, and SATA. 2021 , 105, 2184-2200	3
638	Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. 2019 , 9, CD005049	21
637	Correlation between cardiac rhythm, left atrial appendage flow velocity, and CHA DS -VASc score: Study based on transesophageal echocardiography and 2-dimensional speckle tracking. 2017 , 40, 120-125	10
636	Heart Drugs and Influences on TH Metabolism. 2020 , 311-325	2
635	Acute Exacerbations of Chronic Lung Disease: Cardiac Considerations. 2020 , 229-245	1
634	Arrhythmias and Electrolyte Imbalances as Consequences of Cancer. 2017 , 75-88	2
633	Cognitive Impairment/Dementia in Chronic Renal Disease. 2017 , 515-539	1
632	Arrhythmias in Cancer Patients. 2020 , 733-751	1
631	Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation. 2020 , 133, e554-e567	6
630	Echocardiography and cardiac arrhythmias. 2018 , 59, 140-149	10
629	Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter. 2020 , 2, 747-754	4
628	Left Atrial Appendage Thrombus in Transcatheter Aortic Valve Replacement: Incidence, Clinical Impact, and the Role of Cardiac Computed Tomography. 2017 , 10, 176-184	14
627	Rhythm and rate control of atrial fibrillation in the emergency department - A large community-based observational study. 2018 , 20, 834-840	4
626	Inflammatory and Antioxidant Gene Transcripts: A Novel Profile in Postoperative Atrial Fibrillation. 2021 , 33, 948-955	2
625	GATA6 is a regulator of sinus node development and heart rhythm. 2021 , 118,	2
624	Genomic Prediction of Complex Disease Risk.	2
623	Geriatric Syndromes and Atrial Fibrillation: Prevalence and Association with Anticoagulant Use in a National Cohort of Older Americans. 2021 , 69, 349-356	3

622	Bivalirudin fails to prevent atrial thrombus development in heparin-induced thrombocytopenia and thrombosis syndrome. 2018 , 2018,	1
621	Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. 2018 , 361, k1717	15
620	Atrial Cardiopathy in the Absence of Atrial Fibrillation Increases Risk of Ischemic Stroke, Incident Atrial Fibrillation, and Mortality and Improves Stroke Risk Prediction. 2020 , 9, e013227	8
619	Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience. 2018 , 23, 155-161	8
618	Association of right atrial structure with incident atrial fibrillation: a longitudinal cohort cardiovascular magnetic resonance study from the Multi-Ethnic Study of Atherosclerosis (MESA). 2020 , 22, 36	8
617	A review on atrioventricular junction ablation and pacing for heart rate control of atrial fibrillation. 2015 , 12, 547-54	9
616	Cardiac drug therapy-considerations in the elderly. 2016 , 13, 992-997	5
615	Dual versus single antiplatelet therapy for patients with long-term oral anticoagulation undergoing coronary intervention: a systematic review and meta-analysis. 2017 , 14, 725-736	2
614	2019 Chinese guideline for the management of hypertension in the elderly. 2019 , 16, 67-99	28
613	Atrial-Esophageal Fistula After Catheter Ablation: Diagnosing and Managing a Rare Complication of a Common Procedure. 2019 , 20, 557-561	4
612	External Cardioversion-Defibrillation with Pushing Down on the Chest Wall to Increase the Success Rate in Obese Patients. 2020 , 21, e927009	1
611	The Association Between the Use of Antiarrhythmic Drugs in Non-Valvular Atrial Fibrillation and Patient Prognosis Using Data from the China Atrial Fibrillation (China-AF) Registry. 2019 , 25, 4856-4868	2
610	Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention. 2016 , 5, 2887	3
609	Comparison of the effectiveness and side effects of dofetilide and dronedarone in the treatment of atrial fibrillation during an indicated period in time with perceived equipoise. 5, 216	2
608	Assessment of Direct Oral Anticoagulant Prescribing and Monitoring Pre- and Post-Implementation of a Pharmacy Protocol at a Community Teaching Hospital. 2017 , 52, 207-213	6
607	Rate control management of atrial fibrillation: may a mathematical model suggest an ideal heart rate?. 2015 , 10, e0119868	17
606	The Contribution of Ionic Currents to Rate-Dependent Action Potential Duration and Pattern of Reentry in a Mathematical Model of Human Atrial Fibrillation. 2016 , 11, e0150779	19
605	Shensongyangxin Capsules for Paroxysmal Atrial Fibrillation: A Systematic Review of Randomized Clinical Trials. 2016 , 11, e0151880	8

604	Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States. 2016 , 11, e0157769	27
603	Clinical, Echocardiographic, and Electrocardiographic Predictors of Persistent Atrial Fibrillation after Dual-Chamber Pacemaker Implantation: An Integrated Scoring Model Approach. 2016 , 11, e0160422	1
602	Comparison of Approaches for Stroke Prophylaxis in Patients with Non-Valvular Atrial Fibrillation: Network Meta-Analyses of Randomized Controlled Trials. 2016 , 11, e0163608	6
601	Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study. 2016 , 11, e0166218	22
600	Prediction of Thromboembolic Events in Heart Failure Patients in Sinus Rhythm: The Hong Kong Heart Failure Registry. 2016 , 11, e0169095	6
599	The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and Trial Sequential Analysis. 2017 , 12, e0186856	27
598	Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study. 2017 , 12, e0189495	58
597	Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. 2018 , 13, e0193924	20
596	Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future. 2016 , 43, 287-90	9
595	Proarrhythmic Antiarrhythmic. 2016 , 43, 507-508	0
594	Efficacy of Intravenous Administration of Landiolol in Patients With Acute Heart Failure and Supraventricular Tachyarrhythmia. 2017 , 9, 426-432	7
593	Electrophysiologic Complications in Cancer Patients. 2019 , 15, 282-288	3
592	Ablation of Atrial Fibrillation Drivers. 2017 , 6, 195-201	5
591	Evaluating the Cost-effectiveness of Catheter Ablation of Atrial Fibrillation. 2014 , 3, 177-83	13
590	Upstream Treatment of Atrial Fibrillation with n-3 Polyunsaturated Fatty Acids: Myth or Reality?. 2015 , 4, 163-8	5
589	Pharmacological Therapy of Tachyarrhythmias During Pregnancy. 2016 , 5, 41-4	7
588	Pharmacological Tests in Atrial Fibrillation Ablation. 2016 , 5, 170-176	6
587	Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy. 2017 , 6, 63-68	10

586	Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management. 2018 , 7, 43-48	37
585	Individualised Approaches for Catheter Ablation of AF: Patient Selection and Procedural Endpoints. 2019 , 8, 184-190	7
584	The Evolving Role of Catheter Ablation in Patients With Heart Failure and AF. 2019 , 8, 47-53	1
583	Atrial Tachycardias After Atrial Fibrillation Ablation: How to Manage?. 2020 , 9, 54-60	3
582	Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal. 2016 , 11, 118-122	2
581	A patient with atrial fibrillation and comorbidities in clinical practice. 2020 , 25, 4178	1
580	A novel TBX5 mutation predisposes to familial cardiac septal defects and atrial fibrillation as well as bicuspid aortic valve. 2020 , 43, e20200142	5
579	Perioperative management of patients receiving non-vitamin K antagonist oral anticoagulants: up-to-date recommendations. 2020 , 15, 133-142	1
578	[Chronic obstructive pulmonary disease and cardiovascular comorbidity]. 2019 , 59, 24-36	9
577	Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?. 2018 , 18, e13-e23	4
576	The Persistence of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Non-Valvular Atrial Fibrillation. 2016 , 17, 190-199	1
575	Stroke Prevention in Atrial Fibrillation. 2017 , 18, 137-142	3
574	Prevalence of Atrial Fibrillation in Korean Population. 2017 , 18, 195-204	8
573	Efficacy and Safety Outcomes of Catheter Ablation of Non-valvular Atrial Fibrillation in Korean Practice: Analysis of Nationwide Claims Data. 2018 , 19, 14-21	2
572	2018 Korean Guidelines for Catheter Ablation of Atrial Fibrillation: Part I. 2018 , 19, 186-234	2
571	2018 Korean Guidelines for Catheter Ablation of Atrial Fibrillation: Part II. 2018 , 19, 235-284	1
570	Old age, high risk medication, polypharmacy: a 'trilogy' of risks in older patients with atrial fibrillation. 2016 , 14, 706	22
569	Anticoagulants inhibit proteolytic clearance of plasma amyloid beta. 2018 , 9, 5614-5626	8

568	Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHADS-VASc score-a nationwide cohort study. 2018 , 9, 7623-7630	11
567	Long-term prescribing of new oral anticoagulants. 2016 , 39, 200-204	7
566	Monitoring for AF: Identifying the Burden of Atrial Fibrillation and Assessing Post-Ablation. 2017 , 8, 2575-25824	
565	When Silence Isn't Golden: The Case of "Silent" Atrial Fibrillation. 2017 , 8, 2886-2893	0
564	Hypertension associated with atrial fibrillation. 2017 , 5, 457	4
563	Is early invasive management as ST elevation myocardial infarction warranted in de Winter's sign?-a "peak" into the widow-maker. 2019 , 7, 412	3
562	Technical development in cardiac CT: current standards and future improvements-a narrative review. 2020 , 10, 2018-2035	4
561	Drug Therapy Problems and the Role of Clinical Pharmacist in Surgery Ward: Prospective Observational and Interventional Study. 2020 , 12, 71-83	10
560	Post Cardiovascular Surgery Atrial Fibrillation. Biomarkers Determining Prognosis. 2019 , 26, 916-924	4
559	MicroRNAs in Atrial Fibrillation. 2019 , 26, 855-863	9
558	Antithrombotic Treatment in Cardiomyopathies. 2020 , 26, 2762-2768	0
557	Digoxin in Atrial Fibrillation: An Old Topic Revisited. 2020 , 16, 141-146	1
556	Accuracy and Usability of a Novel Algorithm for Detection of Irregular Pulse Using a Smartwatch Among Older Adults: Observational Study. 2019 , 3, e13850	21
555	Handheld Ultrasound as a Novel Predictive Tool in Atrial Fibrillation: Prediction of Outcomes Following Electrical Cardioversion. 2018 , 2, e7	1
554	Processes and Recommendations for Creating mHealth Apps for Low-Income Populations. 2017 , 5, e41	22
553	The effect of aerobic physical rehabilitation on the quality of life in patients with chronic atrial fibrillation; A randomized controlled clinical trial study. 2019 , 15, 1-8	3
552	Atrial fibrillation without cardiac anomaly in a 9-year-old child. 2018 , 5, 67-71	1
551	Concurrent renal dysfunction with ischemic heart disease is an important determinant for cardiac and cerebrovascular mortality in patients on chronic digoxin therapy for atrial fibrillation. 2018 , 37, 130-137	8

550	Russian clinical guidelines Coronary artery bypass grafting in patients with ischemic heart disease: rehabilitation and secondary prevention. 2016 , 7, 5-71	35
549	Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea. 2019 , 60, 1157-1163	2
548	Ageing related down-regulation of myocardial connexin-43 and up-regulation of MMP-2 may predict propensity to atrial fibrillation in experimental animals. 2016 , 65 Suppl 1, S91-S100	23
547	Changes in heart rate variability in patients with atrial fibrillation after pulmonary vein isolation and ganglionated plexus ablation. 2019 , 68, 49-57	2
546	Extracorporeal Cardiopulmonary Resuscitation in a Cardiac Arrest Patient Due to Digoxin Overdose Who Was Awake During Conventional Cardiopulmonary Resuscitation. 2019 , 10, 124-127	1
545	Severe esophageal injury after radiofrequency ablation - a deadly complication. 2017 , 23, 3374-3378	5
544	Series with complete resolution of left atrial appendage thrombi with apixaban in elderly patients. 2016 , 31, 396-8	3
543	A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a Comparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF). 2020 , 35, 99-108	10
542	The effect of psyllium supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. 2020 , 35, 1385-1399	2
541	Management Of Atrial Fibrillation In Patients With Heart Failure. 2014 , 7, 1105	1
540	Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation. 2014 , 7, 1112	14
539	Electroanatomical mapping of atrial fibrillation: Review of the current techniques and advances. 2014 , 7, 1140	11
538	Outcomes Of Cryoballoon Ablation Of Atrial Fibrillation: A Comprehensive Review. 2015 , 8, 1231	9
537	Electrophysiological Perspectives on Hybrid Ablation of Atrial Fibrillation. 2015 , 8, 1290	4
536	Advanced Mapping Systems To Guide Atrial Fibrillation Ablation: Electrical Information That Matters. 2016 , 8, 1337	15
535	Atrial Fibrillation and Risk of Dementia/Cognitive Decline. 2016 , 8, 1353	13
534	A Comparison Between Dabigatran and Warfarin on Time to Elective Cardioversion. 2016 , 8, 1355	4
533	The Role Of NOACs in Atrial Fibrillation Management: A Qualitative Study. 2016 , 9, 1416	13

532	Cryoballoon versus Radiofrequency Ablation for Atrial Fibrillation: A Meta-analysis of 16 Clinical Trials. 2016 , 9, 1429	9
531	Safety of The Direct Oral Anticoagulant Edoxaban for Atrial Fibrillation After Cardiac Surgery: Pilot Study. 2016 , 9, 1456	8
530	Validation Of The HAS-BLED Tool In Atrial Fibrillation Patients Receiving Rivaroxaban. 2016 , 9, 1461	6
529	Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient. 2016 , 9, 1509	3
528	Percutaneous Left Atrial Appendage Closure: is there a Role in Valvular Atrial Fibrillation. 2017 , 9, 1524	4
527	California study of Ablation (CAABL):early utilization after index hospitalization for non-valvular atrial fibrillation. 2017 , 10, 1599	1
526	Atrial Fibrillation in Patients with Congenital Heart Disease. 2017 , 10, 1612	10
525	Management of Stroke risk in atrial fibrillation patients with bleeding on Oral Anticoagulation Therapy-Role of Left Atrial Appendage Closure, Octreotide and more. 2017 , 10, 1729	2
524	Safety and Efficacy of Inpatient Initiation of Dofetilide versus Sotalol for atrial fibrillation. 2017 , 10, 1805	5
523	California Study of Ablation for Atrial Fibrillation:Re-hospitalization for Cardiac Events (CAABL-CE). 2018 , 11, 2036	2
522	Robotic navigation shows superior improvement in efficiency for atrial fibrillation ablation. 2019 , 11, 2108	2
521	Predictors of long-term outcome in patients undergoing a first repeat ablation consisting solely of re-isolation of reconnected pulmonary veins. 2019 , 11, 2114	1
520	Risk Factors for Symptomatic Atrial Fibrillation-Analysis of an Outpatient Database. 2019 , 12, 2141	5
519	Outcomes of Hemorrhagic Stroke Patients with Atrial Fibrillation or Flutter. 2019 , 11, 2144	1
518	Meta-Analysis of Catheter Ablation versus Medical Therapy in Patients with Atrial Fibrillation Without Heart Failure. 2020 , 12, 2266	2
517	Drug Therapy for Vagally-Mediated Atrial Fibrillation and Sympatho-Vagal Balance in the Genesis of Atrial Fibrillation: A Review of the Current Literature. 2020 , 13, 2410	1
516	Blending Quality Improvement and Research Methods for Implementation Science, Part II: Analysis of the Quality of Implementation. 2015 , 26, 366-371	1
515	Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation. 2020 , 50, 267-277	8

514	Reducing Stroke Risk in Atrial Fibrillation: Adherence to Guidelines Has Improved, but Patient Persistence with Anticoagulant Therapy Remains Suboptimal. 2019 , 49, 883-907	18
513	Critical Issues and Recent Advances in Anticoagulant Therapy: A Review. 2019 , 67, 1200-1212	3
512	Assessment and comparison of CHADS2, CHA2DS2-VASc, and HAS-BLED scores in patients with atrial fibrillation in Saudi Arabia. 2016 , 11, 146-50	6
511	The current approach of atrial fibrillation management. 2016 , 6, 8-16	18
510	Clinicians-related determinants of anticoagulation therapy and prophylaxis in Nigeria. 2017 , 16, 164-169	2
509	Anticoagulation in Patients with Atrial Fibrillation and Coronary Artery Disease. 2020 , 21, 32-36	2
508	Cardiac tachyarrhythmias and anaesthesia: General principles and focus on atrial fibrillation. 2017 , 61, 712-720	4
507	Liver transplantation and atrial fibrillation: A meta-analysis. 2018 , 10, 761-771	14
506	Red blood cell distribution width: A marker of anisocytosis potentially associated with atrial fibrillation. 2019 , 11, 292-304	7
505	The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. 2016 , 16, 595-600	11
504	Atrial fibrillation after cardiac surgery and preoperative vitamin D levels: A systematic review and meta-analysis. 2020 , 28, 101-107	4
503	Towards automated calculation of evidence-based clinical scores. 2017 , 7, 16-24	7
502	Left Atrial Appendage Transcatheter Occlusion with AMPLATZER® Amulet® Device: Real Life Data with Mid-Term Follow-Up Results. 2019 , 113, 712-721	2
501	Association of Left Atrial Appendage Voltage with Ischemic Stroke in Patients with Atrial Fibrillation. 2019 , 35, 592-599	4
500	Computational fluid dynamics modelling of left valvular heart diseases during atrial fibrillation. 2016 , 4, e2240	12
499	Readability Assessment of Online Patient Education Materials on Atrial Fibrillation. 2020 , 12, e10397	2
498	Usability and Perceived Usefulness of the AFib 2gether Mobile App in a Clinical Setting: Single-Arm Intervention Study. 2021 , 5, e27016	0
497	Design and Rationale of a Phase 2 Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation - The NOVA Study. 2021 , 245, 51-51	0

496	Mortality risk and temporal patterns of atrial fibrillation in the nationwide registry. 2021 , 37, 1434-1442	0
495	[Intracerebral hemorrhage under platelet inhibition and oral anticoagulation in patients with cerebral amyloid angiopathy]. 2021 , 1	1
494	Beta-Adrenergic Blockade in Critical Illness. 2021 , 12, 735841	4
493	Co-creating sensible care plans using shared decision making: Patients' reflections and observations of encounters. 2021 ,	1
492	Predicting All-Cause Mortality Risk in Atrial Fibrillation Patients: A Novel LASSO-Cox Model Generated From a Prospective Dataset. 2021 , 8, 730453	2
491	Atrial flutter with flecainide-induced 1:1 conduction at a rate . 2021 , 5, ytab396	0
490	Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article. 2021 , 19, 72	0
489	Predictors of mortality among patients with type 2 diabetes in Jordan. 2021 , 21, 200	3
488	Effect of heart rate control with amiodarone infusion on hemodynamic and clinical outcomes in septic shock patients with tachycardia: a prospective, single-arm clinical study. 2021 , 7, 37	
487	Management of Atrial Tachyarrhythmias in Adults With Single Ventricle Heart Disease. 1	
486	Huatan Dingji Decoction intervening in atrial fibrillation: protocol for a randomized double-blind single-simulated placebo-controlled clinical trial. 2021 , 22, 693	0
485	Atrial fibrillation following transcatheter atrial septal defect closure: a systematic review and meta-analysis. 2021 ,	2
484	Quality of life in patients with long-standing persistent atrial fibrillation after surgical ablation and simultaneous coronary artery bypass grafting. 2021 , 20, 2848	
483	Effectiveness of Direct Oral Anticoagulants in Obese Adults With Atrial Fibrillation: A Systematic Review of Systematic Reviews and Meta-Analysis. 2021 , 8, 732828	0
482	Predictive value of CHA2DS2-VASc and CHA2DS2-VASc-HS scores for failed reperfusion after thrombolytic therapy in patients with ST-segment elevation myocardial infarction. 2019 , 26, 169-175	4
481	Atrial Fibrillation. 2015 , 53-61	
480	When Should Ablation Be Considered in the Treatment of Atrial Fibrillation â A Clinicianâs View. 2015 , 349-359	
479	Radiofrequency ablation and antiarrhythmic therapy in the treatment of patients with paroxysmal and persistent atrial fibrillation: clinical effects. 2015 , 6, 38-47	2

- 478 Can Patients with Known Intracranial and Intraspinal Vascular Lesions Be Anticoagulated?. **2016**, 343-361
- 477 Cardiac Implantable Electronic Devices in the Short Stay Management of Atrial Fibrillation. **2016**, 133-144
- 476 Prevention and Treatment of Arterial Thromboembolism. **2016**, 417-428
- 475 Stroke and Other Complications of Atrial Fibrillation. **2016**, 61-66
- 474 Promoting Cardiovascular Health in Men. **2016**, 125-143
- 473 Catheter ablation for atrial fibrillation-therapeutic dilemmas. **2016**, 35, 23-27
- 472 Anesthesia for Procedures in the Neurointerventional Suite. **2017**, 221-233
- 471 Electrophysiology Updates in Adult Congenital Heart Disease. **2016**, 43, 409-411
- 470 What's New in Anticoagulation. **2016**, 43, 419-421 0
- 469 Hypercoagulable Conditions Leading to Limb Ischemia. **2017**, 267-278
- 468 Kardiovaskuläre Medikamente. **2017**, 3-26
- 467 Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?. **2016**, 11, 115-117 3
- 466 Management of Atrial Flutter. **2016**, 17, 214-219
- 465 Neuroscience and Biobehavioral Psychology Cardiac and Aortic Embolism?. **2017**,
- 464 Novel approaches for quantitative electrogram analysis for intraprocedural guidance for catheter ablation: A case of a patient with persistent atrial fibrillation. **2017**, 2, 2
- 463 Thromboembolism and bleeding risk scores and predictors of cardiac death in a population with atrial fibrillation. **2017**, 109, 5-13 2
- 462 Patient with Concomitant Mitral Valve Stenosis. **2017**, 81-85
- 461 Patient with Concomitant Aortic Valve Stenosis. **2017**, 87-90

460 Arrhythmias in Special Populations. **2017**, 287-297

459 Anticoagulants for Atrial Fibrillation. **2017**, 105-114

458 Electrocardiogram Characteristics that Distinguish Perimitral Reentry from other Atrial Tachycardias after Atrial Fibrillation Ablation. **2017**, 3, 1-6

457 CHA2DS2-VASc and HAS-BLED Risk Stratification Tools. **2017**, 7-13

456 Late Results of Cox Maze III Procedure in Patients with Atrial Fibrillation Associated with Structural Heart Disease. **2017**, 109, 14-22 4

455 Medical scores in clinical practice. Part II. Thromboembolism. **2017**, 94, 928-931 1

454 Cardioembolic Stroke. **2017**, 23, 111-132 9

453 Pulmonary Vein Isolation Lesion Set Assessment During Radiofrequency Catheter Ablation for Atrial Fibrillation. **2017**, 8, 2602-2611

452 [Multidisciplinary meeting about the use of direct oral anticoagulants in nonvalvular atrial fibrillation]. **2017**, 87, 124-143 2

451 Current clinical application of dexmedetomidine for sedation and anesthesia. **2017**, 12, 306-319 2

450 Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review. **2017**, 13, 325-333

449 Cardiothoracic and Vascular Procedures. **2018**, 373-380

448 Factores asociados al ataque cerebrovascular isquémico entre los años 2013 a 2016: estudio de casos y controles. **2017**, 24, 574-582

447 Handheld Ultrasound as a Novel Predictive Tool in Atrial Fibrillation: Prediction of Outcomes Following Electrical Cardioversion (Preprint).

446 OBSOLETE: Clinical Trials for Atrial Fibrillation - What do we know?. **2018**,

445 Perioperative management of patients with bradycardia. **2018**, 21

444 Postoperative atrial fibrillation prediction following isolated surgical aortic valve replacement. **2018**, 19, 394-400 7

443 Laboratory Tests in Assessing the Bleeding Risk in Patients Receiving Direct Oral Anticoagulants (DOACs). **2018**, 08, 257-264

- 442 Successful External Cardioversion via Fluoroscopic Electrode Positioning in Patients with Enlarged Trans-Thoracic Diameter. **2018**, 19, 171-175 1
- 441 Left Atrial Appendage Occlusion: What Are the Options and Where is the Evidence?. **2018**, 9, 3095-3106 0
- 440 Atrial Flutter With Exercise-Induced 1:1 Atrioventricular Conduction. **2018**, 118, 337-340 1
- 439 Clinical Challenges of Using Novel Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. **2018**, 45, 164-165 1
- 438 Association Between the Subtypes of Stroke and the Various Risk Factors of Cerebrovascular Accidents: A Cross-Sectional Study. **2018**, 50, 86-90 1
- 437 Predicting team-performance and leadership in emergency situations by observing standardised operational procedures: a prospective single-blind simulator-based trial.. **2019**, 5, 102-107
- 436 Approaches to the prevention and therapy of ibrutinib-associated bleeding in adult patients. **2018**, 13, 47-54
- 435 Copyright and licensing of E-journals:. **2018**, 38, 221-227
- 434 A Fourier-Bessel Expansion-Based Method for Automated Detection of Atrial Fibrillation From Electrocardiogram Signals. **2019**, 248-277
- 433 Position Statement of the Brazilian Cardiology Society and the Brazilian Society of Hemodynamics and Interventional Cardiology on Training Centers and Professional Certification in Hemodynamics and Interventional Cardiology - 2020. **2020**, 114, 137-193 0
- 432 Recent Advances for Stroke Prevention in Patients With Atrial Fibrillation and Advanced Kidney Disease. **2019**, 736-740.e2
- 431 Acute Atrial Fibrillation and Other Arrhythmias. **2019**, 387-402
- 430 Accuracy and Usability of a Novel Algorithm for Detection of Irregular Pulse Using a Smartwatch Among Older Adults: Observational Study (Preprint).
- 429 The Association Between Obstructive Sleep Apnea and Arrhythmias. **2019**, 11, e4429 0
- 428 Second Generation Cryoballoon vs. Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: Outcomes Beyond One-Year Follow-up. **2019**, 11, 2147 1
- 427 Current Evidence for the Use of Aspirin in Patients with Atrial Fibrillation and a CHA2DS2-Vasc=1. **2019**, 7-9
- 426 Genetic determinants of lipids and cardiovascular disease outcomes: a wide-angled Mendelian randomization investigation. 1
- 425 The Novel CHADS-VASC-FSH Score is Predictive of Severe Coronary Artery Disease on Coronary Angiography in Patients with Atrial Fibrillation and Unstable Symptoms. **2019**, 51, 165-171 2

- 424 Situaci3n actual de la cardioversi3n de la fibrilaci3n auricular en Espa1a: encuesta nacional multidisciplinaria ENCARFA. **2019**, 54, 157-164 0
- 423 In Reply to Keskin and Orhan. **2019**, 36, 256-256
- 422 Anticoagulation Patterns in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention in an Academic Center. **2019**, 10, 3785-3789
- 421 Mapping and Imaging in Non-paroxysmal AF. **2019**, 8, 202-209 1
- 420 Dronedarone-induced Phototoxicity in a Patient with Atrial Fibrillation. **2019**, 11, e5731 2
- 419 Atrial Fibrillation. **2020**, 73-81
- 418 The dilatation factor of left atrium in remote period after the mitral valve prosthesis. **2019**, 86, 9-12
- 417 Anticoagulation in Cardiac Patients. **2020**, 77-102
- 416 Atrial fibrillation, end-stage renal disease and hemorrhagic pleural-pericarditis. **2019**, 6, 103-108
- 415 Genetics of Height and Risk of Atrial Fibrillation: A Mendelian Randomization Study.
- 414 Antiarrhythmic Medications. **2020**, 305-333
- 413 Mechanisms of Action of Antiarrhythmic Drugs. **2020**, 149-168
- 412 Efficacy and Safety of Outpatient Clinic-based Elective External Electrical Cardioversion in Patients with Atrial Fibrillation. **2020**, 50, 511-523 2
- 411 Cardiac Arrhythmia Detection from ECG with Convolutional Recurrent Neural Networks. **2020**, 311-327 1
- 410 Things We Do for No Reason: Routine Thyroid-Stimulating Hormone Testing in the Hospital. **2020**, 15, 560-562 0
- 409 Temporal trend and associated risk factors for new-onset atrial fibrillation following cardiac valve surgery. **2020**, 12, 2129 1
- 408 Long-term individual and population functional outcomes in older adults with atrial fibrillation. **2020**,
- 407 Interleukin-22 is elevated in the atrium and plasma of patients with atrial fibrillation and increases collagen synthesis in transforming growth factor-1-treated cardiac fibroblasts via the JNK pathway. **2020**, 20, 1012-1020 0

- 406 Advances and Application of a Novel Oral Anticoagulant in Specific Populations: Dabigatran Etexilate. **2020**, 21, 106-111
- 405 Reflux Esophagitis is Associated with Higher Risks of Acute Stroke and Transient Ischemic Attacks in Patients Hospitalized with Atrial Fibrillation: A Nationwide Inpatient Sample Analysis.
- 404 Does Catheter Ablation Lower the Long-Term Risk of Stroke and Mortality in Patients with Atrial Fibrillation? A Concise Review of the Current State of Knowledge. **2020**, 12, e9701
- 403 Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstructive hypertrophic cardiomyopathy. **2021**, 1
- 402 Review of Deep Learning-Based Atrial Fibrillation Detection Studies. **2021**, 18, 9
- 401 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, **2021**, 78, e187-e285 15.1 28
- 400 Anticoagulation therapy in patients with post-operative atrial fibrillation: Systematic review with meta-analysis. **2021**, 142, 106929
- 399 Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. **2021**, 375, e066450 0
- 398 Authors' reply. **2020**, 13, 376-377
- 397 Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU-RABLE. **2021**, 37, 70-78 0
- 396 Frequency and Determinants of Spontaneous Conversion to Sinus Rhythm in Patients Presenting to the Emergency Department with Recent-onset Atrial Fibrillation: A Systematic Review. **2020**, 9, 195-201 0
- 395 ECG of the Month. **2020**, 257, 1235-1239
- 394 Atrial Fibrillation and Heart Failure. **2020**, 31, 431-434 0
- 393 SAME-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. **2020**, 61, 641-646 1
- 392 Association between use of amiodarone for non-valvular atrial fibrillation and patient survival: from the prospective China Atrial Fibrillation Registry. **2020**, 134, 309-317
- 391 Contemporary Anticoagulation Practices for Postoperative Atrial Fibrillation: A Single Center Experience.. **2020**, 13, 2443
- 390 Impact of Left Atrial Bipolar Electrogram Voltage on First Pass Pulmonary Vein Isolation During Radiofrequency Catheter Ablation. **2020**, 11, 594654 3
- 389 Anticoagulation in Cancer Patients With Atrial Fibrillation or Atrial Flutter: Are There Gaps in Care?. **2020**, 2, 755-757 1

388	A New Method for the Measurement of International Normalized Ratio in Hemodialysis Patients with Heparin-Locked Tunneled Dialysis Catheters. 2020 , 2020, 7586437	
387	Atrial fibrillation and dementia: an unresolved 'Folie ^Deux'. 2020 , 7,	
386	Effect of genetic polymorphism on peak propafenone concentration: no significant effect of. 2020 , 21, 1279-1288	0
385	Demonstration of the potential of white-box machine learning approaches to gain insights from cardiovascular disease electrocardiograms. 2020 , 15, e0243615	3
384	Herbal glycosides in healthcare. 2022 , 239-282	2
383	Upper Gastrointestinal Bleeding. 2020 , 1-16	
382	Hemodynamic Evaluation and Echocardiography in the Oncologic Intensive Care Unit. 2020 , 753-773	
381	Preoperative Medical Optimization. 2020 , 79-87	1
380	Beta-blocker Therapy at Discharge in Patients with Acute Heart Failure and Atrial Fibrillation. 2020 , 35, e278	1
379	Anticoagulation Therapy in Patients with Non-valvular Atrial Fibrillation in a Private Setting in Brazil: A Real-World Study. 2020 , 114, 457-466	4
378	Thoracoscopic Pulmonary Vein and Left Atrial Posterior Wall Isolation Combined with Left Atrial Appendage Resection in Patients with Long-Standing Persistent Atrial Fibrillation. 2020 , 35, 22-27	1
377	Atrial Fibrillation. 2020 , 141-168	
376	Cardiac Glycosides. 2020 , 1-5	
375	Clinical Implications of Preoperative Nonvalvular Atrial Fibrillation with Respect to Postoperative Cardiovascular Outcomes in Patients Undergoing Non-Cardiac Surgery. 2020 , 50, 148-159	4
374	Atrial Fibrillation and Atrial Flutter. 2020 , 185-196	
373	Photoacoustic image guidance and robotic visual servoing to mitigate fluoroscopy during cardiac catheter interventions. 2020 ,	3
372	Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism. 2020 , 105,	2
371	Thrombolytic therapy and use of apixaban in a stroke patient. 2020 , 9,	

- 370 Multidetector computed tomography in planning the treatment of atrial fibrillation. **2020**, 62, 148-159 ○
- 369 Benefits of prescribing low-dose digoxin in atrial fibrillation. **2021**, 35, 20587384211051955 ○
- 368 Triangular Plasty of Left Atrium in Surgical Treatment of Left Atriomegaly. **2020**, 33-36
- 367 A case report of successful digoxin use for fast atrial fibrillation to facilitate emergency surgery in a bleeding patient. **2020**, 26, 99-101
- 366 Rhythm control treatment strategies for atrial fibrillation: current consensus and future possibilities. **2020**, 20, s4-s5
- 365 Predicting Left Atrial Appendage Thrombus from Left Atrial Volume and Confirmation by Computed Tomography with Delayed Enhancement. **2020**, 47, 78-85 1
- 364 Left atrial shape is independent predictor of arrhythmia recurrence after catheter ablation for atrial fibrillation: A shape statistics study.. **2021**, 2, 622-632 ○
- 363 Closing the Digitalis Divide: Back to the Basics of Randomized Controlled Trials. **2021**, 1
- 362 Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety. **2021**, 17, 668-673 1
- 361 Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: A meta-analysis. **2021**, 51, 248-256 1
- 360 Treatment of atrial fibrillation: a comprehensive review and practice guide. **2020**, 31, 153-158 1
- 359 Ablaci3n de la fibrilaci3n auricular en pacientes con insuficiencia cardiaca: el control del ritmo s3n importa. **2020**, 55, 177-185
- 358 The quality of prior antithrombotic therapy and the severity of ischemic stroke in atrial fibrillation. **2020**, 12, 18-23
- 357 Orthogonal electrical cardioversion in atrial fibrillation refractory to biphasic shocks: a case series. **2020**, 4, 1-5 ○
- 356 Difference in the prevalence of intracardiac thrombus on the first presentation of atrial fibrillation versus flutter in the pediatric and congenital heart disease population. **2020**, 31, 3243-3250 ○
- 355 Systemic Disorders Affecting the Heart. **2021**, 365-386
- 354 Arrhythmias in Chronic Kidney Disease: Working Towards a Clinical Approach in Atrial Fibrillation. **2021**, 47-57
- 353 Cardiac Arrest Following Treatment With Diltiazem for Atrial Fibrillation With Rapid Ventricular Response. **2020**, 12, e11678

352	Carga económica de la fibrilación auricular en Colombia. 2020 , 27, 538-544	2
351	Electrophysiology and heart rhythm disorders in older adults. 2016 , 13, 645-651	5
350	The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis. 2014 , 7, 200-9	14
349	Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. 2014 , 39, 858-80	6
348	Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. 2014 , 7, 376-84	25
347	A Review of the LARIAT Suture Delivery Device for Left Atrial Appendage Closure. 2015 , 10, 69-73	2
346	A meta-analysis of left atrial appendage closure for stroke prevention in atrial fibrillation-adding to the debate but elements remain unresolved. 2015 , 7, E226-9	3
345	Long-term stroke rates after catheter ablation or antiarrhythmic drug therapy for atrial fibrillation: a meta-analysis of randomized trials. 2015 , 12, 507-14	8
344	Atrial fibrillation may be a hidden factor for the development of cognitive impairment in patients with heart failure. 2015 , 12, 590	1
343	Edoxaban (Savaysa): A Factor Xa Inhibitor. 2015 , 40, 651-95	8
342	Management of Dysrhythmia in Emergency Department. 2015 , 3, 2	2
341	Atrial fibrillation and sleep-disordered breathing. 2015 , 7, E575-84	20
340	Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation. 2016 , 13, 202-8	3
339	Optimization Of Stroke Prophylaxis Strategies In Nonvalvular AF -Drugs, Devices Or Both?. 2015 , 8, 1156	
338	My Patient Taking A Novel Oral Anticoagulant Needs Surgery, Device Implantation, Or Ablation. 2014 , 7, 1145	1
337	Cardiac Plug I and Amulet Devices: Left Atrial Appendage Closure for Stroke Prophylaxis in Atrial Fibrillation. 2015 , 7, 1236	5
336	Clinical characteristics and one year outcomes in Chinese atrial fibrillation patients with stable coronary artery disease: a population-based study. 2016 , 13, 665-671	3
335	Cryoablation for the Treatment of Drug Refractory Symptomatic Atrial Fibrillation: A Regional Medical Center Experience. 2016 , 8, 1334	

334	Ablation of Atrial Fibrillation in Combination with Left Atrial Appendage Occlusion in A Single Procedure. Rationale and Technique. 2016 , 8, 1346	2
333	A Comparison Between NOACs and Warfarin on Time to Elective Cardioversion. 2016 , 9, 1451	
332	Which Factors Influence Resident Physicians to Prescribe NOACs to Patients with Non-Valvular Atrial Fibrillation?. 2016 , 9, 1462	3
331	Lone AF: is There a Rationale?. 2015 , 8, 1246	
330	Who Needs Pharmacologic Therapy?. 2014 , 7, 1084	
329	Atrioventricular Junction Ablation In Atrial Fibrillation: Choosing The Right Patient And Pacing Device. 2015 , 8, 1253	1
328	Subclinical Atrial Tachyarrhythmias:Implantable Devices and Remote Monitoring. 2015 , 8, 1249	5
327	Who Needs Catheter Ablation And Which Approach?. 2015 , 8, 1335	1
326	Predictors of Atrial Fibrillation Risk in Hypertrophic Cardiomyopathy. 2015 , 7, 1200	4
325	Seasonal Variation in Paroxysmal Atrial Fibrillation: A Systematic Review. 2015 , 7, 1201	5
324	Elimination Of Triggers Without An Additional Substrate Modification Is Not Sufficient In Patients With Persistent Atrial Fibrillation. 2015 , 7, 1207	1
323	New Insights On Ablation Of Persistent Atrial Fibrillation: Evidence From The SARA Trial. 2014 , 7, 1114	0
322	Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know. 2016 , 16, 531-541	4
321	Knowledge as a Service at the Point of Care. 2016 , 2016, 1139-1148	1
320	Long noncoding RNAs and novel inflammatory genes determined by RNA sequencing in human lymphocytes are up-regulated in permanent atrial fibrillation. 2017 , 9, 2314-2326	25
319	Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment. 2017 , 17, 1-106	1
318	Integrating Temporal Pattern Mining in Ischemic Stroke Prediction and Treatment Pathway Discovery for Atrial Fibrillation. 2017 , 2017, 122-130	3
317	PURLs: Direct oral anticoagulants or warfarin for A fib?. 2017 , 66, 518-519	

316	Association between subjective risk perception and objective risk estimation in patients with atrial fibrillation: a cross-sectional study. 2017 , 7, e018242	6
315	Trends in the rates of hospitalizations for acute stroke among patients over 90 years of age with atrial fibrillation in the United States: from 2005 to 2014. 2017 , 14, 547-552	4
314	The Value of CHADSVASC Score in Predicting All-Cause Mortality in Patients with ST-Segment Elevation Myocardial Infarction Who Have Undergone Primary Percutaneous Coronary Intervention. 2017 , 33, 598-604	8
313	Successful resolution with apixaban of a massive left atrial appendage thrombus due to nonrheumatic atrial fibrillation: A case report and review. 2018 , 21, 76-77	2
312	Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?. 2018 , 15, 229-234	1
311	Bootstrap-based Feature Selection to Balance Model Discrimination and Predictor Significance: A Study of Stroke Prediction in Atrial Fibrillation. 2017 , 2017, 1130-1139	2
310	Dynamic Electrocardiography is Useful in the Diagnosis of Persistent Atrial Fibrillation Accompanied with Second-Degree Atrioventricular Block. 2018 , 34, 409-416	2
309	Decentralized vs Centralized Pharmacist Treatment of Patients With Atrial Fibrillation Managed With Direct Oral Anticoagulants. 2017 , 34, 20-24	
308	Coexistence of Anticoagulant and Anti-vascular Calcification Activities in sp. UTM 267 Metabolites. 2019 , 18, 459-468	1
307	A 58-Year-Old Woman with Weakness and Shortness of Breath. 2018 , 2, e12	
306	Treatment of atrial fibrillation in nursing homes: A place for direct acting oral anticoagulants?. 2018 , 4, 15-19	3
305	Anticoagulant Utilization and Direct Oral Anticoagulant Prescribing in Patients with Nonvalvular Atrial Fibrillation. 2019 , 72, 428-434	2
304	Left atrial enlargement and non-paroxysmal atrial fibrillation as risk factors for left atrial thrombus/spontaneous Echo contrast in patients with atrial fibrillation and low CHADS-VASc score. 2020 , 17, 155-159	3
303	History of major bleeding predicts risk of clinical outcome of patients with atrial fibrillation: results from the COOL-AF registry. 2020 , 17, 184-192	
302	Pulmonary vein isolation implemented by second-generation cryoballoon for treating hypertrophic cardiomyopathy patients with symptomatic atrial fibrillation: a case-control study. 2020 , 17, 476-485	1
301	Quantitative proteomic analysis to identify differentially expressed proteins in the persistent atrial fibrillation using TMT coupled with nano-LC-MS/MS. 2020 , 12, 5032-5047	2
300	Evaluating the cost-effectiveness of catheter ablation of atrial fibrillation. 2020 , 10, 1200-1215	
299	Geriatric issues in patients with or being considered for implanted cardiac rhythm devices: a case-based review. 2020 , 17, 710-722	

- 298 Incident frailty and cognitive impairment by heart failure status in older patients with atrial fibrillation: the SAGE-AF study. **2020**, 17, 653-658 1
- 297 Paroxysmal atrial fibrillation in a dog that was presented for neck wounds. **2021**, 62, 32-36
- 296 Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China. **2020**, 17, 750-758
- 295 Neurohumoral, cardiac and inflammatory markers in the evaluation of heart failure severity and progression. **2021**, 18, 47-66 1
- 294 Prognostic Effect of Restoring Sinus Rhythm in Patients with New-Onset Atrial Fibrillation during Acute Coronary Syndrome. **2021**, 37, 155-165 1
- 293 Efficacy and Safety of Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation Undergoing Elective Surgical Procedures: A Meta-analysis. **2021**, 19, 19-25
- 292 The relationship between coronary microvascular dysfunction, atrial fibrillation and heart failure with preserved ejection fraction. **2021**, 11, 29-38
- 291 Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management. **2021**, 18, 376-397
- 290 The efficacy and safety of radiofrequency ablation on the platelet activation and the inflammatory response in elderly atrial fibrillation patients. **2021**, 13, 9820-9825
- 289 Predictors of Acute Atrial Fibrillation and Flutter Hospitalization across 7 U.S. Emergency Departments: A Prospective Study.. **2021**, 13, 2355 0
- 288 Neglected Tropical Diseases & Atrial Fibrillation. **2022**, 213-228
- 287 Assessing coronary artery disease using coronary computed tomography angiography. **2022**, 129-145
- 286 Atrial appendage closure in patients with heart failure and atrial fibrillation: industry-independent single-centre study. **2021**, 1 1
- 285 The Association Between Recurrence of Atrial Fibrillation and Revascularization in Patients With Coronary Artery Disease After Catheter Ablation. **2021**, 8, 756552 2
- 284 Risk factor management of atrial fibrillation using mHealth: The Atrial Fibrillation - Helping Address Care with Remote Technology (AF-HEART) Pilot Study.. **2022**, 3, 14-20
- 283 Hypertension-mediated organ damage and established cardiovascular disease in patients with hypertension: the China Hypertension Survey, 2012-2015. **2021**, 3 3
- 282 Electrocardiographic findings of the effects of beta-blockers.. **2021**, 62, 520-525
- 281 Clinical Investigations Bimodal Distribution of Atrial Fibrillation Burden in 3 Distinct Cohorts: What is 'Paroxysmal' Atrial Fibrillation?. **2021**, 244, 149-149

- 280 Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?. **2021**, 8, 768730 0
- 279 A double-blind randomised controlled trial on the effect of Tocovid, a tocotrienol-rich capsule on postoperative atrial fibrillation at the National Heart Institute, Kuala Lumpur: an interim blinded analysis. **2021**, 16, 340
- 278 Temporal Association of Atrial Fibrillation With Cardiac Implanted Electronic Device Detected Heart Failure Status.. **2022**, 8, 182-193
- 277 Comparison of mortality rates among rate-control agents in patients with atrial fibrillation: a systematic review and meta-analysis. **2022**, 23, e39-e41 0
- 276 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. **2021**, 6
- 275 Characteristics of warfarin under-prescription in older adults with atrial fibrillation. **2021**, 37, 100914
- 274 Hemoptysis in Quadriplegia with Atrial Fibrillation Who Was Taking Edoxaban: a Case Report. **2021**, 14,
- 273 Encyclopedia of Molecular Pharmacology. **2021**, 410-414
- 272 Conditional immortalization of human atrial myocytes for the generation of in vitro models of atrial fibrillation.. **2022**, 1
- 271 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. *Journal of the American College of Cardiology*, **2021**, 15.1 42
- 270 Efficacy and Safety of Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation Undergoing Elective Surgical Procedures: A Meta-analysis. **2021**, 19, 19-25 1
- 269 Evaluating the cost-effectiveness of catheter ablation of atrial fibrillation. **2020**, 10, 1200-1215
- 268 Multidimensional Fibrillatory Waves Analysis for Improved Electrical Cardioversion Outcome Prediction in Persistent Atrial Fibrillation. **2020**,
- 267 Safety of Atrial Fibrillation Ablation in the Young - A Real World Analysis.. **2021**, 13, 20200489
- 266 Predictors Of Left Ventricular Apical Thrombus Formation in Patients With Acute Anterior Myocardial Infarction and Treated Primary Percutaneous Coronary Intervention: Importance of Syntax Score.
- 265 Risk of left atrial appendage thrombus and stroke in patients with atrial fibrillation and mitral regurgitation. **2022**, 108, 29-36
- 264 The Relationship Between Vitamin D Deficiency And CHA₂DS₂-VASc Score in Chronic Coronary Syndrome.
- 263 A Multisite Retrospective Review of Direct Oral Anticoagulants Compared to Warfarin in Adult Fontan Patients.. **2022**, 1

262 Digoxin Holiday. 32, 50-54

261 Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies.. **2022,**

260 Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation patients.. **2022, 1**

259 Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement.. **2022, 327, 360-367**

13

258 Characteristics of anatomical difficulty for cryoballoon ablation: insights from CT.. **2022, 9,**

2

257 Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany.. **2022, 1**

2

256 Comparisons of HATCH, HAVOC and CHA2DS2-VASc scores for all-cause mortality prediction in atrial fibrillation: a real-world evidence study.. **2022,**

255 Screening for Atrial Fibrillation: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.. **2022, 327, 368-383**

3

254 Research Opportunities in Autonomic Neural Mechanisms of Cardiopulmonary Regulation: A Report From the National Heart, Lung, and Blood Institute and the National Institutes of Health Office of the Director Workshop.. **2022, 7, 265-293**

2

253 Predicting New-Onset Postoperative Atrial Fibrillation Following Isolated Coronary Artery Bypass Grafting: Development and Validation of a Novel Nomogram.. **2022, 15, 937-948**

1

252 2019 Chinese expert consensus statement on left atrial appendage closure in patients with atrial fibrillation.. **2022,**

0

251 Will Apple devices' passive atrial fibrillation detection prevent strokes? Estimating the proportion of high-risk actionable patients with real-world user data.. **2022,**

1

250 Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation.. **2021, 12, 812018**

1

249 Does aspirin monotherapy reduce stroke risk in patient with atrial fibrillation and CHA2DS2-VASc score >2 who are not candidates for anticoagulation therapy?. **2022, Publish Ahead of Print,**

248 The Role of Inflammation in the Pathogenesis and Treatment of Arrhythmias.. **2022,**

2

247 Drug-Induced Atrial Fibrillation / Atrial Flutter. **2022, 17, 1-18**

246 Indirect comparison of nonvitamin K oral anticoagulants and left atrial appendage occlusion. **2022, 4, 18-25**

245 Clinical significance of diastolic dysfunction on outcomes of pulmonary valve replacement for pulmonary insufficiency.. **2022,**

1

244	Risks and Benefits of Early Rhythm Control in Patients With Acute Strokes and Atrial Fibrillation: A Multicenter, Prospective, Randomized Study (the RAFAS Trial).. 2022 , e023391	0
243	Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.. 2022 , 28, 266-274	
242	Extent of Left Atrial Fibrosis Correlates with Descending Aorta Proximity at 3D Late Gadolinium Enhancement Cardiac MRI in Patients with Atrial Fibrillation. 2022 , 4,	1
241	Healthcare Resource Utilization for Oral Anticoagulant Reversal Therapies in Non-Valvular Atrial Fibrillation/Venous Thromboembolism Patients.. 2022 , 13, 27-43	1
240	Epicardial Fat Tissue Thickness and Omentin in Patients with Atrial Fibrillation. 2022 ,	
239	Telemedicine in Cardiology: Modern Technologies to Improve Cardiovascular Patients' Outcomes-A Narrative Review.. 2022 , 58,	2
238	Kidney Function According to Different Equations in Patients Admitted to a Cardiology Unit and Impact on Outcome.. 2022 , 11,	2
237	Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials.. 2022 , 1	0
236	Ischemic Stroke in Non-Gender-Related CHADS-VA Score 0~1 Is Associated With HFPEF Score Among the Patients With Atrial Fibrillation.. 2021 , 8, 791112	0
235	Cryoballoon ablation for paroxysmal atrial fibrillation in Japan: 2-year safety and efficacy results from the Cryo AF Global Registry.. 2022 , 1	1
234	Edoxaban-Based Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Stable Coronary Disease: Rationale and Design of the Randomized EPIC-CAD Trial.. 2022 ,	0
233	Rhythm Monitoring Strategy and Arrhythmia Recurrence in Atrial Fibrillation Ablation Trials: A Systematic Review. 2022 ,	0
232	Calcium dysregulation in heart diseases: Targeting calcium channels to achieve a correct calcium homeostasis.. 2022 , 177, 106119	4
231	[Studies on the energy for sperm motility (author's transl)]. 1975 , 20, 6-13	
230	Traditional risk factors for QT interval prolongation and torsades de pointes. 2022 , 79-111	
229	Stroke and Systemic Thromboembolism according to CHADS-VASc Score in Contemporary Korean Patients with Atrial Fibrillation.. 2022 , 63, 317-324	0
228	Refinement of CHADS2 and CHA2DS2-VASc scores predict left atrial thrombus or spontaneous echo contrast in nonvalvular atrial fibrillation patients.. 2022 , 50, 3000605221074520	0
227	Antiarrhythmic agents and torsades de pointes. 2022 , 183-211	

- 226 Safety and Efficacy Evaluation of Antithrombotic Therapy with Rivaroxaban and Clopidogrel After PCI in Chinese Patients.. **2022**, 28, 10760296221074681 0
- 225 Digoxin Impact on Heart Failure Patients with Atrial Fibrillation.. **2022**, 76, 23-28
- 224 AmuletâShines and Protects; Pacing Battle Intensifies with "More Leads or No Leads"?. **2022**, 13, 4833-4839 0
- 223 Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease.. **2022**, 24, A19-A31 0
- 222 Temporal trends and predictors of surgical ablation for atrial fibrillation across a multistate healthcare system.. **2022**, 3, 32-39 0
- 221 Arrhythmias in Patients With Valvular Heart Disease: Gaps in Knowledge and the Way Forward.. **2022**, 9, 792559 1
- 220 Risk of Death and Ischemic Stroke in Patients with Atrial Arrhythmia and Thrombus or Sludge in Left Atrial Appendage at One-Year Follow-Up.. **2022**, 11, 1
- 219 A Systematic Review and Meta-Analysis of the Direct Comparison of Second-Generation Cryoballoon Ablation and Contact Force-Sensing Radiofrequency Ablation in Patients with Paroxysmal Atrial Fibrillation.. **2022**, 12, 0
- 218 Prevalence and Outcome of Cardio-Embolic Stroke Patients Admitted at Referral Neurology Hospital in Bangladesh.
- 217 An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps.. **2022**, 1 0
- 216 JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.
- 215 Management of Cardiac Diseases in Liver Transplant Recipients: Comprehensive Review and Multidisciplinary Practice-Based Recommendations.. **2022**, 2
- 214 LncRNA H19 Drives Proliferation of Cardiac Fibroblasts and Collagen Production via Suppression of the miR-29a-3p/miR-29b-3p-VEGFA/TGF-Î¸Axis. **2021**, 0
- 213 Evaluation of Safety and Effectiveness on Catheter Ablation of Atrial Fibrillation in Patients Aged â80 Years.. **2022**, 0
- 212 Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States.. **2022**, 1
- 211 Developing a Risk Prediction Model for Early Atrial Fibrillation Recurrence After MAZE Procedure.. **2022**,
- 210 Hybrid Ablation for Atrial Fibrillation: Safety & Efficacy of Unilateral Epicardial Access.. **2022**, 1
- 209 Evaluation of oral anticoagulant prescribing patterns and associated hospital acquired complications â a single centre Australian study.

208	Characteristics of non-valvular atrial fibrillation with left atrial appendage thrombus who are undergoing appropriate oral anticoagulation therapy. 1		0
207	Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation.. 2022 , 1		3
206	Impact of renin-angiotensin-aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension.. 2022 , 22, 141		0
205	Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.. 2022 , 399, 1383-1390		9
204	Commentary: Atrial fibrillation: Surgeons can do more than operate.. 2022 ,		
203	Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department. 2022 ,		0
202	Rate versus rhythm control for atrial fibrillation: from AFFIRM to EAST-AFNET 4 -'a paradigm shift.. 2022 ,		
201	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Journal of the American College of Cardiology</i> , 2022 ,	15.1	49
200	Augmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence (AWARE) Trial: Design and Rationale.. 2022 , 248, 1-1		0
199	Effects of Acupuncture on Cardiac Remodeling in Patients with Persistent Atrial Fibrillation: Results of a Randomized, Placebo-Controlled, Patient- and Assessor-Blinded Pilot Trial and Its Implications for Future Research.. 2021 , 58,		0
198	Obstructive sleep apnea and nocturnal attacks of paroxysmal atrial fibrillation.. 2021 ,		0
197	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction.. 2021 ,		0
196	Radiofrequency ablation to achieve durable pulmonary vein isolation.. 2021 ,		1
195	Predicting atrial fibrillation episodes with rapid ventricular rates associated with low levels of activity.. 2021 , 21, 364		1
194	A Revised Comorbidity Model for Administrative Databases Using Clinical Classifications Software Refined Variables.. 2021 , 13, e20407		2
193	2021 Asia Pacific Heart Rhythm Society (APHRS) practice guidance on atrial fibrillation screening.. 2022 , 38, 31-49		0
192	Diagnosis of Atrial Fibrillation Using Machine Learning with Wearable Devices after Cardiac Surgery (Preprint).		
191	Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries. 2021 , 4, e2137288		4

- 190 Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Penny wise . .Pound Foolish.. **2021**,
- 189 Time in therapeutic range of anticoagulation among patients with atrial fibrillation and cerebral amyloid angiopathy.. **2022**, 35, 162-167
- 188 Evaluation of Anticoagulation Control among Patients Taking Warfarin in University of Gondar Hospital, Northwest Ethiopia.. **2021**, 2021, 7530997 1
- 187 COVID-19 and Anticoagulation for Atrial Fibrillation: An Analysis of US Nationwide Pharmacy Claims Data.. **2021**, e023235 1
- 186 OUP accepted manuscript.
- 185 OUP accepted manuscript.
- 184 Epicardial adipose tissue, obesity and the occurrence of atrial fibrillation: an overview of pathophysiology and treatment methods.. **2022**, 0
- 183 USABILITY OF A SMARTWATCH FOR ATRIAL FIBRILLATION DETECTION IN OLDER ADULTS AFTER STROKE. **2022**, 2
- 182 Role of Inflammation in the Pathogenesis of Atrial Fibrillation.. **2022**, 13, 862164 2
- 181 Heart Rhythm Society Atrial Fibrillation Centers of Excellence Study: A survey analysis of stakeholder practices, needs, and barriers.. **2022**, 1
- 180 image_1.jpeg. **2017**,
- 179 table_1.docx. **2017**,
- 178 DataSheet_1.pdf. **2019**,
- 177 Presentation_1.pdf. **2018**,
- 176 Data_Sheet_1.PDF. **2019**,
- 175 Video_1.MP4. **2019**,
- 174 Video_10.MP4. **2019**,
- 173 Video_2.MP4. **2019**,

172 Video_3.MP4. 2019,

171 Video_4.MP4. 2019,

170 Video_5.MP4. 2019,

169 Video_6.MP4. 2019,

168 Video_7.MP4. 2019,

167 Video_8.MP4. 2019,

166 Video_9.MP4. 2019,

165 Alcohol consumption in relation to the incidence of atrial fibrillation in an elderly Chinese population.. 2022, 19, 52-60

164 A Model Incorporating Left Ventricular Impedance Index may be Explanatory for Late Pulmonary Vein Isolation Failure.. 2020, 6,

163 Value of echocardiography in evaluating efficacy of radiofrequency catheter ablation in patients with atrial fibrillation.. 2022, 14, 1778-1787

162 A Novel and Efficient CNN Architecture for Detection and Classification of ECG Arrhythmia. 2022, 217-225

161 SK Channels and Heart Disease.

160 2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders.. 2022,

1

159 A Dilated Residual Vision Transformer for Atrial Fibrillation Detection from Stacked Time-Frequency ECG Representations. 2022,

0

158 Left Atrial Appendage Exclusion. 2022, 547-553

157 Conduction System Pacing versus Conventional Pacing in Patients Undergoing Atrioventricular Node Ablation: Non-randomized, On-Treatment Comparison. 2022,

1

156 The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review.. *Journal of the American College of Cardiology*, 2022, 79, 1932-1948

15.1 5

155 Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore.. 2022,

1

- 154 The Role of Echocardiography in Patients with Atrial Fibrillation and Flutter. **2017**, 822-836
- 153 Implantation of Watchman FLX for Patients with Difficult Left Atrial Appendage Anatomy: A Case-Based Discussion. **2022**, 101266
- 152 Age-dependent risk for thromboembolism in atrial fibrillation: The Fushimi AF registry. **2022**, 41, 101055
- 151 Cardioversion of Post-Ablation Atrial Tachyarrhythmia with Ibutilide and Amiodarone: A Registry-Based Cohort Study. **2022**, 19, 6606
- 150 Amiodarone versus beta-blockers for the prevention of postoperative atrial fibrillation after cardiac surgery: An updated systematic review and meta-analysis of randomised controlled trials. **2022**, 11, 569
- 149 Effect of catheter ablation combined with left appendage occlusion for non-valvular atrial fibrillation: a meta-analysis. **2022**, 17, ○
- 148 Photoswitching of Ion Channels. **2022**, 945-971
- 147 Automated Indicator of Atrial Fibrillations Risk Using Machine Learning. **2021**,
- 146 Diagnosis of Atrial Fibrillation Using Machine Learning with Wearable Devices after Cardiac Surgery (Preprint). ○
- 145 Impact of Atrial Fibrillation Ablation on Activity Minutes in Patients With Cardiac Implantable Electronic Devices. **2022**, ○
- 144 Clinical Characteristics and Prognostic Importance of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy. **2022**, ○
- 143 Left Atrial Appendage Occlusion as an Alternative to Anticoagulants in Brivaritinib-Induced Hemorrhagic Pericardial Effusion. **2022**, 4, 755-757 ○
- 142 DIFFERENCES IN OUTCOMES AMONG PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING CATHETER ABLATION WITH VERSUS WITHOUT INTRACARDIAC ECHOCARDIOGRAPHY. 1
- 141 Prediction of atrial fibrillation in patients with hypertension: A comprehensive comparison of office and ambulatory blood pressure measurements. 1
- 140 Development and Validation of a Novel Score for Predicting Paroxysmal Atrial Fibrillation in Acute Ischemic Stroke. **2022**, 19, 7277 ○
- 139 The AF Tsunami, Fee-for-Service Medicine, and the Role of Self-governance.
- 138 Anticoagulation use in patients with perioperative atrial fibrillation after cardiac surgery: A systematic review and meta-analysis. **2022**,
- 137 Prognostic impact of the presence of chronic kidney disease on percutaneous left atrial appendage closure for atrial fibrillation: A single center experience. **2022**, ○

- 136 Esophageal thermal lesions in radiofrequency ablation for atrial fibrillation: A prospective comparative study of thermal sensors.
- 135 Contemporary Trends in the Use of and Expenditures on Digoxin in the United States. ○
- 134 Rhythm vs. Rate control for Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction. **2022,** ○
- 133 Repeat catheter ablation in patients with atrial arrhythmia recurrence despite durable pulmonary vein isolation. ○
- 132 Colchicine for the primary prevention of cardiovascular events. **2022, 2022,**
- 131 Silent Brain Infarction, Delirium, and Cognition in Three Invasive Cardiovascular Procedures: a Systematic Review. ○
- 130 Increased Risk of Stroke Due to Non-adherence and Non-persistence with Direct Oral Anticoagulants (DOACs): Real-World Analyses Using a Nested Caseâ€“Control Study from The Netherlands, Italy and Germany. ○
- 129 New-onset atrial fibrillation in intensive care: epidemiology and outcomes. ○
- 128 Detection of Atrial Fibrillation in Compressively Sensed Electrocardiogram for Remote Monitoring. 3,
- 127 Left Atrial Appendage Occlusion: Current Stroke Prevention Strategies and a Shift Toward Data-Driven, Patient-Specific Approaches. **2022, 100405**
- 126 Historical Aspects of the Use of Antiarrhythmic Drugs in Clinical Practice. **2022, 18, 350-358**
- 125 Epidemiology of atrial fibrillation and risk of CVD mortality among hypertensive population: A prospective cohort study in Northeast China. 9,
- 124 Spontaneous Hemopericardium: A Lesson on Risk-Benefit Profile of Contemporary Oral Anticoagulant Therapy Prompted by an Uncommon Occurrence. **2022, 1,**
- 123 Alteration of Skin Sympathetic Nerve Activity after Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation. **2022, 12, 1286** ○
- 122 Neuromodulation Therapy for Atrial Fibrillation. **2022,** ○
- 121 CHA2DS2-VASc Score, Mortality and Acute Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. **2022,**
- 120 Atrial fibrillation patterns and their cardiovascular risk profiles in the general population: the Rotterdam study.
- 119 Preclinical models of congestive heart failure, advantages, and limitations for application in clinical practice. 13, ○

- 118 Atrioventricular Synchronization for Detection of Atrial Fibrillation and Flutter in One to Twelve ECG Leads Using a Dense Neural Network Classifier. **2022**, 22, 6071 1
- 117 Preventing preventable strokes: A study protocol to push guideline-driven atrial fibrillation patient education via patient portal. **2022**,
- 116 A new scoring system: PAT2C2H score. Its clinical use and comparison with HATCH and CHA2DS2-VASc scores in predicting arrhythmia recurrence after cryoballoon ablation of paroxysmal atrial fibrillation.
- 115 Impact of Catheter Ablation on Long-Term Outcomes in Patients With Atrial Fibrillation: A Meta-Analysis. **2022**, 1
- 114 Catheter Ablation for Atrial Fibrillation: Are We Isolating Our Most Vulnerable Patients?. **2022**, 31, 1315-1317 0
- 113 Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit. **2022**, 42, 101117 0
- 112 Assessment of knowledge and practice of cardiovascular nurses regarding warfarin. **2022**, 11, 270 0
- 111 The Association Between High CHA2DS2-VASc Scores and Short and Long-Term Mortality for Coronary Care Unit Patients. **2022**, 28, 107602962211179 0
- 110 Association between Serum Cystatin C levels and long-term cardiovascular outcomes and all-cause mortality in older patients with obstructive sleep apnea. 13, 0
- 109 Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation. **2022**, 0
- 108 Trombo Atrial Esquerdo e Contraste Espontâneo Denso no Uso de Anticoagulante Oral de A Direta em Fibrila Atrial: Vis de Centro Referenciado. **2022**, 0
- 107 Impact of a dedicated atrial fibrillation clinic on diagnosis-to-ablation time. **2022**, 0
- 106 Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients With Active Cancer. **2022**, 4, 341-350 0
- 105 Stroke Prevention in Atrial Fibrillation. 0
- 104 Efficacy and Safety of Anticoagulants in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: A Systematic Review and Multilevel Meta-Analysis. 0
- 103 Ripple Frequency Determined via a Novel Algorithm is Associated with Atrial Fibrillation Termination and Freedom from Atrial Fibrillation. **2022**, 0
- 102 An iPS -derived in vitro model of human atrial conduction. **2022**, 10, 0
- 101 Real-time Monitoring and Early Warning of Atrial Fibrillation. 0

100	Effect of concomitant surgical atrial fibrillation ablation in patients with reduced left ventricle ejection fraction: A propensity-score matching analysis. 2022 , 37, 3598-3606	0
99	The Relationship between Atrial Fibrillation and Coronary Artery Disease: Understanding common denominators. 2022 ,	0
98	Impact of right atrial enlargement on clinical outcome in patients with atrial fibrillation. 9,	1
97	Early detection of obstructive sleep apnea in patients with atrial fibrillation. 2022 , 34, 1083-1089	0
96	Anaesthetic management of a horse with atrial fibrillation undergoing transvenous electrical cardioversion in combination with amiodarone.	0
95	Safety of left atrial appendage closure in heart failure patients.	0
94	Off-label dose direct oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation: A new evidence of Asian dose. 2022 ,	0
93	Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants. 2022 ,	0
92	Effect of perioperative intravenous amiodarone on cardioversion of atrial fibrillation early after video-assisted thoracoscopic surgical ablation: Study protocol for a double-blind randomized controlled trial. 2022 , 30, 101010	0
91	The Preoperative Patient Evaluation. 2022 , 117-149	0
90	Outcome of New-Onset Postoperative Atrial Fibrillation After Cardiac Surgery in Adults With Congenital Heart Disease. 2022 ,	0
89	Efficacy and Safety of Sustained-Release Metoprolol With Dronedarone After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation: A Propensity Matched Analysis. 2022 ,	0
88	Efficacy and safety of oral anticoagulants in elderly patients with stable coronary artery disease and atrial fibrillation. 2022 , 20,	0
87	A genetic risk score improves risk stratification for anticoagulation-related intracerebral hemorrhage.	0
86	Recent Advances in Catheter Ablation for Atrial Fibrillation and Non-pharmacological Stroke Prevention.	0
85	A novel murine model of atrial fibrillation by diphtheria toxin-induced injury. 13,	0
84	Association of Intravenous Potassium and Magnesium Administration With Spontaneous Conversion of Atrial Fibrillation and Atrial Flutter in the Emergency Department. 2022 , 5, e2237234	0
83	Characteristics and health-status outcomes in patients with atrial fibrillation detected via health screening.	0

- 82 Influenza vaccination is associated with a decreased risk of atrial fibrillation: A systematic review and meta-analysis. 9, ○
- 81 Stroke prevention of thoracoscopic left atrial appendage clipping in patients with non-valvular atrial fibrillation at high risk of stroke and bleeding: study protocol for a non-randomised controlled clinical trial. **2022**, 12, e063931 ○
- 80 Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review. ○
- 79 Cardiac MRI Left Atrial Strain Associated With New-Onset Atrial Fibrillation in Patients With ST-Segment Elevation Myocardial Infarction. ○
- 78 Target heart rate in heart failure with reduced ejection fraction and atrial fibrillation: Goldilocks zone. **2022**, 23, 100218 ○
- 77 Right Atrial Appendage Thrombus in a Patient Undergoing Thoracoscopic Left Atrial Appendectomy for Atrial Fibrillation. **2022**, ○
- 76 Left atrial appendage occlusion with Watchman device after incomplete surgical ligation. **2022**, 15, e251905 ○
- 75 Intersection of Atrial Fibrillation and Heart Failure with Mildly Reduced and Preserved Ejection Fraction in >400,000 Participants in the Get With The Guidelines Heart Failure Registry. 1
- 74 Evidence for pharmacological interventions to reduce cardiovascular risk for patients with chronic kidney disease: a study protocol of an evidence map. **2022**, 11, ○
- 73 DOsing Strategy Effectiveness of Diltiazem in Atrial Fibrillation With Rapid Ventricular Response. **2022**, ○
- 72 Combined atrial fibrillation ablation and left atrial appendage occlusion procedure in the United States: a propensity score matched analysis from 2016–2019 national readmission database. 1
- 71 Factors influencing self-management behavior during the “Blanking Period” in patients with atrial fibrillation: A cross-sectional study based on the information-motivation-behavioral skills model. **2023**, 58, 62-68 ○
- 70 The association of pre-transplant atrial fibrillation with in-hospital outcomes in patients undergoing orthotopic liver transplantation: A propensity score matching analysis. ○
- 69 Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. **2023**, 22, 45-54 ○
- 68 Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry. 64, ○
- 67 DG-ECG: Multi-stream deep graph learning for the recognition of disease-altered patterns in electrocardiogram. **2023**, 80, 104388 ○
- 66 Dysrhythmias associated with COVID-19: Review and management considerations. **2023**, 64, 161-168 ○
- 65 Prescribing Patterns of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Retrospective Cohort Analysis. **2022**, 27, 107424842211422 ○

- 64 Identifying unmet antithrombotic therapeutic need, and implications for stroke and systemic embolism in atrial fibrillation patients: a population-scale longitudinal study. **2022**, 2, ○
- 63 Association of chronic kidney disease with all-cause mortality in patients hospitalized for atrial fibrillation and impact of clinical and socioeconomic factors on this association. 9, ○
- 62 Impact and predictors of device-related thrombus after percutaneous left atrial appendage closure. Publish Ahead of Print, 1
- 61 Radiofrequency Pulmonary Vein Isolation without Esophageal Temperature Monitoring: Contact-Force Characteristics and Incidence of Esophageal Thermal Damage. **2022**, 11, 6917 ○
- 60 Distribution of risk factors differs from coronary heart disease and stroke in China: a national population survey. **2022**, 12, e065970 ○
- 59 Trends of use and factors that determine the choice of oral anticoagulants in women and men with atrial fibrillation. **2022**, 10, ○
- 58 Techniques improving electrical cardioversion success for patients with atrial fibrillation: a systematic review and meta-analysis. ○
- 57 Incidence of atrial functional tricuspid regurgitation and its correlation with tricuspid valvular deformation in patients with persistent atrial fibrillation. 9, ○
- 56 Characterization of high-density mapping in catheter ablation for persistent atrial fibrillation: results from the AdvisorâHD Grid Mapping Catheter Observational study. ○
- 55 Acupuncture decreases risk of stroke among patients with atrial fibrillation: A nationwide investigation. **2022**, 101, e31889 ○
- 54 Nocturnal ventricular tachycardia storm: A man-made form. **2022**, 8, 859-860 ○
- 53 His Bundle Pacing and AV nodal ablation for non-controlled atrial arrhythmia: a technical challenge with major clinical benefits. **2022**, ○
- 52 Mechanisms and Management of Thyroid Disease and Atrial Fibrillation: Impact of Atrial Electrical Remodeling and Cardiac Fibrosis. **2022**, 11, 4047 ○
- 51 Alcohol Consumption and Atrial Arrhythmia Recurrence After Atrial Fibrillation Ablation: A Systematic Review and Meta-analysis. **2022**, ○
- 50 In a large primary care dataset, the CHAâDSâVASc score leads to almost universal recommendation for anticoagulation treatment in those aged â³5 years with atrial fibrillation. ○
- 49 Impact of atrial fibrillation type (paroxysmal vs. non-paroxysmal) on long-term clinical outcomes: The RAFFINE registry subanalysis. **2023**, ○
- 48 Prognostic value of interleukin-34 and interleukin-38 in patients with newly diagnosed atrial fibrillation. 9, ○
- 47 First-Line Catheter Ablation for Paroxysmal Atrial Fibrillation âHave We Reached the Tipping Point?. **2023**, 388, 177-178 ○

- 46 Comparison of Commercial Low Molecular Weight Heparin and Homemade Anti-Xa Calibrators to a Commercial Specific Anti-Xa Calibrator for Plasma Rivaroxaban Quantification by Anti-Xa Oral Anticoagulant Plasma Concentration Chromogenic Assay. ○
- 45 An Exercise and Physical Activity Program in Patients With Atrial Fibrillation. **2023**, ○
- 44 Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban. **2023**, 2, 100175 ○
- 43 Comparison of Early Complications of Oral Anticoagulants after Totally Thoracoscopic Ablation: Warfarin versus Non-vitamin K Antagonist Oral Anticoagulants. **2023**, ○
- 42 Postoperative atrial fibrillation: from mechanisms to treatment. ○
- 41 Initial In-Hospital Visit-to-Visit Heart Rate Variability Is Associated with Higher Risk of Atrial Fibrillation in Patients with Acute Ischemic Stroke. **2023**, 12, 1050 ○
- 40 Genetic Risk Score Improves Risk Stratification for Anticoagulation-Related Intracerebral Hemorrhage. **2023**, 54, 791-799 ○
- 39 Failure of Guidelines and Consensus Statements to Recommend Follow-up for Chronic Cardiovascular Conditions. **2023**, 59, 128-138 ○
- 38 Prognostic impact of plasma xanthine oxidoreductase activity in patients with heart failure with atrial fibrillation. **2023**, 81, 469-475 ○
- 37 Cardiac MRI: An Alternative Method to Determine the Left Ventricular Function. **2023**, 13, 1437 ○
- 36 Anticoagulation for Atrial Fibrillation. Publish Ahead of Print, ○
- 35 Device-detected atrial fibrillation in a large remote-monitored cohort: implications for anticoagulation and need for new pathways of service delivery. ○
- 34 Implementation of a clinical decision support alert to prevent use of intravenous β -blockers and nondihydropyridine calcium channel blockers in hospitalized patients with acute decompensated heart failure. **2023**, 80, e119-e125 ○
- 33 Supraventricular Arrhythmias After PFO Closure. **2023**, 16, 360 ○
- 32 Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trials. ○
- 31 Intermedin 1-53 Ameliorates Atrial Fibrosis and Reduces Inducibility of Atrial Fibrillation via TGF- β /pSmad3 and Nox4 Pathway in a Rat Model of Heart Failure. **2023**, 12, 1537 ○
- 30 Fractures in CKD Patients—Risk Analysis in RRT Lombardy Patients. **2023**, 3, 95-110 ○
- 29 “Bill-in-Pocket” Anticoagulation for stroke prevention in atrial fibrillation. ○

- 28 Early mortality after inpatient versus outpatient catheter ablation in patients with atrial fibrillation. **2023**, ○
- 27 The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease. **2023**, ○
- 26 Atrial fibrillation in a pediatric patient caused by an unusual malignant etiology: A case report. 11, ○
- 25 Impact of left atrial appendage closure in patients on anticoagulation for atrial fibrillation and recurrent or chronic gastrointestinal bleeding. **2023**, ○
- 24 Comparison of a direct aspiration first pass technique vs. stent retriever thrombectomy for the treatment of acute large vessel occlusion stroke in the anterior circulation with atrial fibrillation. 14, ○
- 23 Mean Platelet Volume to Platelet Count Ratio Predicts Left Atrial Stasis in Patients with Non-Valvular Atrial Fibrillation. Volume 16, 847-858 ○
- 22 First description of atrial fibrillation and congenital thrombotic thrombocytopenic purpura treated by left atrial appendage occlusion. ○
- 21 Incidence of the Atrial Fibrillation in Patients with Chronic Obstructive Pulmonary Disease (COPD) in Sindh, Pakistan. 145-149 ○
- 20 Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Cancer. **2023**, 5, 203-212 ○
- 19 Post-operative atrial fibrillation after cardiac surgery: Challenges throughout the patient journey. 10, ○
- 18 The Minimum Number of Ablation Lines for Complete Isolation of the Pulmonary Veins during Thoracoscopic Ablation for Atrial Fibrillation. **2023**, 13, 770 ○
- 17 Impact of baseline blood pressure on all-cause mortality in patients with atrial fibrillation: results from a multicenter registry study. **2023**, 136, 683-689 ○
- 16 Opportunistic Screening for Atrial Fibrillation on Routine Chest Computed Tomography. Publish Ahead of Print, ○
- 15 Polarization-Sensitive Optical Coherence Tomography (PSOCT) for identifying and analyzing gaps in lesion lines during ex vivo simulated radiofrequency ablation procedure. **2023**, ○
- 14 Randomized feasibility trial of prophylactic radiofrequency ablation to prevent atrial fibrillation after cardiac surgery. **2023**, ○
- 13 Accuracy of the Apple watch for detection of AF: A multicenter experience. ○
- 12 Pulmonary Vein Myocardial Sleeve Length and Its Association With Sex and 4q25/PITX2 Genotype. **2023**, ○
- 11 Markov Chain Models for Cardiac Rhythm Dynamics in Patients Undergoing Catheter Ablation of Atrial Fibrillation. **2023**, 85, ○

- | | | |
|----|---|---|
| 10 | Trends in antiplatelet strategies 12-months following coronary stent placement in anticoagulated patients. 2023 , 23, | ○ |
| 9 | His-Purkinje conduction system pacing combined with atrioventricular node ablation improves quality of life in older patients with persistent atrial fibrillation refractory to multiple ablation procedures. 2023 , 20, 130-138 | ○ |
| 8 | Medications to Avoid When Treating Heart Failure. 2023 , 285-306 | ○ |
| 7 | Bleeding related to oral anticoagulants: Trends in US emergency department visits, 2016-2020. 2023 , 225, 110-115 | ○ |
| 6 | Clinical decision support to Optimize Care of patients with Atrial Fibrillation or flutter in the Emergency department: protocol of a stepped-wedge cluster randomized pragmatic trial (Oâ€œAF trial). 2023 , 24, | ○ |
| 5 | Safety and efficacy of direct oral anticoagulation in patients with and without radiofrequency ablation of non-valvular atrial fibrillation: a multicenter retrospective cohort study. 2023 , 21, | ○ |
| 4 | Socioeconomic Status and Burden of Atrial Fibrillation Hospitalizations among Black US Adults: A Fifteen Year Analysis. 2023 , 101737 | ○ |
| 3 | Benefits of early rhythm control of atrial fibrillation. 2023 , | ○ |
| 2 | Anticoagulation use in perioperative atrial fibrillation after noncardiac surgery: a systematic review and meta-analysis. 2023 , 153, 40056 | ○ |
| 1 | Late recurrence of atrial fibrillation 5 years after catheter ablation: predictors and outcome. | ○ |